<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JANUARY 2, 1996
LABORATORY SPECIALISTS OF AMERICA, INC.
(Exact name of registrant as specified in its charter)
OKLAHOMA 0-24988 73-145065
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation) Identification No.)
1101-A SOVEREIGN ROW
OKLAHOMA CITY, OKLAHOMA 74108-1827
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (405) 949-1722
<PAGE>
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS
On January 2, 1996, Laboratory Specialists of America, Inc. (the "Company")
acquired all of the issued and outstanding capital stock (the "NPLI Stock") of
National Psychopharmacology Laboratory, Inc., a Tennessee corporation ("NPLI"),
and purchased goodwill (the "NPLI Goodwill"), pursuant to a Stock Purchase
Agreement dated January 1, 1996 (the "Purchase Agreement"), and NPLI became a
wholly-owned subsidiary of the Company. The NPLI Acquisition was accounted for
under the purchase method of accounting. NPLI is engaged in the providing of
two lines of product services, forensic drug testing (urine drug screening with
chain of custody) and clinical testing and analysis.
Pursuant to the Purchase Agreement, (i) the Company agreed to pay
$1,513,000 for the NPLI Stock (the "NPLI Stock Purchase Price") of which
$800,000 was paid at closing to the shareholders of NPLI (the "NPLI
Shareholders"), two unsecured promissory notes (the "Promissory Notes"), in the
aggregate principal amount of $638,000, were issued and delivered to the NPLI
Shareholders, and NPLI conveyed to the NPLI Shareholders (pursuant to a certain
Bill of Sale and Assignment of Leases) an office building and NPLI's leasehold
interest in the real property on which the office building is located and
affixed at an agreed market value of $75,000, and (ii) the Company agreed to pay
$140,000 for the NPLI Goodwill payable in 24 monthly installments commencing on
February 1, 1996.
The aggregate principal amount of the Promissory Notes is subject to
adjustment (increase or decrease) in the event (i) stockholders' equity of NPLI
(determined in accordance with generally accepted accounting principles as of
September 30, 1995, increases or decreases as reflected on the balance sheet of
NPLI as of December 31, 1995, (the "Net Worth Adjustment") and/or (ii) revenues
from forensic testing (employee urine drug screens that have a chain of custody)
("Testing Revenues") are greater or less than $1,700,000 during the 12 months
ending on January 2, 1997, determined in accordance with generally accepted
accounting principles (the "Testing Revenues Adjustment"). In the event the
aggregate principal amount of the Promissory Notes is decreased as a result of
the Testing Revenues Adjustment, on the date of such adjustment, the Company
will be required to issue and deliver to the NPLI Shareholders, such number of
shares of common stock, $.001 par value per share, of the Company ("Contingent
Shares") that have, in the aggregate, a value equal to the Testing Revenues
Adjustment. For purposes of determining the number of Contingent Shares, the
value of each Contingent Share to be issued and delivered will be equal to
average bid and asked prices for the 30 trading days ending on January 2, 1997,
of the Company's common stock. The Promissory Notes require payment of interest
only during the initial six months and interest and principal during the
remaining 30 months of their terms. The Promissory Notes bear interest at the
rate of seven percent per annum on their outstanding principal amounts and
require quarterly payments of interest ($5,582.50 during each of the initial two
quarters), and principal and interest ($35,050.23 during each of the subsequent
10 quarters) with the final quarterly installment becoming due and payable on
January 2, 1999. Effective January 2, 1996, the aggregate principal amount of
the Promissory Notes was reduced to $510,000 in accordance with the Net Worth
Adjustment.
Furthermore, pursuant to the Purchase Agreement, (i) the Company paid
certain NPLI shareholder loans in the aggregate amount of $275,000, (ii) entered
into a certain First Amendment of Lease Agreement with DJ Associates, a general
partnership of which the NPLI Shareholders are the general partners, and
pursuant to which the Company and NPLI leased certain office and laboratory
facilities for a term of six months and agreed to pay monthly rent of $3,000,
and (iii) entered into a certain Registration Rights Agreement with each of the
NPLI Shareholders, pursuant to which the Company, at its expense, agreed to
include the Contingent Shares, if issued and delivered pursuant to the Purchase
Agreement, in a registration statement filed by the Company for the registration
of its common stock under the Securities Act of 1933, as amended, subject to
certain conditions.
The Company intends to consolidate and assimilate the forensic drug testing
operations of NPLI with those of the Company. The Company initially continued
the clinical testing and analysis operations of NPLI from its office and
laboratory facility in Knoxville, Tennessee, and, in connection therewith,
retained certain of the clinical personnel employed in such office and
laboratory in order to maintain NPLI's market share of clinical testing services
pending sale of the clinical testing and analysis operations. However, during
the fourth quarter of 1996, after a
2
<PAGE>
number of attempts to sell the clinical operations of NPLI, the Company elected
to discontinue the clinical operations and terminated the clinical personnel.
The Company anticipates recording a loss of $1.6 to $2.1 million in the fourth
quarter of 1996 as a result of the discontinuance of the clinical operations of
NPLI.
There is no assurance that the Company will be able to maintain the market
share of NPLI's forensic drug testing operations. All forensic drug testing
operations formerly conducted and performed by NPLI at its laboratory facilities
in Knoxville, Tennessee, have been conducted and performed at the laboratory
facilities of Laboratory Specialists, Inc. in Belle Chasse, Louisiana. It is
currently anticipated by management of the Company that the laboratory
facilities and the capacity thereof will be adequate to conduct and perform the
increased forensic drug testing volume acquired by the Company from NPLI.
In connection with the purchase of the NPLI Stock, because of the nature of
the assets of NPLI, it is anticipated that the Company, on a consolidated
financial reporting basis, will be required to record substantially all of the
purchase price of the NPLI Stock attributable to the forensic drug testing
operations of NPLI as goodwill and customer list (intangible assets) which will
be amortized on a straight-line basis over 20 and 15 years, respectively, or the
estimated period that the Company will be benefited by the purchase of NPLI and
its assets, whichever is the shorter period. The carrying value and
recoverability of such intangible assets will be periodically reviewed by
management of the Company. If the facts and circumstances suggest that such
intangible assets may be impaired, the carrying value of such assets will be
adjusted which will result in an immediate charge against income during the
period of adjustment an/or the length of the remaining amortization period may
be shortened which will result in an increase in the amount of amortization
during the period of adjustment and each period thereafter until fully
amortized. Once adjusted, there can be no assurance that there will not be
further adjustments for impairment and recoverability in future periods of such
intangible assets. Of the various factors to be considered by management of the
Company in determining impairment of such intangible assets, the most
significant will be (i) the loss of all or a portion of the customer base of
NPLI, (ii) losses from operations, (iii) developments within the drug and
clinical testing industry, including the Company's inability to maintain NPLI
market share, development of forensic and clinical testing technologies,
imposition of additional regulatory and certification requirements, and (iv)
loss or suspension for an extended period of laboratory certification,
especially by the Substance Abuse and Mental Health Services Administration. In
the event management of the Company determines that such intangible assets have
become impaired, the adjustments for impairment and recoverability may occur
during a period of operations in which the Company has sustained losses or has
only marginal profitability from operations, and the impairment and/or increased
amortization amount will either increase such losses from operations or reduce
profitability.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(a) FINANCIAL STATEMENTS AND EXHIBITS.
The audited financial statements of NPLI appear at pages F-1 through F-11
and the unaudited financial statements of NPLI appear at pages F-12 through F-
15.
(b) PRO FORMA FINANCIAL INFORMATION.
The pro forma financial statements appear at pages F-16 through F-22.
(c) EXHIBITS.
--------
2.1 -Stock Purchase Agreement between Registrant, National
Psychopharmacology Laboratory, Inc., Haroutune K. Dekirmenjian, PhD.
and Kenneth O. Jobson, M.D., dated January 1, 1996.
2.2 -Registration Rights Agreement between Registrant and Haroutune K.
Dekirmenjian, PhD, dated January 2, 1996.
3
<PAGE>
2.3 -Registration Rights Agreement between Registrant and Kenneth O.
Jobson, M.D., dated January 2, 1996.
23 -Consent of Independent Accountants
4
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LABORATORY SPECIALISTS OF AMERICA, INC.
(Registrant)
By: /s/ JOHN SIMONELLI
------------------------------------
John Simonelli
Chief Executive Officer
Date: April 9, 1997
5
<PAGE>
Independent Auditors' Report
----------------------------
The Board of Directors
National Psychopharmacology
Laboratory, Inc.
We have audited the accompanying balance sheets of National Psychopharmacology
Laboratory, Inc. as of June 30, 1995 and 1994, and the related statements of
income (loss) and retained earnings and cash flows for the years then ended.
These financial statements are the responsibility of the Company's management.
Our responsibility is to express an opinion on these financial statements based
on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audits to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our
opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of National Psychopharmacology
Laboratory, Inc. at June 30, 1995 and 1994, and the results of its operations
and its cash flows for the years then ended in conformity with generally
accepted accounting principles.
The accompanying financial statements have been prepared assuming the Company
will continue as s going concern. As discussed in Note 12 to the financial
statements, the Company has incurred recurring losses from operations and there
are uncertainties about the Company's ability to retain current bank financing
or to replace that financing. These circumstances raise substantial doubt about
the Company's ability to continue as a going concern. Management's plans in
regard to these matters are also described in Note 12. The financial statements
do not include any adjustments that might result form the outcome of this
uncertainty.
As discussed in Note 6 to the financial statements, the Company changed its
method of accounting for income taxes in 1994 as required by provisions of
Statement of Financial Accounting Standards No. 109.
HG&A Associates, P.C.
August 31, 1995
F-1
<PAGE>
NATIONAL PSYCHOPHARMACOLOGY LABORATORY, INC.
BALANCE SHEET
JUNE 30, 1995 AND 1994 (PAGE 1 OF 2)
<TABLE>
<CAPTION>
1995 1994
---------- ----------
<S> <C> <C>
ASSETS
------
CURRENT ASSETS:
Cash......................................................... $ 21,793 $ 6,836
Accounts receivable, less allowance for uncollectible
accounts of $133,000 in 1995 and $195,976 in 1994......... 842,609 860,210
Income tax receivable........................................ 19,288 30,535
Other receivables............................................ -- 95
Supplied inventory........................................... 55,794 77,843
Prepaid expenses............................................. 50,745 28,279
Deferred tax asset........................................... 14,297 3,621
---------- ----------
Total current assets............................. 1,004,466 1,007,419
---------- ----------
PROPERTY, PLANT AND EQUIPMENT,.................................. 1,582,376 1,558,044
Less accumulated depreciation................................ 1,148,481 1,001,143
---------- ----------
433,895 556,901
---------- ----------
OTHER ASSETS:
Computer software costs - net of accumulated amortization
of $18,546 in 1995 and $15,484 in 1994................... 7,241 8,749
---------- ----------
Total assets..................................... $1,445,602 $1,573,069
========== ==========
</TABLE>
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
F-2
<PAGE>
NATIONAL PSYCHOPHARMACOLOGY LABORATORY, INC.
BALANCE SHEET
JUNE 30, 1995 AND 1994 (PAGE 2 OF 2)
<TABLE>
<CAPTION>
1995 1994
----------- ----------
LIABILITIES AND STOCKHOLDERS' EQUITY
------------------------------------
CURRENT LIABILITIES:
<S> <C> <C>
Note payable - line of credit.......................... $ 379,960 $ 310,784
Current installments of long-term debt................. 91,337 92,108
Current installments of capital lease obligations...... 77,728 83,987
Accounts payable....................................... 523,178 467,386
Accrued expenses:
Payroll............................................ 72,373 100,761
Vacation pay....................................... 36,446 56,003
Interest........................................... 16,510 6,339
Payroll and other taxes............................ 19,418 8,645
Other.............................................. 6,903 8,789
---------- ----------
Total current liabilities...................... 1,223,853 1,134,802
NOTES PAYABLE TO OFFICERS.................................. 275,000 75,000
LONG-TERM DEBT - less current installments................ 81,858 172,790
CAPITAL LEASE OBLIGATIONS - less current installments...... 44,733 113,187
DEFERRED TAX LIABILITY..................................... 14,297 12,764
---------- ----------
Total liabilities............................... 1,639,741 1,508,543
---------- ----------
STOCKHOLDERS' EQUITY:
Common stock - no par value; 2,000 shares authorized;
200 shares issued and outstanding.................. 8,000 8,000
Retained earnings (deficit)............................ (202,139) 56,526
---------- ----------
Total stockholders' equity..................... (194,139) 64,526
---------- ----------
Total liabilities and stockholders' equity..... $1,445,602 $1,573,069
========== ==========
</TABLE>
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
F-3
<PAGE>
NATIONAL PSYCHOPHARMACOLOGY LABORATORY, INC.
STATEMENTS OF INCOME (LOSS) AND RETAINED EARNINGS
YEARS ENDED JUNE 30, 1995 AND 1994
<TABLE>
<CAPTION>
1995 1994
----------- -----------
<S> <C> <C>
FEE INCOME.................................................. $5,789,763 $6,666,311
COST OF SALES............................................... 3,921,024 4,330,648
---------- ----------
Gross profit........................................ 1,868,739 2,335,663
GENERAL AND ADMINISTRATIVE EXPENSES......................... 2,097,819 2,449,495
---------- ----------
Loss from operations................................ (229,080) (113,832)
OTHER INCOME (EXPENSE):
Rent income......................................... 29,700 29,724
Interest expense.................................... (87,796) (72,788)
Interest income..................................... 120 --
Miscellaneous....................................... 20 393
---------- ----------
Loss before income taxes and change
in accounting principle..................... (287,036) (156,503)
---------- ----------
PROVISION FOR INCOME TAXES:
Currently recoverable............................... 19,228 1,440
Deferred tax benefit................................ 9,143 21,790
---------- ----------
28,371 23,230
---------- ----------
Loss before change in accounting principle.... (258,665) (133,273)
CHANGE IN ACCOUNTING PRINCIPLE:
Cumulative effect to June 30, 1993, of application of
Statement of Financial Account Standard No. 109
"Accounting for Income taxes........................ -- 38,489
---------- ----------
Net loss..................................... (258,665) (94,784)
---------- ----------
RETAINED EARNINGS, beginning of year........................ 56,526 151,310
---------- ----------
RETAINED EARNINGS (DEFICIT), end of year.................... $ (202,139) $ 56,526
========== ==========
</TABLE>
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
F-4
<PAGE>
NATIONAL PSYCHOPHARMACOLOGY LABORATORY, INC.
STATEMENTS OF CASH FLOWS
YEARS ENDED JUNE 30, 1995 AND 1994
<TABLE>
<CAPTION>
1995 1994
---------- ----------
NET CASH PROVIDED (USED) BY OPERATING ACTIVITIES:
<S> <C> <C>
Net Loss....................................................... $(258,665) $ (94,784)
--------- ---------
Adjustments to reconcile net loss to net cash provided
(used) by operating activities:
Depreciation and amortization.............................. 150,639 158,151
Deferred income tax benefits............................... (9,143) (60,279)
Decrease (increase) in assets:
Accounts receivables................................... 17,601 183,275
Other receivables...................................... 11,402 (30,630)
Supplies inventory..................................... 22,049 7,301
Prepaid expenses....................................... (22,466) (8,781)
Increase (decrease) in liabilities:
Accounts payable....................................... 55,792 (4,788)
Accrued liabilities.................................... (28,887) (20,950)
--------- ---------
Total adjustments.................................. 196,987 223,299
--------- ---------
Net cash provided (used) by operating activities... (61,678) 128,515
--------- ---------
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of computer software............................... (1,554) (1,216)
Acquisition of property and equipment.......................... (24,571) (39,939)
--------- ---------
Net cash (used) by investing activities.............. (26,125) (41,155)
--------- ---------
CASH FLOWS FROM FINANCING ACTIVITIES:
Net increase (decrease) in line of credit...................... 69,176 (58,868)
Proceeds from issuance of notes payable to officers............ 200,000 75,000
Principal payments on long-term debt........................... (91,703) (72,436)
Principal payments on capital lease obligations................ (74,713) (70,000)
--------- ---------
Net cash provided (used) by investing activities....... 102,760 (126,304)
--------- ---------
NET INCREASE (DECREASE) IN CASH.................................... 14,957 (38,944)
Cash at beginning of year.......................................... 6,836 45,780
--------- ---------
Cash at end of year................................................ $ 21,793 $ 6,836
========= =========
</TABLE>
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
F-5
<PAGE>
NATIONAL PSYCHOPHARMACOLOGY LABORATORY, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 1995 AND 1994
1) NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
National Psychopharmacology Laboratory, Inc. was incorporated under the
laws of the State of Tennessee on January 30, 1978. The Company's
operations consist of performing drug and medical testing. The Company
grants credit to its customers, substantially all of whom are health care
providers, private industry or individuals located throughout the United
States.
Supplies Inventories
Supplies inventories are stated at the lower of cost or market. Cost is
determined using the first-in, first-out method.
Property and Equipment
Property and equipment are stated at cost. Equipment under capital leases
is stated at the present value of minimum lease payments at the inception
of the lease.
Depreciation on building, equipment and leasehold improvements is
calculated using both straight-line and accelerated methods over the
estimated useful lives of the assets which range from 5 to 40 years.
Equipment held under capital leases is amortized over the shorter of the
lease term or estimated useful life of the asset using the straight-line
method.
Other Assets
Included in other assets are computer software costs which are being
amortized over five years using the straight-line method.
Research and Development
Research and development costs included in general and administrative
expenses amounted to $70,919 and $72,506 in 1995 and 1994, respectively.
2) PROPERTY PLANT AND EQUIPMENT
Major classes of property, plant and equipment are as follows:
<TABLE>
<CAPTION>
1995 1994
---------- ----------
<S> <C> <C>
Building................................. $ 196,852 $ 196,852
Leasehold improvements................... 86,602 86,602
Booth.................................... 11,734 11,734
Automobiles.............................. 36,162 36,162
Laboratory equipment..................... 684,403 676,773
Office furniture and equipment........... 121,027 121,027
Computer equipment....................... 445,596 428,894
---------- ----------
$1,582,376 $1,558,044
---------- ----------
</TABLE>
F-6
<PAGE>
Depreciation expense was $147,577 and $155,197 in 1995 and 1994,
respectively.
3) NOTES PAYABLE
In 1994, the Company entered into an amended and restated financing
agreement with a commercial bank which allows the Company to borrow up to
the lesser of 75 % of current accounts receivable or $650,000 less the
outstanding balance of the term loan described in Note 4. The line of credit
expires October 30, 1995, and bears interest, payable monthly, at the prime
rate which was 10.5% at June 30, 1995. The line of credit is secured by the
Company's accounts receivable, inventory and equipment.
The Company has also entered into agreements with officers of the Company
for $275,000, payable on demand. The notes bear interest (which accrues
monthly) at rates ranging from 7.25% to 9.0%. The Company has executed a
debt subordination agreement with the bank whereby notes payable to the
officers are subordinate to amounts owed under the line of credit and
installment note. As a result, notes payable to officers are shown as
noncurrent on the accompanying balance sheets.
4) LONG-TERM DEBT
In 1993, the Company converted $350,000 of its outstanding line of credit
balance at June 30, 1992, to a term note with the same commercial bank.
Principal and interest at 6.9% are payable monthly through April, 1997. The
note is secured by the Company's accounts receivable, inventory and
equipment.
Maturities of long-term debt are as follows:
<TABLE>
<CAPTION>
<S> <C>
1996................................... $ 91,337
1997................................... 81,858
--------
$173,195
========
</TABLE>
5) LEASES
The Company is obligated under capital leases for certain machinery and
equipment. The leases expire at various dates through January, 1997. The
original cost of the equipment and related amortization recorded under
capital leases are as follows:
<TABLE>
<CAPTION>
1995 1994
-------- --------
<S> <C> <C>
Machinery and equipment...................... $377,791 $377,791
Less accumulated amortization................ 231,954 172,675
-------- --------
$145,837 $205,116
======== ========
</TABLE>
Amortization of assets held under capital leases is included with
depreciation expense.
The Company has several noncancellable operating leases for its building,
office space and various equipment. The leases expire in various years
through March, 1997, and require the Company to pay all executory costs such
as maintenance and insurance. The Company also leases certain office space,
storage space and a parcel of land under month-to-month operating leases.
Rental expense for all operating leases for the years ended June 30, 1995
and 1994 consists of the following:
F-7
<PAGE>
<TABLE>
<CAPTION>
1995 1994
-------- --------
<S> <C> <C>
Building, office and storage space ............. $200,695 $202,713
Land............................................ 3,000 3,000
Equipment....................................... 8,396 5,297
-------- --------
$212,091 $211,010
======== ========
</TABLE>
Included in rent expense are amounts paid to related parties of $200,469 and
$202,593 during 1995 and 1994, respectively.
Future minimum lease payments, by year and in the aggregate, under capital
leases and noncancellable operating leases with initial or remaining terms
of one year or more consist of the following at June 30, 1995:
<TABLE>
<CAPTION>
Capital Operating
Year ended June 30 Leases Leases
--------------------- -------- ---------
<S> <C> <C>
1996...................................... $ 91,199 $152,095
1997...................................... 46,920 21,933
-------- --------
Total minimum lease payments................ 138,119 $174,028
========
Amounts representing interest............... (15,658)
--------
Present value of net minimum
lease payments............................ 122,461
Less current installments................... 77,728
--------
Long-term capital lease obligations......... $ 44,733
========
</TABLE>
Interest rates on capitalized leases range from 11.3% to 14.5% and are
imputed based on the lower of the Company's incremental borrowing rate at
the inception of the lease or the lessor's implicit rate of return.
The Company is the lessor of a building to a related party, under a lease
agreement dated December 1 , 1989. The lease originally expired in November,
1994, and was verbally renewed for one year. Monthly rental payments are
$2,475. Rental income was $29,700 in 1995 and $29,724 in 1994. The carrying
value of the leased building and related improvements is as follows:
<TABLE>
<CAPTION>
1995 1994
-------- --------
<S> <C> <C>
Original cost........................................ $196,852 $196,852
Less accumulated depreciation........................ 119,310 111,496
-------- --------
$ 77,542 $ 85,356
======== ========
</TABLE>
6) CHANGE IN ACCOUNTING PRINCIPLE
In 1994, the Company adopted Statement of Financial Accounting Standards No.
109, Accounting for Income Taxes, which requires an asset and liability
approach to financial accounting and reporting for income taxes. Under this
approach, deferred income tax assets and liabilities are computed annually
for differences between the financial statement and tax basis of assets and
liabilities that will result in taxable or deductible amounts in future
years based on enacted tax laws and rates applicable to the periods in which
the differences are expected to affect taxable income. Valuation allowances
are established, if necessary, to
F-8
<PAGE>
reduce deferred tax assets to the amount expected to be realized. Income tax
expense is the tax payable or refundable plus or minus the change during the
year in deferred tax assets and liabilities.
As permitted by Statement of Financial Accounting Standards No. 109, the
1994 financial statements reflect a $38,489 cumulative effect to June 30,
1993 of application of this change in accounting principle.
7) INCOME TAX EXPENSE
Net deferred income tax assets and liabilities consist of the following:
<TABLE>
<CAPTION>
1995 1994
-------- ---------
<S> <C> <C>
Deferred tax asset:
Allowance for uncollectible accounts............ $19,950 $ 21,355
Accrued valuation............................... 4,013 4,727
Section 481 adjustment.......................... -- (22,461)
------- --------
23,963 3,621
Less valuation allowance........................ 9,666 --
------- --------
$14,297 $ 3,621
======= ========
Deferred tax liability:
Excess tax depreciation taken for
tax purposes.................................. $14,297 $ 26,308
Research and development credit................. -- (7,614)
Minimum tax credit.............................. -- (5,930)
------- --------
$14,297 $ 12,764
======= ========
</TABLE>
Tax credit carryforwards totaling $17,186 at June 30, 1995, have been
excluded from deferred taxes due to uncertainty as to when and if the tax
credits will be utilized (see below).
Total income tax expense (recoveries) differed from the amounts computed by
applying the U.S. Federal income tax rates to income before income taxes as
a result of the following:
<TABLE>
<CAPTION>
1995 1994
--------- ----------
<S> <C> <C>
Computed "expected" tax expense (recovery)............$(70,123) $ (44,286)
Increase (reduction) in income taxes resulting from:
Nondeductible expenses............................. 8,226 10,702
Reduction in rates used to establish deferred
tax assets and liabilities........................ 4,672 --
Reserves established against deferred tax assets... 24,457 --
Other, net......................................... 4,397 6,165
Rate differential between alternative minimum
tax and regular tax............................... -- 4,189
-------- --------
$(28,371) $(23,230)
======== ========
</TABLE>
During 1991, the Company changed its method of accounting, for income tax
purposes, from the cash basis to the accrual method giving rise to a total
adjustment of $403,794 which is being recognized into income over a four-
year period for federal income tax purposes according to Internal Revenue
Code Sec. 481.
F-9
<PAGE>
The Company has an alterative minimum tax credit of $8,325 available to
offset federal income taxes in future years. The minimum tax credit has no
expiration date. The Company also has a research and development credit of
$8,861 available to offset federal income taxes in future years as follows:
<TABLE>
<CAPTION>
Year of expiration
------------------
<S> <C>
2006.................................. $2,656
2007.................................. 4,808
2008.................................. 1,397
------
$8,861
======
</TABLE>
8) RETIREMENT PLAN
The Company has a 401(k) retirement plan through, which qualified employees
may contribute up to 20% of their gross salary on a pretax basis. The
Company has not provided any matching funds. Executory costs of the plan are
paid by the Company.
9) EMPLOYEE INCENTIVE PLAN
The Company has a plan to provide incentive for certain key employees to
attain certain performance levels and to promote long-term loyalty to the
Company. The plan does not convey stock or equity ownership in the Company
to its participants. Payment will be made to the employees upon a triggering
event, defined as the voluntary transfer by sale or exchange for any
ownership interest in the common stock of the Company by those individuals
collectively owning one hundred percent (100%) of the common stock of the
Company immediately prior to the transfer so that immediately after the
transfer the said individuals collectively own less than fifty percent (50%)
of the common stock of the Company.
The employees are credited incentive compensation units, which are assigned
a unit base value, at the absolute discretion of the Board of Directors.
Total incentive compensation units outstanding at June 30, 1995 were 250
units with a base value per unit of $500. In the case of a triggering event,
compensation due to the participating employees will be calculated by
dividing the purchase price by 10,000. The resulting quotient reduced by the
unit base value of $500 represents the net unit value of each incentive
compensation unit. Based on the $500 assigned base value per unit, a
triggering event purchase price would have to exceed $5 million before an
incentive compensation unit would have any value.
10) COMMITMENTS, AND CONTINGENT LIABILITIES
In connection with a capital lease for lab equipment, the Company is
obligated to make a minimum monthly payment for service and supplies of
$7,361 through January, 1997. The Company purchased $141,204 and $131,462 of
supplies under this contract during 1995 and 1994, respectively. Future
required payments under this contract are as follows:
<TABLE>
<CAPTION>
<S> <C>
1996....................... $ 88,333
1997....................... 51,527
--------
$139,859
--------
</TABLE>
The Company is the defendant in three lawsuits. The lawsuits are covered
under the Company's professional liability insurance which has a maximum
limit of $5 million. Management and its outside legal counsel do not believe
the Company will incur a liability in connection with the lawsuits.
F-10
<PAGE>
11) SUPPLEMENTARY CASH FLOW INFORMATION
Supplementary cash flow information is as follows:
<TABLE>
<CAPTION>
1995 1994
------- -------
<S> <C> <C>
Income taxes paid $ -- $ 6,462
======= =======
Interest paid $77,626 $68,844
======= =======
</TABLE>
12) CONTINUING OPERATIONS
During the last two years the Company has incurred operating losses as the
result of increased costs and declining revenues. Although the Company had
not met certain financial ratios, the Company's lending institution extended
its line of credit to January 27, 1996. If the balance of the line and term
note has been reduced to $250,000, the bank will extend the notes for an
additional 90 days. Should the balance not be reduced to $250,000 by January
27, 1996, the entire balance would be payable immediately. The loans are
secured by the Company's accounts receivable, equipment, inventories and
general intangibles. Should the loans be called or if they are not renewed
in April, 1996, and the Company fails to obtain alternative financing, the
Company may not have the ability to continue as a going concern.
Management is currently negotiating to sell the Company. Management believes
that cost savings from a sale of the Company to another company within its
industry would allow the Company to regain profitability. It would also
provide sufficient capitalization to eliminate or to secure refinancing of
its debt structure. Management hopes to conclude current negotiations by
December 31,1995. Should current negotiations not result in the sale of the
Company, management intends to continue to seek a buyer for the Company or
for certain lines of the Company.
Subsequent to June 30, 1995, management implemented certain cost reductions
involving payroll and other administrative costs. Management estimates these
savings at approximately $20,000 per month. In addition, certain
shareholders intend to temporarily provide funds to allow the Company to
meet its required debt reduction on January 27, 1996.
F-11
<PAGE>
NATIONAL PSYCHOPHARMACOLOGY LABORATORY, INC.
BALANCE SHEETS
UNAUDITED
<TABLE>
<CAPTION>
DECEMBER 31, JUNE 30,
1995 1995
------------- -----------
<S> <C> <C>
ASSETS
------
CURRENT ASSETS:
Cash and cash equivalents....................................... $ 52,403 $ 21,793
Accounts receivable, net of allowances of $133,000.............. 752,275 842,609
Income tax refund receivable.................................... 19,228 19,288
Inventories..................................................... 55,794 55,794
Deferred Taxes.................................................. 14,297 14,297
Prepaid expenses and other...................................... 56,878 50,745
---------- ----------
Total current assets.......................................... 950,875 1,004,466
---------- ----------
PROPERTY, PLANT AND EQUIPMENT, net of accumulated
depreciation of $1,196,272, at June 30, 1995 and $1,148,481
at December 31, 1995............................................ 395,867 433,895
OTHER ASSETS:
Computer Software , net of accumulated amortization of
$20,083 at December 31, 1995 and $18,546 at
December 31, 1995............................................. 5,704 7,241
---------- ----------
Total assets.................................................. $1,352,446 $1,445,602
========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
------------------------------------
CURRENT LIABILITIES:
Accounts payable................................................ $ 636,060 $ 523,178
Accrued payroll................................................. 144,534 72,373
Accrued expenses................................................ 42,279 62,767
Current notes payable........................................... 374,960 379,960
Current portion of long-term debt............................... 175,692 169,065
---------- ----------
Total current liabilities..................................... 1,373,525 1,223,853
---------- ----------
NOTES PAYABLE TO OFFICERS......................................... 275,000 275,000
LONG-TERM DEBT, net of current portion............................ 41,131 126,591
DEFERRED INCOME TAXES............................................. 14,297 14,297
---------- ----------
Total Liabilities......................................... 1,703,953 1,639,741
---------- ----------
STOCKHOLDERS' EQUITY:
Capital Stock................................................... 8,000 8,000
Retained earnings............................................... (359,507) (202,139)
---------- ----------
Total stockholders' equity.................................... (351,507) (194,139)
---------- ----------
Total liabilities and stockholders' equity.................... $1,352,446 $1,445,602
========== ==========
</TABLE>
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
F-12
<PAGE>
NATIONAL PSYCHOPHARMACOLOGY LABORATORY, INC.
STATEMENTS OF INCOME
UNAUDITED
<TABLE>
<CAPTION>
FOR THE SIX MONTHS ENDED FOR THE SIX MONTHS ENDED
------------------------------------- -----------------------------
DECEMBER 31, 1995 DECEMBER 31,1994 JUNE 30, 1995 JUNE 30, 1994
------------------ ----------------- -------------- -------------
<S> <C> <C> <C> <C>
REVENUES........................... $2,635,775 $3,333,156 $2,894,882 $3,333,156
COST OF LABORATORY SERVICES........ 1,864,437 2,165,324 1,960,512 2,165,324
---------- ---------- ---------- ----------
Gross profit..................... 771,338 1,167,832 934,370 1,167,832
---------- ---------- ---------- ----------
OPERATING EXPENSES:
General and administrative....... 839,389 1,224,748 1,048,910 1,224,748
Depreciation and amortization.... 60,424 79,076 75,320 79,076
---------- ---------- ---------- ----------
Total operating expenses....... 899,813 1,303,823 1,124,229 1,303,823
---------- ---------- ---------- ----------
Loss from operations........... (128,475) (135,992) (189,860) (135,992)
---------- ---------- ---------- ----------
OTHER INCOME (EXPENSE):
Interest expense................. (44,042) (36,394) (43,898) (36,394)
Interest income.................. -- -- 60 --
Other income..................... 15,150 15,059 14,860 15,059
---------- ---------- ---------- ----------
Total other income (expense)... (28,892) (21,336) (28,978) (21,336)
---------- ---------- ---------- ----------
Loss before income taxes....... (157,367) (157,327) (218,838) (157,327)
INCOME TAX EXPENSE (BENEFIT)....... -- (11,615) (14,188) (11,615)
---------- ---------- ---------- ----------
Loss income before change
in accounting principle.... (157,367) (145,712) (204,652) (145,712)
CHANGE IN ACCOUNTING PRINCIPLE..... -- (19,245) -- (19,245)
---------- ---------- ---------- ----------
Net Loss....................... $ (157,367) $ (126,467) $ (204,652) $ (126,467)
========== ========== ========== ==========
</TABLE>
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
F-13
<PAGE>
NATIONAL PSYCHOPHARMACOLOGY LABORATORY, INC.
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
1. GENERAL
-------
The financial statements included in this report have been prepared by
National Psychopharmacology Laboratory, Inc. (the "Company") pursuant to
the rules and regulations of the Securities and Exchange Commission for
interim reporting and include all adjustments which are, in the opinion
of management, necessary for a fair presentation. These financial
statements have not been audited by an independent accountant. The
consolidated balance sheet at June 30, 1995, has been derived from the
audited balance sheet of the Company.
Certain information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted
accounting principles have been condensed or omitted pursuant to such
rules and regulations for interim reporting. The Company believes that
the disclosures are adequate to make the information presented not
misleading. However, these financial statements should be read in
conjunction with the audited financial statements and notes thereto of
the Company included in this Report. The financial data for the interim
periods presented may not necessarily reflect the results to be expected
for the full year.
2. SUBSEQUENT EVENT - LSAI ACQUISITION
-----------------------------------
On January 2, 1996, Laboratory Specialists of America, Inc. ("LSAI")
acquired all of the issued and outstanding capital stock (the "Stock") of
the Company, and purchased goodwill (the "Goodwill"), pursuant to a Stock
Purchase Agreement dated January 1, 1996 (the "Purchase Agreement"), and
the Company became a wholly-owned subsidiary of LSAI (the "Acquisition").
The Company is engaged in forensic drug testing (urine drug screening
with chain of custody) and clinical testing and analysis.
Pursuant to the Purchase Agreement, (i) LSAI agreed to pay $1,513,000 for
the Stock (the "Stock Purchase Price") of which $800,000 was paid at
closing to the shareholders of the Company (the "Shareholders"), two
unsecured promissory notes (the "Promissory Notes"), in the aggregate
principal amount of $638,000, were issued and delivered to the
Shareholders, and NPLI conveyed to the Shareholders (pursuant to a
certain Bill of Sale and Assignment of Leases) an office building and
NPLI's leasehold interest in the real property on which the office
building is located and affixed at an agreed market value of $75,000, and
(ii) LSAI agreed to pay $140,000 for the Goodwill, payable in 24 monthly
installments commencing on February 1, 1996.
The aggregate principal amount of the Promissory Notes is subject to
adjustment (increase or decrease) in the event (i) stockholders' equity
of the Company (determined in accordance with generally accepted
accounting principles as of September 30, 1995, increases or decreases as
reflected on the balance sheet of the Company as of December 31, 1995,
(the "Net Worth Adjustment") and/or (ii) revenues from forensic testing
(employee urine drug screens that have a chain of custody) ("Testing
Revenues") are greater or less than $1,700,000 during the 12 months
ending on January 2, 1997, determined in accordance with generally
accepted accounting principles (the "Testing Revenues Adjustment"). In
the event the aggregate principal amount of the Promissory Notes is
decreased as a result of the Testing Revenues Adjustment, on the date of
such adjustment, LSAI will be required to issue and deliver to the
Shareholders, such number of shares of common stock, $.001 par value per
share, of LSAI ("Contingent Shares") that have, in the aggregate, a value
equal to the Testing Revenues Adjustment. For purposes of determining the
number of Contingent Shares, the value of each Contingent Share to be
issued and delivered will be equal to average bid and asked prices for
the 30 trading days ending on January 2, 1997, of LSAI's common stock.
The Promissory Notes require payment of interest only during the initial
six months and interest and principal during the remaining
F-14
<PAGE>
30 months of their terms. The Promissory Notes bear interest at the rate
of seven percent per annum on their outstanding principal amounts and
require quarterly payments of interest ($5,582.50 during each of the
initial two quarters), and principal and interest ($35,050.23 during each
of the subsequent 10 quarters) with the final quarterly installment
becoming due and payable on January 2, 1999. Effective January 2, 1996,
the aggregate principal amount of the Promissory Notes was reduced to
$510,000 in accordance with the Net Worth Adjustment.
Furthermore, pursuant to the Purchase Agreement, (i) LSAI paid certain
Shareholder loans in the aggregate amount of $275,000 and (ii) entered
into a certain First Amendment of Lease Agreement with DJ Associates, a
general partnership of which the Shareholders are the general partners,
and pursuant to which LSAI and the Company leased certain office and
laboratory facilities for a term of six months and agreed to pay monthly
rent of $3,000.
LSAI (i) consolidated and assimilated the forensic drug testing
operations of the Company with those of LSAI and (ii) has continued the
clinical testing and analysis operations of the Company and retained the
clinical personnel to maintain the Company's market share of clinical
testing services.
F-15
<PAGE>
LABORATORY SPECIALISTS OF AMERICA, INC. AND SUBSIDIARY
PRO FORMA CONSOLIDATED BALANCE SHEET
DECEMBER 31, 1995 (PAGE 1 OF 2)
<TABLE>
<CAPTION>
LABORATORY
SPECIALISTS OF NATIONAL
AMERICA, INC. PSYCHOPHARMACOLOGY
-------------- LABORATORY, INC.
DECEMBER 31, ------------------ PRO FORMA PRO FORMA
1995 DECEMBER 31, 1995 ADJUSTMENTS COMBINED
-------------- ------------------ ----------- ----------
(NOTE 2)
<S> <C> <C> <C> <C>
ASSETS
------
CURRENT ASSETS:
Cash and cash equivalents........................ $2,411,051 $ 52,403 $(1,589,365)(a) $ 438,006
(435,084)(b)
Accounts receivable, net of allowances
of $91,546 and $133,000, respectively......... 1,096,477 752,275 (117,000)(c) 1,731,750
Income tax refund receivable..................... 131,626 19,228 -- 150,854
Inventories...................................... 87,542 55,794 -- 143,336
Prepaid expenses and other....................... 115,491 56,878 -- 172,369
Deferred tax...................................... -- 14,297 -- 14,297
---------- ---------- ------------ ----------
Total current assets................. 3,842,187 950,875 (2,141,449) 2,650,612
---------- ---------- ------------ ----------
PROPERTY, PLANT AND EQUIPMENT,...................... (1,542,139)(c)
net of accumulated depreciation of $899,559...... 1,196,272 (c)
and $1,196,272, respectively..................... 830,660 395,867 105,000 (d) 985,660
---------- ---------- ------------ ----------
OTHER ASSETS:
Goodwill, net of accumulated amortization........ 1,784,209 (c)
of $69,104................................... 1,539,045 -- (155,877)(e) 3,167,377
Customer list, net of accumulated................
amortization of $77,783...................... 1,001,707 -- 2,000,000 (e) 3,001,707
Deferred costs................................... 105,437 -- -- 105,437
Computer software, net of accumulated............. (25,787)(c)
amortization of $20,083....................... -- 5,704 20,083 (c) --
---------- ---------- ------------ ----------
Total other assets................... 2,646,189 5,704 3,622,628 6,274,521
---------- ---------- ------------ ----------
Total assets......................... $7,319,036 $1,352,446 $1,239,312 $9,910,794
========== ========== ============ ==========
</TABLE>
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
F-16
<PAGE>
LABORATORY SPECIALISTS OF AMERICA, INC. AND SUBSIDIARY
PRO FORMA CONSOLIDATED BALANCE SHEET
DECEMBER 31, 1995 (PAGE 2 OF 2)
<TABLE>
<CAPTION>
LABORATORY
SPECIALISTS OF NATIONAL
AMERICA, INC. PSYCHOPHARMACOLOGY
-------------- LABORATORY, INC.
DECEMBER 31, ----------------- PRO FORMA PRO FORMA
1995 DECEMBER 31, 1995 ADJUSTMENTS COMBINED
-------------- ----------------- ------------ ----------
(NOTE 2)
<S> <C> <C> <C> <C>
LIABILITIES AND STOCKHOLDERS' EQUITY
------------------------------------
CURRENT LIABILITIES:
Accounts payable................................. $ 446,223 $ 636,060 $ -- $1,082,283
Accrued payroll expenses......................... 215,308 144,535 -- 359,843
Other accrued expenses........................... 51,838 12,054 540,000 (c) 603,892
Accrued interest................................. -- 25,869 (25,869)(c) --
Current portion of long-term debt................ -- 175,692 182,073 (c) 357,765
Note payable-line of credit...................... -- 374,960 (374,960)(a) --
Notes payable-shareholders....................... -- 275,000 (275,000)(a) --
Due to related company........................... -- 4,355 (4,355)(a) --
Total current liabilities............. 713,369 1,648,525 1,098,637 2,403,782
---------- ---------- ------------ ----------
(136,049)(a)
397,927 (c)
LONG-TERM DEBT, net of current portion............... 353,123 41,131 70,000 (c) 726,132
---------- ------ ------------ ----------
DEFERRED TAX LIABILITY............................... 40,958 14,297 1,000,000 (c) 1,056,255
---------- ---------- ------------ ----------
Total liabilities...................... 1,107,450 1,703,953 1,373,766 4,185,169
---------- ---------- ------------ ----------
STOCKHOLDERS' EQUITY:
Common stock..................................... 3,298 8,000 (8,000)(c) 3,298
Paid in capital in excess of par, common stock... 5,341,667 -- -- 5,341,667
(435,084)(b)
359,507 (c)
105,000 (d)
Retained earnings................................ 886,621 (359,507) (155,877)(e) 380,660
---------- --------- ------------ ---------
Total stockholders' equity............ 6,211,586 (351,507) (134,454) 5,725,625
---------- ---------- ------------ ----------
Total liabilities and
stockholders' equity.............. $7,319,036 $1,352,446 $1,239,312 $9,910,794
========== ========== ============ ==========
</TABLE>
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
F-17
<PAGE>
LABORATORY SPECIALISTS OF AMERICA, INC. AND SUBSIDIARY
PRO FORMA CONSOLIDATED STATEMENT OF INCOME
<TABLE>
<CAPTION>
LABORATORY
SPECIALISTS OF
AMERICA, INC. NATIONAL
--------------- PSYCHOPHARMACOLOGY
FOR THE LABORATORY, INC.
YEAR ENDED -------------------
DECEMBER 31, FOR THE YEAR ENDED PRO FORMA PRO FORMA
1995 DECEMBER 31, 1995 ADJUSTMENTS COMBINED
--------------- ------------------- ----------------- ----------
(NOTE 2)
<S> <C> <C> <C> <C>
REVENUES..................................... $6,925,716 $5,497,492 $(3,797,492)(f) $8,625,716
COST OF LABORATORY SERVICES.................. 3,246,470 3,794,781 (2,995,781)(g) 4,045,470
---------- ---------- ------------- ----------
Gross profit............................. 3,679,246 1,702,711 (801,711) 4,580,246
---------- ---------- ------------- ----------
OPERATING EXPENSES:
Selling.................................. 561,470 -- 65,000 (h) 626,470
General and administrative............... 2,157,410 1,780,745 (1,525,745)(i) 3,863,155
(105,000)(d)
Depreciation and amortization............ 232,535 135,178 155,877 (e) 418,590
---------- ---------- ------------- ----------
Total operating expenses............. 2,951,415 1,915,923 (1,409,868) 3,457,470
---------- ---------- ------------- ----------
Income from operations............... 727,831 (213,212) 608,157 1,122,776
---------- ---------- ------------- ----------
OTHER INCOME (EXPENSE):
Interest expense......................... (29,651) (90,763) 50,000 (j) (70,414)
Interest income.......................... 126,939 120 (63,000)(k) 64,059
Other income............................. 323,846 30,000 (30,000)(l) 323,846
---------- ---------- ------------- ----------
Total other income (expense)......... 421,134 (60,643) (34,000) 317,491
---------- ---------- ------------- ----------
Income before income taxes........... 1,148,965 (273,855) 565,157 1,440,267
INCOME TAX EXPENSE (BENEFIT)................. 474,405 (28,371) (130,073)(m) 576,107
---------- ---------- ------------- ----------
Net income........................... 674,560 (245,484) 435,084 864,160
DIVIDENDS ON PREFERRED STOCK................. 13,344 -- -- 13,344
---------- ---------- ------------- ----------
Net income available for
common stockholders.............. $ 661,216 $ (245,484) $ 435,084 $ 850,816
========== ========== ============= ==========
Weighted average number of common shares
outstanding.............................. 3,301,582 3,301,582
========== ==========
Net income per common stock share............ $.20 $.26
========== ==========
</TABLE>
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
F-18
<PAGE>
LABORATORY SPECIALISTS OF AMERICA, INC. AND SUBSIDIARY
NOTES TO PRO FORMA FINANCIAL STATEMENTS
1. BASIS FOR PRESENTATION:
The pro forma balance sheet and statement of income present the pro forma
effects of the acquisition on January 2, 1996, by Laboratory Specialists of
America, Inc. (the "Company") of the issued and outstanding capital stock
(the "NPLI Stock") of National Psychopharmacology Laboratory, Inc., a
Tennessee corporation ("NPLI"), and the purchase of goodwill (the "NPLI
Goodwill") pursuant to a Stock Purchase Agreement (the "Purchase Agreement")
dated January 1, 1996 (the "NPLI Acquisition"). The NPLI Acquisition was
accounted for under the purchase method of accounting, and, as a result of
this acquisition, NPLI became a wholly-owned subsidiary of the Company. NPLI
is engaged in forensic drug testing (urine drug screening with chain of
custody) and clinical testing and analysis.
Pursuant to the Purchase Agreement, (i) the Company agreed to pay $1,513,000
for the NPLI Stock (the "NPLI Stock Purchase Price") of which $800,000 was
paid at closing to the shareholders of NPLI (the "NPLI Shareholders"), two
unsecured promissory notes (the "Promissory Notes"), in the aggregate
principal amount of $638,000, were issued and delivered to the NPLI
shareholders, and NPLI conveyed to the NPLI shareholders (pursuant to a
certain Bill of Sale and Assignment of Leases) an office building and NPLI's
leasehold interest in the real property on which the office building is
located and affixed at an agreed market value of $75,000, and (ii) the
Company agreed to pay $140,000 for the NPLI Goodwill, payable in 24 monthly
installments commencing on February 1, 1996.
The aggregate principal amount of the Promissory Notes is subject to
adjustment (increase or decrease) in the event (i) stockholders' equity of
NPLI (determined in accordance with generally accepted accounting principles
as of September 30, 1995, increases or decreases as reflected on the balance
sheet of NPLI as of December 31, 1995, (the "Net Worth Adjustment") and/or
(ii) revenues from forensic testing (employee urine drug screens that have a
chain of custody) ("Testing Revenues") are greater or less than $1,700,000
during the 12 months ending on January 2, 1997, determined in accordance
with generally accepted accounting principles (the "Testing Revenues
Adjustment"). In the event the aggregate principal amount of the Promissory
Notes is decreased as a result of the Testing Revenues Adjustment, on the
date of such adjustment, the Company will be required to issue and deliver
to the NPLI shareholders, such number of shares of common stock, $.001 par
value per share, of the Company ("Contingent Shares") that have, in the
aggregate, a value equal to the Testing Revenues Adjustment. For purposes of
determining the number of Contingent Shares, the value of each Contingent
Share to be issued and delivered will be equal to average bid and asked
prices for the 30 trading days ending on January 2, 1997, of the Company's
common stock. The Promissory Notes require payment of interest only during
the initial six months and interest and principal during the remaining 30
months of their terms. The Promissory Notes bear interest at the rate of
seven percent per annum on their outstanding principal amounts and require
quarterly payments of interest ($5,582.50 during each of the initial two
quarters), and principal and interest ($35,050.23 during each of the
subsequent 10 quarters) with the final quarterly installment becoming due
and payable on January 2, 1999. Effective January 2, 1996, the aggregate
principal amount of the Promissory Notes was reduced to $510,000 in
accordance with the Net Worth Adjustment.
Furthermore, pursuant to the Purchase Agreement, (i) the Company paid
certain NPLI shareholder loans in the aggregate amount of $275,000, (ii)
entered into a certain First Amendment of Lease Agreement with DJ
Associates, a general partnership of which the NPLI shareholders are the
general partners, and pursuant to which the Company and NPLI leased certain
office and laboratory facilities for a term of six months and agreed to pay
monthly rent of $3,000, and (iii) entered into a certain Registration Rights
Agreement with each of the NPLI shareholders, pursuant to which the Company,
at its expense, agreed to include the Contingent Shares, if issued and
delivered pursuant to the Purchase Agreement, in a registration statement
filed by the Company for the registration of its common stock under the
Securities Act of 1933, as amended, subject to certain conditions.
F-19
<PAGE>
The Company (i) consolidated and assimilated the forensic drug testing
operations of NPLI with those of the Company and (ii) has continued the
clinical testing and analysis operations of NPLI and retained the clinical
personnel to maintain NPLI's market share of clinical testing services.
In connection with the purchase of the NPLI Stock, substantially all of the
purchase price of the NPLI Stock ($1,385,000, as adjusted for the Net Worth
Adjustment) was recorded as intangible assets (goodwill and customer list)
which will be amortized on a straight-line basis over the estimated period
that the Company will be benefitted by the purchase of NPLI and its assets.
The carrying value and recoverability of such intangible assets will be
periodically reviewed by management of the Company. If the facts and
circumstances suggest that such intangible assets may be impaired, the
carrying value of such assets will be adjusted which will result in an
immediate charge against income during the period of adjustment an/or the
length of the remaining amortization period may be shortened which will
result in an increase in the amount of amortization during the period of
adjustment and each period thereafter until fully amortized. Once adjusted,
there can be no assurance that there will not be further adjustments for
impairment and recoverability in future periods of such intangible assets.
Of the various factors to be considered by management of the Company in
determining impairment of such intangible assets, the most significant will
be (i) the loss of all or a portion of the customer base of NPLI, (ii)
losses from operations, (iii) developments within the drug and clinical
testing industry, including the Company's inability to maintain NPLI market
share, development of forensic and clinical testing technologies, imposition
of additional regulatory and certification requirements, and (iv) loss or
suspension for an extended period of laboratory certification. In the event
management of the Company determines that such intangible assets have become
impaired, the adjustments for impairment and recoverability may occur during
a period of operations in which the Company has sustained losses or has only
marginal profitability from operations, and the impairment and/or increased
amortization amount will either increase such losses from operations or
reduce profitability.
The accompanying unaudited pro forma financial statements are presented
assuming the NPLI Acquisition occurred or was consummated as of December 31,
1995, the date of the balance sheet, or on January 1, 1995, the first day of
the year ended December 31, 1995, the period presented. The historical
information presented for the Company as of and for the year ended December
31, 1995, is derived from the audited financial statements of the Company as
of such date and for such period. The historical information presented for
NPLI as of December 31, 1995, is derived from the unaudited financial
statements of NPLI as of such date. The historical information presented for
NPLI for the year ended December 31, 1995, is derived in part from the
audited statement of operations of NPLI for the year ended June 30, 1995,
and from the unaudited statement of operations of NPLI for the six months
ended December 31, 1995. The clinical operations of NPLI have been
eliminated through the adjustments to the pro forma consolidated statement
of income to give effect to discontinuance of the clinical operations during
the year ended December 31, 1995. The Company anticipates recording a loss
of $1.6 to $2.1 million in the fourth quarter of 1996 as a result of the
discontinuance of the clinical operations of NPLI. This loss has not be
reflected in the accompanying pro forma financial statements.
The pro forma financial information presented in the unaudited pro forma
financial statements is not necessarily indicative of the financial position
or results of operations that would have been achieved had the operations
been those of a single consolidated corporate entity. The results of
operations presented in the unaudited pro forma statement of operations are
not necessarily indicative of the consolidated results of future operations
of the Company following consummation of the NPLI Acquisition.
2. ADJUSTMENTS:
The accompanying unaudited pro forma consolidated financial statements have
been adjusted to record and give effect to the NPLI Acquisition as follows:
F-20
<PAGE>
(a) The $1,589,365 reduction in cash and cash equivalents due to the
$800,000 payment of the purchase of the NPLI Stock and the $789,365
reduction of NPLI indebtedness at closing of the NPLI Acquisition;
(b) The $435,084 reduction in cash and cash equivalents to reflect use of
cash and cash equivalents in operations for the year ended December 31,
1995;
(c) The purchase of the NPLI Stock and NPLI Goodwill and reflect the
carrying value of NPLI assets and liabilities as followings:
(i) the $117,000 increase in the allowance for collectability of
accounts receivable;
(ii) the reduction of NPLI property, plant and equipment by $1,542,139
to $50,000 and to give effect to sale of certain real property and
improvements, and elimination of accumulated depreciation of $1,196,272;
(iii) the write-off of computer software and the accumulated
amortization;
(iv) the $25,869 elimination of accrued interest paid at closing of the
NPLI Acquisition;
(v) the $540,000 increase in other accrued liabilities which include
reagent supply, lease buyout, transaction costs, employee severance and
acquitance costs;
(vi) the $182,073 increase in current portion of long-term liabilities
and the increase of $397,927 in long-term liabilities evidenced by the
Promissory Notes and the $70,000 long-term portion of the liability for
payment of the purchase price of the NPLI Goodwill;
(vii) the addition to deferred tax liability of $1,000,000;
(viii) the $8,000 elimination of NPLI common stock; and
(ix) the $359,507 elimination of the deficit retain earnings of NPLI;
(d) The $105,000 reduction in depreciation due to the write-down of the
carrying value of NPLI property, plant and equipment;
(e) The recording of additional goodwill of $1,784,209 and customer list of
$2,000,000 acquired and amortization of such goodwill and customer lists
over 20 and 15 years, respectively, and the amortization of the
additional goodwill and customer list of $155,877;
(f) The reduction of $3,797,492 in NPLI revenues due to the declining
clinical testing revenues and the anticipated loss of forensic revenues
due to the transition and consolidation of NPLI forensic operations with
those of the Company;
(g) The reduction of $2,995,781 in cost of laboratory services attributable
to the reduction in NPLI clinical and forensic revenues;
(h) The increase of $65,000 in selling expenses due to the addition of a
sales representative to maintain the NPLI forensic customer base;
F-21
<PAGE>
(i) The reduction of $1,525,745 in overhead attributable to consolidation
of the NPLI forensic testing operations with those of the Company;
(j) The reduction of $50,000 in interest expense due to the reduction in
NPLI indebtedness paid at closing;
(k) The reduction of $63,000 in interest income due to the reduction in
cash and cash equivalents available for investment;
(l) The elimination of other income of $30,000 representing rental income
from certain real property owned by NPLI and sold to the NPLI
shareholders at closing; and
(m) The increase of $130,073 in income taxes at the effective combined
federal and state statutory rates applicable during the period
presented.
3. GOODWILL AND CUSTOMER LIST:
Goodwill and the customer list acquired in connection with the NPLI Acquisition
will be amortized on a straight-line basis over 20 and 15 years, respectively.
The Company will continually evaluates whether events and circumstances have
occurred that indicate the remaining estimated useful life of goodwill and the
customer list may warrant revision or that the remaining unamortized balance of
goodwill or the customer list may not be recoverable. When factors, such as
operating losses, loss of customers, loss or suspension for an extended period
of laboratory certification, or changes in the forensic drug testing industry,
if present, indicate that goodwill or the customer list should be evaluated for
possible impairment, the Company will use an estimate of the related
undiscounted net income over the remaining life of the goodwill or the customer
list in measuring whether the goodwill and the customer list is recoverable.
Although management believes that goodwill and the customer list will be
recoverable over the respective remaining amortization periods, it is possible,
due to a change in circumstances, that the carrying value of goodwill and the
customer list could become impaired in the future. Such impairment could have a
material effect on the results of operations in a particular reporting period.
4. EARNINGS PER COMMON SHARE:
Pro forma income per common share has been computed based upon the weighted
average number of common shares outstanding during the year ended December 31,
1995. Outstanding warrants are not included in the weighted average shares
outstanding for the period because their effect on earnings per share
calculation is anti-dilutive.
F-22
<PAGE>
INDEX TO EXHIBITS
EXHIBIT
NUMBER EXHIBIT
------- -------
2.1 -Stock Purchase Agreement between Registrant, National
Psychopharmacology Laboratory, Inc., Haroutune K.
Dekirmenjian, PhD. and Kenneth O. Jobson, M.D., dated
January 1, 1996.
2.2 -Registration Rights Agreement between Registrant and
Haroutune K. Dekirmenjian, PhD, dated January 2, 1996.
2.3 -Registration Rights Agreement between Registrant and
Kenneth O. Jobson, M.D., dated January 2, 1996.
23 -Consent of Independent Accountants
<PAGE>
EXHIBIT 2.1
STOCK PURCHASE AGREEMENT
THIS STOCK PURCHASE AGREEMENT (this "Agreement") dated as of and having an
effective date of January 1, 1996, between Laboratory Specialists of America,
Inc., an Oklahoma corporation ("LSAI"), National Psychopharmacology Laboratory,
Inc., a Tennessee corporation ("NPLI"), Haroutune K. Dekirmenjian, PhD., an
individual ("Dekirmenjian") and Kenneth O. Jobson, M.D., an individual
("Jobson"), both Dekirmenjian and Jobson are the owners of all of the issued and
outstanding capital stock of NPLI (Dekirmenjian and Jobson are collectively
referred to as the "NPLI Shareholders").
RECITALS
1. All of the issued and outstanding capital stock of NPLI is owned directly
by the NPLI Shareholders.
2. The NPLI Shareholders desire to sell and LSAI desires to purchase, all of
the issued and outstanding capital stock of NPLI (the "NPLI Stock").
3. Dekirmenjian desires to sell and LSAI desires to purchase certain
goodwill and reputation created and established by Dekirmenjian through the
development of the business enterprise and operations of NPLI (the "Goodwill").
4. The Board of Directors of LSAI has approved and adopted, and through its
duly authorized officers, LSAI has executed, this Agreement, and NPLI
Shareholders have approved and executed this Agreement, pursuant to which LSAI
is to purchase all of the issued and outstanding capital stock of NPLI.
NOW, THEREFORE, in consideration of the premises and of the mutual
representations, warranties, covenants and agreements contained in this
Agreement LSAI and the NPLI Shareholders hereby agree as follows:
ARTICLE I
SALE AND PURCHASE OF STOCK
1.1 Sale and Purchase of Stock and Goodwill. Subject to the terms and
---------------------------------------
conditions of this Agreement and in reliance upon the representations,
warranties, covenants and agreements contained in this Agreement, NPLI
Shareholders hereby agrees to sell and LSAI hereby agrees to purchase, the Stock
and Goodwill, on the Closing Date (as defined in Section 1.10 hereof).
1.2 Purchase Price of NPLI Stock and Goodwill. The purchase price of the
-----------------------------------------
Stock (the "Stock Purchase Price") shall be an amount equal to $1,513,000 and
the purchase price of the Goodwill shall be an amount equal to $140,000 (the
"Goodwill Purchase Price"), which shall be payable as follows:
1.2.1 Payment of Cash Portion of Stock Purchase Price. At Closing (as
-----------------------------------------------
defined in Section 1.10), LSAI shall deliver and pay to Dekirmenjian the sum
of $400,000 and to Jobson the sum of $400,000 in immediately available funds.
1.2.2 Delivery of Promissory Notes. At Closing, LSAI shall make, issue and
----------------------------
deliver to Dekirmenjian a promissory note in the form attached hereto as
Exhibit A-1 (the "Dekirmenjian Promissory Note") in the principal sum of
$319,000 (the "Dekirmenjian Note Principal") and to Jobson a promissory note
in the form attached hereto as Exhibit A-2 (the "Jobson Promissory Note") in
the principal sum of $319,000 (the "Jobson
<PAGE>
Note Principal"). Collectively the Dekirmenjian Promissory Note and the
Jobson Promissory Note are referred to herein as the "Promissory Notes" and
the Dekirmenjian Note Principal and the Jobson Note Principal are sometimes
referred to herein as the "Note Principal"). The Note Principal of each
Promissory Note shall be subject to adjustment as follows:
1.2.2.1 Net Worth Adjustment. In the event stockholders' equity of
--------------------
NPLI, determined in accordance with generally accepted accounting
principles consistent with past practices, as of September 30, 1995,
increases (or decreases) as of the Balance Sheet Date (as defined in
Section 9.11) as reflected on the Final Balance Sheet (as defined in
Section 9.11), the Note Principal of each Promissory Note shall be
increased (or decreased) by 50 percent of the amount of such increase (or
decrease), such adjustment of the Note Principal shall be effective as of
the date of Closing (the "Net Worth Adjustment").
1.2.2.2 Forensic Testing Revenues Adjustment. In the event gross
------------------------------------
revenues (determined in accordance with generally accepted accounting
principles consistent with past practice) from Forensic Testing (as
defined below) drug testing ("Testing Revenues") is greater than or less
than $1,700,000 during the 12 months immediately following Closing ( the
"Anniversary Period") based upon the Final Testing Revenue Accounting (as
defined in Section 9.12), the Note Principal of each Promissory Note shall
be adjusted as follows:
(a) 50 percent of Testing Revenues in excess of $1,700,000 shall
increase the remaining outstanding Note Principal of each Promissory
Note, and LSAI shall make, issue and deliver to each of the respective
NPLI Shareholders (or the holder or holders of the respective
Promissory Notes) a replacement promissory note substantially identical
to each of the respective Promissory Notes reflecting the increase in
the Note Principal of each Promissory Note pursuant to this Section
1.2.2.2(a) and the terms of payment of the increased Note Principal
over the remaining term of each of the respective Promissory Notes; or
(b) 50 percent of the excess of $1,700,000 over Testing Revenues
shall reduce and decrease the remaining outstanding Note Principal of
each Promissory Note, and LSAI shall make, issue and deliver to each of
the respective NPLI Shareholders (or the holder or holders of the
respective Promissory Notes) a replacement promissory note
substantially identical to each of the respective Promissory Notes
reflecting the reduction and decrease in the Note Principal of each
Promissory Note pursuant to this Section 1.2.2.2(b) and the terms of
payment of the reduced and decreased Note Principal over the remaining
term of each of respective the Promissory Notes. Provided, further,
subject to Section 9.5, LSAI shall on the date of the adjustment of the
Note Principal of each of the respective Promissory Notes pursuant to
this Section 1.2.2.2(b), issue and deliver to each of the NPLI
Shareholders (or holder or holders of the Promissory Note) such number
of shares of fully paid and non-assessable Common Stock of LSAI
("Contingent Shares") that in the aggregate have an Agreed Value (as
defined below) equal to the amount of the reduction and decrease in the
Note Principal of each Promissory Note pursuant to this Section
1.2.2.2(b). The Contingent Shares shall be issued by LSAI pursuant to
registration exemptions under the Securities Act of 1933, as amended
(the "Securities Act"), and any applicable state securities laws. For
purposes hereof, (i) "Agreed Value" shall mean the average Closing
Price (as defined below) of LSAI's Common Stock during each of the last
30 Trading Days (as defined below) of the Anniversary Period, (ii)
"Closing Price" shall mean a day that the closing bid and asked prices
of LSAI's Common Stock are reported by NASDAQ for a trading day, and
(iii) "Trading Day" shall mean a day that the closing bid and asked
prices of LSAI's Common Stock are reported on NASDAQ.
2
<PAGE>
For purposes hereof, "Forensic Testing" shall mean NIDA and non-NIDA
employee urine drug screens that have a chain of custody. For purposes of
determining Testing Revenues, any and all gross revenues from clinical
testing and analysis shall not be included.
1.2.3 Assignment and Transfer of Real Property and Leases. At Closing and
---------------------------------------------------
in partial payment of the Stock Purchase Price, NPLI shall execute and
deliver to DJ Associates, a general partnership of which the NPLI
Shareholders are the general partners, that certain Bill of Sale and
Assignment of Leases, attached hereto as Exhibit B, that assigns, transfers
and conveys unto DJ Associates all of NPLI's right, title and interest in and
to (i) that certain office building and the real property on which the office
building is located and affixed located at 9405 Park West Boulevard,
Knoxville, Tennessee, as more specifically described therein and (ii) those
certain leases as more specifically identified and described therein (the
"Office Building and Leases"). The NPLI Shareholders and LSAI hereby agree
that the market value of the Office Building and Leases is $75,000.
1.2.4 Payment of Goodwill Purchase Price. The Goodwill Purchase Price shall
----------------------------------
be payable by LSAI to Dekirmenjian in 24 monthly installments consisting of
23 installments of $5,833.33 payable on the first day of each month
commencing on February 1, 1996, and a final monthly payment of $5,833.41 on
January 1, 1998.
1.3 Payment of Shareholder Loans. At Closing, LSAI shall pay in full, in
----------------------------
immediately available funds, those certain loans made by the NPLI Shareholders
to NPLI in the aggregate principal amount of $275,000 (the "Shareholder Loans"),
and upon receipt of such payment, the promissory notes evidencing the
Shareholder Loans shall be marked and notated "Paid in Full" at Closing.
1.4 Amendment to Lease of Laboratory Facility. At Closing, LSAI and
-----------------------------------------
Dekirmenjian and Jobson in their capacities as general partners, and for and on
behalf, of DJ Associates shall execute that certain First Amendment of Lease
Agreement attached hereto as Exhibit C.
1.5 Registration Rights Agreement. At Closing, LSAI and each of the NPLI
-----------------------------
Shareholders shall execute that certain Registration Rights Agreement attached
hereto as Exhibit D-1 or Exhibit D-2, as the case may be.
1.6 Employment Severance. LSAI hereby agrees to loan NPLI, on such terms as
--------------------
LSAI shall determine in its sole and absolute discretion, any and all amounts
required for the payment and funding of all severance compensation payments to
the employees of NPLI, other than each of the NPLI Shareholders in their
respective capacities as employees of NPLI.
1.7 Deliveries and Exchanges. LSAI and the NPLI Shareholders shall, pursuant
------------------------
to this Agreement, make the deliveries and payments as follows:
1.7.1 LSAI Deliveries. LSAI shall make the following payments and
---------------
deliveries:
1.7.1.1 Cash Payments and Promissory Notes. At Closing, LSAI shall
----------------------------------
deliver to the NPLI Shareholders the payments, in immediately available
funds, required pursuant to Section 1.2.1 and the Promissory Notes required
pursuant to Section 1.2.2.
1.7.1.2 Payment of Shareholder Loans. At Closing, LSAI shall pay
----------------------------
$275,000 representing the aggregate outstanding principal amount, in
immediately available funds, of that (i) certain loan made by Dekirmenjian
to NPLI (the "Dekirmenjian Loan") in the outstanding principal amount of
$175,000, against delivery of the promissory note evidencing the
Dekirmenjian Loan, marked and notated "Paid in
3
<PAGE>
Full" and (ii) certain loan made by Jobson to NPLI (the "Jobson Loan") in
the outstanding principal amount of $100,000, against delivery of the
promissory note evidencing the Jobson Loan, marked and notated "Paid in
Full."
1.7.1.3 First Amendment of Lease Agreement. At Closing, LSAI shall
----------------------------------
execute and deliver to Dekirmenjian and Jobson in their capacities as the
general partners of DJ Associates that certain Lease Agreement attached
hereto as Exhibit C .
1.7.1.4 Registration Rights Agreements. At Closing, LSAI shall execute
------------------------------
and deliver that certain Registration Rights Agreement to each of the NPLI
Shareholders attached hereto as Exhibit D-1 or Exhibit D-2, as the case may
be.
1.7.1.5 Contingent Shares. At such time that the Note Principal of each
-----------------
of the Promissory Notes shall be reduced pursuant to Section 1.2.2.2(b),
subject to Section 9.5, LSAI shall issue and delivery to the respective
NPLI Shareholders (or holder or holders of the each of the Promissory
Notes) the Contingent Shares.
1.7.1.6 Replacement Promissory Notes. At such time that the Note
----------------------------
Principal of each of the Promissory Notes shall be adjusted pursuant to
either or both of Sections 1.2.2.1 and 1.2.2.2, LSAI shall issue and
deliver to the respective NPLI Shareholders (or the holder or holders of
each of the Promissory Notes) a promissory note in replacement of the
Promissory Note as required pursuant to Section 1.2.2.1 and Section 1.2.2.2
("Replacement Note") in exchange for the Promissory Note.
1.7.1.7 Release of First American National Bank Loan Guaranties. At
-------------------------------------------------------
Closing, LSAI shall deliver the NPLI Shareholders written evidence
reasonably satisfactory to the NPLI Shareholders of the release and
cancellation of guaranties by the NPLI Shareholders and their respective
spouses of NPLI's indebtedness to First American National Bank under that
certain Loan Agreement made as of December 24, 1994, and as amended
pursuant to that certain Amendment to Loan Agreement dated November 20,
1995.
1.7.2 NPLI Shareholder Deliveries. At Closing (as defined in Section 1.10),
---------------------------
NPLI Shareholders shall make the following deliveries:
1.7.2.1 NPLI Stock. NPLI Shareholders shall deliver to LSAI all of the
----------
outstanding shares of the capital stock of NPLI (free and clear of any
lien, charge, claim, pledge, security interest or other encumbrance of any
type or kind whatsoever) against payment and delivery of the Stock Purchase
Price of the NPLI Stock. The transfer of the shares of NPLI Stock shall be
effected by the delivery to LSAI of certificates representing the
transferred shares endorsed in blank or accompanied by stock powers
executed in blank and with all necessary transfer tax and other revenue
stamps, acquired at the expense of NPLI Shareholders, affixed.
1.7.2.2 Dekirmenjian and Jobson Promissory Notes. At Closing, (i)
----------------------------------------
Dekirmenjian shall delivery to LSAI the promissory note evidencing the
Dekirmenjian Loan, marked and notated "Paid in Full," against payment of
the outstanding principal amount thereof by LSAI pursuant to Section
1.7.1.2 and (ii) Jobson shall delivery to LSAI the promissory note
evidencing the Jobson Loan, marked and notated "Paid in Full," against
payment of the outstanding principal amount thereof by LSAI pursuant to
Section 1.7.1.2.
4
<PAGE>
1.7.2.3 Bill of Sale and Assignment of Leases Agreement. At Closing,
-----------------------------------------------
the NPLI Shareholders shall execute and delivery to the NPLI that certain
Bill of Sale and Assignment of Leases Agreement attached hereto as Exhibit
B.
1.7.2.4 First Amendment of Lease Agreement. At Closing, the NPLI
----------------------------------
Shareholders, in their capacities as general partners of DJ Associates,
shall execute and deliver to LSAI that certain First Amendment of Lease
Agreement attached hereto as Exhibit C.
1.7.2.5 Registration Rights Agreements. At Closing, each of the NPLI
------------------------------
Shareholders shall execute and deliver the Registration Rights Agreement to
LSAI attached hereto as Exhibit D-1 or Exhibit D-2, as the case may be.
1.7.3 NPLI Deliveries. At Closing (as defined in Section 1.10), the NPLI
---------------
Shareholders shall make the following delivery:
1.7.3.1 Bill of Sale and Assignment of Leases Agreement. At Closing,
-----------------------------------------------
NPLI shall execute and delivery to Dekirmenjian and Jobson in their
capacities as the general partners of DJ Associates that certain Bill of
Sale and Assignment of Leases Agreement attached hereto as Exhibit B.
1.7.3.2 Assignment of Life Insurance Policy. At Closing, NPLI shall
-----------------------------------
assign and transfer the ownership of (i) those certain policies of
insurance insuring the life of Jobson issued by First Colony Life Insurance
Company (policy number 1832286) and U.S.A.A. Life Insurance Company (policy
number 1128513-60-04) to Jobson and (ii) those certain policies of
insurance insuring the life of Dekirmenjian issued by Old Republic
Insurance Company (policy number 542904) and U.S.A.A. Life Insurance
Company (policy number 1859426-60-01) to Dekirmenjian.
1.10 The Closing and Closing Date. Subject to the terms and conditions of
----------------------------
this Agreement, the transactions contemplated under this Agreement shall be
closed (the "Closing") at the offices of Bass, Berry & Sims, Knoxville,
Tennessee, on the Closing Date, or at such other place and time as the parties
hereto shall agree. The date on which the transactions contemplated in this
Agreement shall be closed (the "Closing Date") shall occur on January 2, 1996,
or such other date as mutually agreed by LSAI and the NPLI Shareholders.
ARTICLE II
REPRESENTATIONS AND WARRANTIES OF NPLI SHAREHOLDERS
NPLI and NPLI Shareholders represent and warrant unto LSAI as follows:
2.1 Organization, Good Standing, Power, Etc. NPLI is a corporation duly
----------------------------------------
organized, validly existing and in good standing under the laws of the State of
Tennessee and has the corporate power and is entitled to own or lease its
properties and to carry on its business as, and in the places where, such
properties are now owned or leased and such business is now conducted. NPLI is
duly qualified to do business and is in good standing as a foreign corporation
in the state of Florida which, to the actual acknowledge of the NPLI
Shareholders, is the only other jurisdiction in which the ownership, operation
or leasing of its properties or assets or the nature of its business requires
such qualification as a foreign corporation or the failure to qualify to do
business and obtain good standing as a foreign corporation in any other state
would have any adverse material effect upon NPLI.
5
<PAGE>
2.2 Delivery of Corporate Charter and Bylaws. NPLI Shareholders have
----------------------------------------
delivered to LSAI complete and correct copies of the Charter of NPLI and the
Bylaws of NPLI as in effect on the date hereof.
2.3 Capitalization. The authorized capital stock of NPLI consists of (i)
--------------
2,000 shares of common stock, no par value (the NPLI Common Stock"), of which
200 shares are issued and outstanding, fully paid and non-assessable (the"NPLI
Stock"). NPLI Shareholders represents that (i) they own all of the issued and
outstanding shares of the NPLI Stock and (ii) there are no outstanding
subscriptions, options, warrants or other agreements or commitments obligating
NPLI Shareholders to transfer, deliver, assign, pledge, encumber or reissued the
NPLI Stock to any person, or any option, right or interest, beneficial or
otherwise, in the NPLI Stock. NPLI has no treasury stock. As of the date of
this Agreement and immediately prior to the Closing, there are no and will not
be any (i) other authorized or outstanding equity securities of NPLI of any
class, kind or character and (ii) outstanding subscriptions, options, warrants
or other agreements or commitments obligating NPLI to issue any additional
shares of its capital stock of any class, or any option or right with respect
thereto, or any securities convertible into shares of stock of any class of
NPLI. All shares of NPLI Stock that are outstanding at the date of this
Agreement, and will be outstanding immediately prior to the Closing, are or will
be duly and validly authorized and issued, fully paid and non-assessable, and
are not or will not be subject to or issued in violation of any preemptive right
of any shareholder.
2.4 Equity Interest. Except as set forth on Schedule 2.4, NPLI does not own
---------------
any stock or other equity or ownership interest (controlling or otherwise) in
any corporation, association, partnership, tax partnership, joint venture or
other entity.
2.5 Ownership of NPLI Stock. NPLI Shareholders represent that they are, and
-----------------------
on the date of this Agreement and at Closing will be, the lawful owner of all of
the issued and outstanding shares of the NPLI Stock, and such shares are and
will be Closing, free and clear of all liens, claims, encumbrances and
restrictions of every kind, and NPLI Shareholders have full legal right, power
and authority to sell, assign and transfer the NPLI Stock; and the delivery of
such shares pursuant to the provisions of this Agreement will transfer valid
title thereto, free and clear of all liens, encumbrances, claims, and
restrictions of every kind. From the date of this Agreement through the
Closing, (i) NPLI Shareholders shall not transfer, assign, encumber, pledge, or
grant any person an interest in each outstanding share of the NPLI Stock, (ii)
each outstanding share of the capital stock of NPLI shall remain unchanged and
shall be an outstanding, fully paid and non-assessable share at the Closing, and
(iii) the certificate or certificates evidencing ownership of the NPLI Stock
(representing all of the outstanding capital stock of NPLI) by NPLI Shareholders
shall continue to evidence ownership of all of the issued and outstanding
capital stock of NPLI.
2.6 Authorization of Agreement. NPLI has all requisite corporate power and
--------------------------
authority to enter into and perform all of its obligations under this Agreement.
The execution and delivery of this Agreement by NPLI and consummation by NPLI of
the transactions contemplated hereby have been duly authorized by all necessary
corporate action on the part of NPLI. This Agreement has been duly executed and
delivered by NPLI and constitutes the legal, valid and binding obligation of
NPLI, enforceable against NPLI in accordance with its terms, except as
enforceability may be limited by (a) any applicable bankruptcy, insolvency,
reorganization or other law relating to or affecting creditors' rights
generally, and (b) general principles of equity (regardless of whether such
enforceability is considered in a proceeding in equity or at law. NPLI
Shareholders represents that they have approved this Agreement and the
transactions contemplated hereby as evidenced by their execution of this
Agreement. NPLI Shareholders represent that they have full power, authority and
legal right to enter into this Agreement and to consummate the transactions
contemplated hereby.
2.7 No Conflicting Agreements. Neither the execution nor the delivery of
-------------------------
this Agreement, nor the consummation of the transactions as contemplated in this
Agreement in accordance with the terms of this
6
<PAGE>
Agreement, will conflict with, or result in a breach of, any term of, or
constitute a default under, (i) the Charter or Bylaws of NPLI, or (ii) to the
actual acknowledge of the NPLI Shareholders, any material agreement or
instrument to which NPLI is a party, or (iii) to the actual acknowledge of the
NPLI Shareholders, any material judgment, decree, order, statute, rule or
regulation to which NPLI is subject. Each of the NPLI Shareholders represents
that, to the actual acknowledge of the NPLI Shareholders, neither the execution
nor the delivery of this Agreement, nor the consummation of the transactions as
contemplated in this Agreement in accordance with the terms of this Agreement,
will conflict with, or result in a breach of, any term of, or constitute a
default under (i) any material agreement or instrument to which either of the
NPLI Shareholders is a party, (ii) any material judgment, decree, order,
statute, rule or regulation to which either of the NPLI Shareholders is subject,
or (iii) result in the creation of material lien, charge or encumbrance on the
shares of the NPLI Stock held by either of the NPLI Shareholders. To the actual
acknowledge of the NPLI Shareholders, NPLI is not and NPLI Shareholders are not
in default or would be in default with lapse of time or notice or both, in
respect to any such term.
2.8 Financial Statements. NPLI Shareholders have furnished to LSAI the
--------------------
following financial statements (hereinafter collectively called the "NPLI
Financial Statements"): (i) the balance sheet of NPLI as of June 30, 1995
,together with statement of income and retained deficit, and statement of cash
flows of NPLI for the fiscal year then ended and the notes thereto, all examined
and reported upon, without qualification, by HG&A Associates, P.C., NPLI's
independent public accountants; (ii) the unaudited balance sheet of NPLI as of
September 30, 1995 (the "NPLI September Balance Sheet"), together with
statements of operations and statements of cash flows for the three months then
ended, in conformity with generally accepted accounting principles applied on a
consistent basis as of the date thereof and throughout the period specified
therein and (iii) the unaudited balance sheet of NPLI as of October 31, 1995
(the "1995 NPLI Balance Sheet"), together with statements of operations and
statements of cash flows for the four months then ended, to the actual
knowledge of the NPLI Shareholders in conformity with generally accepted
accounting principles applied on a consistent basis as of the date thereof and
throughout the period specified therein.
2.9 Absence of Undisclosed Liabilities. To the actual knowledge of the NPLI
----------------------------------
Shareholders, all obligations and liabilities, contingent or otherwise, of NPLI
arising from events that occurred on or before the date of the 1995 NPLI Balance
Sheet, whether or not required to be accrued or reserved, have been fully
accrued or reserved in the 1994 NPLI Balance Sheet in accordance with and to the
extent required by generally accepted accounting principles. NPLI has not
incurred any such obligation or liability, contingent or otherwise, subsequent
to the date of the 1995 NPLI Balance Sheet, except for obligations and
liabilities incurred in the ordinary course of business. The reserves reflected
in the 1995 NPLI Balance Sheet are adequate, appropriate and reasonable.
2.10 Absence of Certain Events. Except as set forth on Schedule 2.10, since
-------------------------
September 30, 1995, and in the case of clause (iii) below, except for current
transactions in the ordinary course of business consistent with past practices
of NPLI, the NPLI Shareholders represent that NPLI has not (i) issued, delivered
or agreed to issue or deliver any stock, bonds or other corporate securities of
NPLI, whether authorized and unissued or held in the treasury, or granted or
agreed to grant any subscriptions, options, warrants, rights or other agreements
or commitments obligating NPLI to issue additional shares of it capital stock or
any securities convertible into or having the right to purchase shares of its
capital stock; (ii) borrowed or agreed to borrow any funds or to the actual
knowledge of the NPLI Shareholders incurred, or become subject to, any
obligation or liability (absolute or contingent), except obligations and
liabilities incurred in the ordinary course of business; (iii) paid any material
obligation or liability (absolute or contingent), other than current liabilities
reflected in or shown on the NPLI September Balance Sheet, and current
liabilities incurred since the date of the NPLI September Balance Sheet in the
ordinary course of business; (iv) declared or made, or agreed to declare or
make, any payment of dividends or distributions of any kind whatsoever to the
NPLI Shareholders or purchased or redeemed any shares of its capital stock; (v)
sold, transferred or otherwise disposed of, or agreed to sell, transfer or
otherwise dispose of,
7
<PAGE>
any material assets; (vi) canceled, or agreed to cancel, any material debts or
claims; (vii) entered or agreed to enter into any agreement or arrangement
granting any preferential rights to purchase any of its material assets,
properties or rights or requiring the consent of any party to the transfer and
assignment of any such assets, properties or rights; (viii) to the actual
knowledge of the NPLI Shareholders, suffered any losses or waived any rights of
value which in the aggregate are material; (ix) made or permitted any amendment
or termination of any contract, agreement or license to which it is a party, if
such amendment or termination is material to include, without limitation, any
material amendment, or a termination of any material contract, lease,
arrangement, license or other instrument including, without limitation, any
bonus, deferred compensation, savings, insurance or other employee benefit plan,
e.g. any qualified pension and/or profit sharing plans; (x) directly or
indirectly paid to or made a commitment to pay an severance or termination
payment to any officer or executive employee other than in the ordinary course
of business; (xi) made any material change in its method of accounting; (xii)
made any capital expenditures or entered into commitments therefor; (xiii) made
any material investment or commitment therefor in any person, corporation,
association, partnership, joint venture or other entity; (xiv) made any accrual
or arrangement for or payment of bonuses or special compensation of any kind to
any of its present or former officers, or to any employee, or made any increase
in any compensation, bonus, deferred compensation, savings, insurance or other
employee benefit plan, payment or arrangement made to, for or with any such
director, executive officer or employee; (xv) suffered any change in its
executive officers or directors; (xvi) discharged or satisfied any lien or
encumbrance or paid any obligation or liability (fixed or contingent), other
than accruals and accounts payable reflected on the NPLI September Balance Sheet
and accruals and accounts payable incurred since the date of the NPLI September
Balance Sheet in the ordinary course of business; (xvii) amended its Charter or
Bylaws; (xviii) made any capital expenditures or entered into any commitments
therefor; (xix) to the actual knowledge of the NPLI Shareholders, experienced or
suffered any material adverse change in its business, assets, condition,
financial or otherwise (including, without limitation, changes in value of
investments), or results of operation; (xx) entered into any employment
agreements with its officers or employees; or (xxi) to the actual knowledge of
the NPLI Shareholders made any material change in its business or operations, or
entered into any other material transaction except in the ordinary course of
business consistent with past practices of NPLI. Between the date hereof and
the Closing, the NPLI Shareholders shall use commercially reasonable efforts to
cause NPLI to not, without the prior written consent of LSAI, to do any of the
things listed in this Section 2.10.
2.11 Title to Properties; Absence of Liens and Encumbrances. To the actual
------------------------------------------------------
knowledge of the NPLI Shareholders, NPLI has good and marketable title to the
properties and assets reflected on the NPLI September Balance Sheet as being
owned by NPLI, and all properties and assets thereafter acquired by it, except
to the extent such properties and assets are or were thereafter disposed of for
fair value in the ordinary course of business; all such properties and assets
are free and clear of all liens, charges and encumbrances, except (i) those set
forth or reflected in the NPLI September Balance Sheet, (ii) liens for taxes not
yet due and payable or that are being contested in good faith, or (iii) defects
in title and liens, charges and encumbrances, if any, that do not materially
detract from the value, or materially interfere with the present or proposed
use, of the property or assets subject thereof or affected thereby, or otherwise
materially impair business operations of NPLI, taken as a whole. To the actual
knowledge of the NPLI Shareholders, the operation of the properties and business
of NPLI in the manner in which they are now operated do not violate any zoning
ordinances or municipal regulations in such a way as could, if such ordinances
or regulations were enforced, result in any material impairment of the uses of
the respective properties for the purposes for which they are now operated. To
the actual knowledge of the NPLI Shareholders, all real and personal property
leased by NPLI is held by NPLI under valid, subsisting and enforceable leases.
2.12 Tax Matters. Except as set forth on Schedule 2.12, (i) NPLI has timely
-----------
filed all federal, state, local and foreign tax returns required to be filed by
it, (ii) all taxes, assessments, fees, and other governmental charges levied or
assessed against the property or the business of NPLI have been paid in full,
other than taxes or charges,
8
<PAGE>
the payment of which is not yet due or which, if due, is not yet delinquent or
is being contested in good faith or has not been finally determined, and (iii)
the amounts set up as accruals for taxes on the NPLI September Balance Sheet and
1995 NPLI Balance Sheet are sufficient in all material respects for the payment
of all unpaid taxes and governmental charges of all kinds, applicable to the
property or business of NPLI for the three months ended September 30, 1995, and
for the four months ended October 31, 1995, respectively, and all periods prior
thereto, (iv) no assessment, deficiency or adjustment has been asserted or
proposed with respect to any tax return of or with respect to NPLI, except for
any assessment against NPLI for which adequate provision in accordance with
generally accepted accounting principles has been made as set forth on Schedule
2.12, and (v) there is not in force any extension of time with respect to the
due date of any tax return or the assessment or payment of tax.
2.13 Compliance with Laws. To the actual knowledge of the NPLI
--------------------
Shareholders, NPLI has complied with all laws, regulations, licensing
requirements and orders applicable to its business the breach or violation of
which could have a material adverse effect on said business and has filed with
the proper authorities, all statements and reports required by the laws,
regulations, licensing requirements and orders to which it or any of its
employees (because of such employee's activities on behalf of NPLI) is subject,
and, to the actual knowledge of the NPLI Shareholders, NPLI possesses all
necessary licenses, franchises and permits to conduct its business in the manner
in which and in the jurisdictions and places where such businesses are now
conducted.
2.14 Litigation. Except as set forth on Schedule 2.14, to the actual
----------
knowledge of the NPLI Shareholders (i) there are no actions, suits, proceedings
or investigations pending or, threatened, against or affecting NPLI or any
property or rights of NPLI at law or in equity or before or by any federal,
state, municipal, or other governmental department, commission, board, bureau,
agency, or instrumentality, domestic or foreign, (ii) there are no actions or
proceedings at law or in equity pending, threatened against or affecting NPLI
before or by any federal, state, municipal, or other governmental department,
commission, board, bureau, agency, or instrumentality, domestic or foreign, that
involve any claim not fully covered by insurance or provided for by adequate
reserves established in the NPLI September Balance Sheet and the 1995 NPLI
Balance Sheet, nor any basis for same, (iii) there is no action, suit or
proceeding that will result in any material adverse change in the business,
operations, properties or assets, or in the condition, financial or otherwise,
of NPLI, and (iv) NPLI is not in default with respect to any order, writ,
injunction, judgment or decree of any court or federal, state, municipal or
other governmental department, commission, board, bureau, agency or
instrumentality, domestic or foreign or of any arbitrator.
2.15 Contracts. Except as set forth on Schedule 2.15, to the actual
---------
knowledge of the NPLI Shareholders, NPLI is not a party to or is its property
bound or affected by or receives benefits under any written or oral, express or
implied, (i) contract for the employment of any officer or employee which is not
terminable on 30 days (or less) notice without payment of any amount on account
of such termination, (ii) bonus, deferred compensation, savings, stock option,
retirement, pension, profit-sharing or severance pay agreement, plan or
arrangement, (iii) agreement, contract or indenture relating to the borrowing of
money by NPLI, (iv) guaranty of any obligation for the borrowing of money or
otherwise, excluding endorsements made for collection and guaranties made in the
ordinary course of business, (v) management, consulting or other similar
contract or arrangement, (vi) collective bargaining agreement, (vii) agreement
with any current or former officer, director or shareholder of NPLI, (viii)
material licenses, whether as licensor or licensee, (ix) material contract or
commitment for the purchase of materials or supplies or for the performance of
services over a period of over 60 days, (x) contract, agreement or other
commitment not made in the ordinary course of business, (xi) contingent
liabilities, including letter of credit of all types, (xii) contract to purchase
or sell securities of all types, (xiii) contract or commitment for capital
expenditures in excess of $5,000, (xiv) contract or option to purchase or sell
any real property or any material personal property, other than in the ordinary
course of business, (xv) other contract, agreement or commitment which is
material to the business, operations, properties or assets or to the condition,
financial or otherwise, of NPLI, or (xvi) contract or other arrangement which is
not in the ordinary
9
<PAGE>
course of business consistent with the past practice of NPLI, or in which a
material interest is held by any person or entity which is an Affiliate of NPLI
which is not substantially on the same terms (including without limitation, in
the case of lending transactions, interest rates and collateral) as those
prevailing at the time of comparable transactions with unrelated parties or
which involves more than the normal risk of collectibility or which involves
more than the normal risk of collectibility or which involves other unfavorable
features. For purposes of this Agreement, "Affiliate" when used with respect to
NPLI and the NPLI Shareholders shall refer to and mean any "affiliate" within
the meaning of Rule 145 of the Securities and Exchange Commission (the
"Commission") under the Securities Act, any officer or director of NPLI or of
any "affiliate" of NPLI or any "associate" of any such officer or director as
that term is defined in Rule 14a-1 of the General Rules and Regulations under
the Securities Exchange Act of 1934, as amended (the "Exchange Act").
Between the date hereof and the Closing, NPLI, without the prior written
consent of LSAI, shall not allow or permit to enter into, amend, extend or renew
any agreement, contract or plan specified above in this Section 2.15.
2.16 Defaults. Except as set forth on Schedule 2.16, to the actual
--------
knowledge of the NPLI Shareholders, NPLI is not in default in any material
respect under any of the contracts, leases, or other instruments, to which NPLI
is a party or by which NPLI or its property may be bound or affected or under
which NPLI or its property receives benefits, and with respect to such
contracts, lease or other instruments, (i) there has not occurred any event
which with the lapse of time or giving of notice or both would constitute such
default to NPLI, (ii) such contracts, leases or other instruments are binding
obligations of the respective parties thereto in accordance with their terms,
(iii) there are no defenses, offsets or counterclaims thereto which may be made
by any party thereto other than NPLI, and (iv) NPLI has not waived any
substantial rights thereunder.
2.17 Employee Matters. (a) Employee Welfare Benefit Plans. Except as set
---------------- ------------------------------
forth on Schedule 2.17, to the actual knowledge of the NPLI Shareholders (i)
NPLI is not, and has not ever been, a party to or subject to any "employee
welfare benefit plan" (as defined in Section 3(1) of the Employee Retirement
Income Security Act of 1974, as amended ("ERISA")) to which NPLI contributes, is
required to contribute or has contributed, (ii) NPLI is not and has never been a
party to or subject to any "employee pension benefit plan" (as defined in
Section 3(2) of ERISA) to which NPLI contributes, is required to contribute or
has contributed. To the actual knowledge of the NPLI Shareholders, all employee
welfare benefit plans and employee pension benefit plans of NPLI ("NPLI Employee
Welfare Benefit Plans") and any related trust agreements and any other documents
relating to the funding of NPLI Employee Welfare Benefit Plans (i) in all
material respects comply and have complied in the past, with the provisions of
ERISA, the Code, and any predecessor to the Code and any other applicable laws,
rules and regulations, (ii) have been administered consistent with and in
compliance in all material respect with applicable requirements of the Code,
ERISA and any other applicable law, including without limitation compliance on a
timely basis with all requirements for reporting and disclosure concerning each
of the NPLI Employee Welfare Benefit Plans. To the actual knowledge of the NPLI
Shareholders, neither NPLI nor any plan fiduciary of any NPLI Employee Welfare
Benefit Plan has (i) engaged in any transaction or acted or failed to act in a
manner which violates Section 404 or 406 of ERISA for which there exits neither
a statutory nor regulatory exemption and which results in material liability, or
(ii) has acted or failed to act in any manner which violates Section 404 of
ERISA and results in material liability.
(b) Other Employee Benefit Arrangements. To the actual knowledge of the
-----------------------------------
NPLI Shareholders, NPLI has delivered to LSAI true and correct copies of each
NPLI Employee Welfare Benefit Plan and each and every other personnel policy,
stock option plan, employment, bonus, incentive award, vacation pay, severance
pay, consulting and employment agreement and any other employee or fringe
benefit plan, agreement, arrangement, practice or understanding, whether formal
or informal, which NPLI maintains or to or under which NPLI contributes or is
required to contribute.
10
<PAGE>
(c) Claims and Litigation. To the actual knowledge of the NPLI
---------------------
Shareholders, (i) there are no threatened or pending claims, suits or other
proceedings by any of NPLI's employees, former employees, plan participants,
beneficiaries or spouses of any of the above involving any employee benefit plan
or arrangement described in this Section 2.17 or any rights or benefits under
any such employee benefit plan or arrangement other than ordinary and usual
claims for benefits by participants or beneficiaries; (ii) neither NPLI nor any
of its directors, officers, employees or any other "fiduciary" (as such term is
defined in Section 3(21) of ERISA) has any liability for an act or for a failure
to act in connection with either administration or investment of assets of such
plans or the transactions contemplated by this Agreement; and (iii) there is no
pending or threatened legal action or proceeding or investigation against or
involving any employee benefit plan or arrangement described in this Section
2.17 and there is no basis for any such legal action, proceeding or
investigation.
(d) Union Contracts. NPLI is not or has never been a party to or subject to
---------------
any agreement with any union or collective bargaining unit. To the actual
knowledge of the NPLI Shareholders, there is no pending union activity involving
NPLI employees.
2.18 Contractual Commitments. To the actual knowledge of the NPLI
-----------------------
Shareholders, Schedule 2.18 contains a list of all agreements, contracts,
guarantees and commitments, together with all amendment thereto, to which NPLI
is a party or by which any of its properties or assets are bound and which
involve in each case aggregate future payments, potential or otherwise, in
excess of $5,000 or are otherwise material. To the actual knowledge of the NPLI
Shareholders, true and correct copies of all such written agreements, contracts,
guarantees and commitments have been provided to LSAI. To the actual knowledge
of the NPLI Shareholders, NPLI and the other parties to such agreements,
contracts, guarantees and commitments have performed all obligations required to
be performed by them to the date of this Agreement and are not in default
thereunder in any material respect.
2.19 Insurance. Schedule 2.19 contains a list of all insurance coverage
---------
carried by NPLI. True and correct copies of all policies relating to insurance
carried by NPLI have been delivered to LSAI. To the actual knowledge of the
NPLI Shareholders, all such insurance policies are in full force and effect, all
premiums due thereon have been paid, and no notice of cancellation or
termination has been received with respect to any such policy. To the actual
knowledge of the NPLI Shareholders, NPLI has complied with the provisions of all
such policies.
2.20 Finder's Fees. Except as set forth on Schedule 2.20, no director,
-------------
officer or employee of NPLI has incurred or will incur any brokerage, finder's
or similar fee in connection with the transactions contemplated by this
Agreement.
2.21 Ordinary Course of Business. The term "ordinary course of business,"
---------------------------
as used in this Agreement shall be construed to mean the conduct of business
consistent with good corporate practices and policies.
2.22 Patents, Trademarks, Etc. NPLI owns or holds licenses under such
-------------------------
patents, trademarks, trade names and copyrights as it deems necessary for the
conduct of its business as being conducted on the date of this Agreement as set
forth on Schedule 2.22, and, to the actual knowledge of the NPLI Shareholders,
the NPLI Shareholders and NPLI are not, as of the date of this Agreement, in
receipt of any notice of infringement or notice of conflict with the asserted
rights of others in such patents, trademarks, trade names and copyrights and are
not otherwise aware of such infringement or conflict, or of any infringement by,
or conflict on the part of, others of NPLI's patents, trademarks, trade names or
copyrights.
2.23 Full Disclosure. To the actual knowledge of the NPLI Shareholders, (i)
---------------
all written information regarding NPLI previously delivered to LSAI, including
all financial information and statements provided to LSAI, is true and correct,
(ii) all additional information regarding NPLI delivered to LSAI pursuant to
this
11
<PAGE>
Agreement is or will be true and correct, and (iii) other than the properties
shown on the NPLI September Balance Sheet, NPLI Financial Statements and 1995
NPLI Balance Sheet, and previously disclosed to LSAI pursuant to this Agreement,
there are no properties, tangible or intangible, which are used in and material
to the normal day-to-day operations of NPLI as conducted by NPLI prior to the
date of this Agreement.
2.24 Investment Intent. NPLI Shareholders represents to LSAI and its
-----------------
officers and directors that the LSAI Common Stock that may be issued to NPLI
Shareholders pursuant to Sections 1.2.2.2(b), if applicable, at the time of
issuance, will be acquired by the NPLI Shareholders (or the holder or holders of
the Promissory Note) for investment purposes only without the intent to resell
such stock and will not be transferred except pursuant to registration under the
Securities Act and the applicable state securities acts unless pursuant to
exemption from registration under such acts. The NPLI Shareholders hereby
acknowledges that the LSAI Common Stock that may be issued to NPLI Shareholders
pursuant to Section 1.2.2.2(b), if applicable, will be issued pursuant to
exception from registration under the Securities Act and the applicable state
securities acts and the certificates evidencing the LSAI Common Stock will bear
appropriate restrictive transfer legends as required pursuant to the Securities
Act and the applicable state securities acts.
2.25 Accuracy of Representations, Covenants and Warranties. No
-----------------------------------------------------
representation, covenant or warranty by the NPLI Shareholders in this Agreement
and, to the actual acknowledge of the NPLI Shareholders, no written information,
agreements or documents furnished to LSAI by the NPLI Shareholders in connection
with the transactions contemplated in this Agreement, contain or will contain
any untrue statement of a material fact or omits or will omit to contain a
material fact necessary in order to make the statements or information contained
herein or therein, in light of the circumstances under which they were made, not
misleading.
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF LSAI
LSAI hereby represents and warrants to the NPLI Shareholders as follows:
3.1 Organization, Good Standing, Power, Etc. LSAI is a corporation duly
----------------------------------------
organized, validly existing and in good standing under the laws of the State of
Oklahoma and has the corporate power and is entitled to own or lease its
properties and to carry on its business as, and in the places where, such
properties are now owned or leased and such business is now conducted. To the
actual knowledge of LSAI, the State of Oklahoma is the only jurisdiction in
which the property owned or leased or the business conducted by LSAI would make
any such qualifications necessary.
3.2 Equity Interest. Other than Laboratory Specialists, Inc, a Louisiana
---------------
corporation and wholly owned subsidiary of LSAI ("LSI"), LSAI does not have any
stock or other equity or ownership interest (controlling or otherwise) in any
corporation, association, partnership, tax partnership, joint venture or other
entity. No equity or voting securities of LSI are or may become required to be
issued by reason of any warrants, rights, options, calls, commitments,
convertible securities or other agreements. All of the equity and voting
securities of LSI are owned by LSAI free and clear of any claim, lien,
encumbrance or agreement with respect thereto.
3.3 LSI Organization, Good Standing, Power, Etc. LSI is a corporation duly
--------------------------------------------
organized, validly existing and in good standing under the laws of the State of
Louisiana and has the corporate power and is entitled to own or lease its
properties and to carry on its business as, and in the places where, such
properties are now owned or leased and such business is now conducted. To the
actual knowledge of LSAI, the State of Louisiana is the only
12
<PAGE>
jurisdiction in which the property owned or leased or the business conducted by
LSI would make any such qualifications necessary.
3.4 Delivery of Certificate of Incorporation and Bylaws. LSAI has delivered
---------------------------------------------------
to the NPLI Shareholders complete and correct copies of Certificate of
Incorporation and Bylaws of LSAI and the Articles of Incorporation and Bylaws
of Subsidiary and LSI as in effect on the date hereof.
3.5 Capitalization. The total number of shares of capital stock which LSAI
--------------
is authorized to issue is 30,000,000 shares, consisting of (i) 20,000,000 shares
of Common Stock, $.001 par value, of which 3,298,405 shares are issued and
outstanding, and (ii) 10,000,000 shares of Preferred Stock, $.001 par value,
none are issued and outstanding. In addition, warrants, convertible securities
for the purchase of LSAI Common Stock and agreements for the issuance of LSAI
Common Stock are outstanding and, if applicable, unexercised as follows: (i)
1994 Warrants exercisable for the purchase of 1,320,000 shares of LSAI Common
Stock, at a current exercise price of $3.50 per share (subject to adjustment),
expiring on September 27, 1999, (ii) warrants for the purchase of 66,000 units
at an exercise price of $7.32 per unit, expiring October 11, 1999, each unit is
comprised of two shares of LSAI Common Stock (132,000 shares of LSAI Common
Stock, in the aggregate) and one 1994 Warrant exercisable for the purchase of
two shares of LSAI Common Stock (132,000 shares of LSAI Common Stock, in the
aggregate) at an exercise price of $3.50 per share, expiring September 27, 1999,
(iii) stock options for the purchase of 65,000 shares of LSAI Common Stock at
3.00 per share, expiring July 20, 2005, (iv) stock options for the purchase of
10,000 shares of LSAI Common Stock at $3.00 per share, expiring March 27, 1998,
and (v) 15,000 shares of LSAI Common Stock to be issued to SGA Goldstar, Inc.
and a stock options to be granted to SGA Goldstar, Inc. for the purchase of
15,000 shares of LSAI Common Stock at $3.00 per share, the period of exercise to
be determined. LSAI has 1,689,000 shares of LSAI Common Stock reserved for
issuance upon exercise of warrants, stock options and other commitments. In
addition, LSAI has 175,000 shares of LSAI Common Stock reserved for grant of
additional options pursuant to Laboratory Specialists of America, Inc. 1994
Stock Option Plan (the "LSAI Stock Option Plan"). LSAI has no treasury stock
and has not granted any options under the LSAI Stock Option Plan. The anti-
dilution and other adjustment provisions contained in the warrants and stock
options will not be triggered by consummation of the transactions contemplated
in this Agreement. Furthermore, pursuant to that certain Asset Purchase
Agreement with National Drug Assessment Corporation, dated November 30, 1994,
LSAI is obligated to issue and deliver a currently indeterminable number of
shares of LSAI Common Stock. All shares of LSAI Common Stock that are
outstanding as of the date of this Agreement, or will be outstanding immediately
prior to Closing, are or will be duly authorized, validly issued, fully paid and
non-assessable, and are not or will not be subject to or issued in violation of
any preemptive rights. Except as set forth above, as of the date of this
Agreement and immediately prior to the Closing, there are no or will not be any
(i) other authorized or outstanding equity securities of LSAI of any class, kind
or character, and (ii) other outstanding subscriptions, options, warrants or
other agreements or commitments obligating LSAI to issue any additional shares
of its capital stock of any class, or any option or right with respect thereto,
or any securities convertible into shares of any class.
3.6 Authorization of Agreement. The Board of Directors of LSAI has duly
--------------------------
approved this Agreement and the transactions contemplated hereby, including,
without limitation, the issuance of the Promissory Notes and the Contingent
Shares, and has authorized the execution and delivery of this Agreement by LSAI.
LSAI has full power, authority and legal right to enter into this Agreement and
to consummate the transactions contemplated hereunder, including, without
limitation, the issuance of the Promissory Notes and the Contingent Shares.
3.7 No Conflicting Agreements. Neither the execution nor the delivery of
-------------------------
this Agreement, nor the consummation of the transactions contemplated hereby in
accordance with the terms of this Agreement, will conflict with, or result in a
breach of, any term of, or constitute a default under, (i) the Certificate of
Incorporation or Bylaws of LSAI or (ii) to the actual acknowledge of LSAI, any
material agreement or instrument
13
<PAGE>
to which LSAI is a party, or (iii) to the actual acknowledge of LSAI, any
material judgment, decree, order, statute, rule or regulation to which LSAI is
subject, or result in the creation of material lien, charge or encumbrance on
any of the properties of LSAI. LSAI, to its actual knowledge, is not in default
or would be in default with lapse of time or notice or both, in respect to any
such term.
3.8 Financial Statements. LSAI has furnished to the NPLI Shareholders the
--------------------
following financial statements (hereinafter collectively called the "LSAI
Financial Statements"): (i) the balance sheet as of December 31, 1994, and the
related statements of stockholders' equity, income, and cash flows for the
fiscal year ended December 31, 1994 and the notes thereto, all examined and
reported upon, without qualification, by Arthur Andersen LLP, LSAI's independent
public accountants, and (ii) the unaudited balance sheet of LSAI as of September
30, 1995 (the "LSAI Balance Sheet"), and related statements of income and cash
flows for the three months and nine months ended September 30, 1995.
3.9 Securities and Exchange Commission Reports. LSAI has filed in a timely
------------------------------------------
manner (except the late filing of Form 8-K/A in March 1995 with respect to an
acquisition that occurred on December 1, 1994) any and all reports required to
be filed pursuant to Sections 13, 14 and 15(d) of the Securities Exchange Act of
1934, as amended (the "Exchange Act") since September 27, 1994. At the
respective times of filing thereof, none of such reports contained any untrue
statement of a material fact or omitted to state a material fact necessary in
order to make the statements made therein, in the light of the circumstance
under which they were made, not misleading. Each audited and unaudited financial
statement (and the notes relating thereto) contained in such reports was
prepared in accordance with generally accepted accounting principles
consistently applied (except as otherwise indicated therein) and fairly presents
the financial condition of LSAI as of the date thereof and the related results
of operations, stockholders' equity, and cash flows and changes in financial
position, as applicable, of LSAI for and during the period covered thereby.
Each unaudited financial statement (and the notes relating thereto) contained in
such reports was prepared on the same basis as the audited financial statements
and included all necessary adjustments, consisting only of normal recurring
accruals, and fairly presents the financial condition of LSAI as of the date
thereof and the related results of operations, stockholders' equity, and cash
flows or changes in financial position, as applicable, of LSAI for and during
the period covered thereby. LSAI has delivered to the NPLI Shareholders true
and correct copies of LSAI's annual report on Form 10-KSB for the fiscal year
ended December 31, 1994 and LSAI's quarterly reports on Form 10-QSB for each of
the calendar quarters ended September 30, 1994, March 31, June 30 and September
30, 1995. LSAI did not hold any annual or special meeting of its shareholders
during 1994 or 1995.
3.10 Absence of Undisclosed Liabilities. To the actual acknowledge of LSAI,
----------------------------------
all obligations and liabilities, contingent or otherwise, of LSAI arising from
events that occurred on or before the date of the LSAI Balance Sheet, whether or
not required to be accrued or reserved, have been fully accrued or reserved in
the LSAI Balance Sheet in accordance with and to the extent required by
generally accepted accounting principles. LSAI has not incurred any such
obligation or liability, contingent or otherwise, subsequent to the date of the
LSAI Balance Sheet, except for obligations and liabilities incurred in the
ordinary course of business. The reserves reflected in the LSAI Balance Sheet
are adequate, appropriate and reasonable.
3.11 Compliance with Laws. To the actual knowledge of LSAI, LSAI and LSI
--------------------
have complied with all laws, regulations, licensing requirements and orders
applicable to their respective businesses the breach or violation of which could
have a material adverse effect on said businesses and have filed with the proper
authorities, all statements and reports required by the laws, regulations,
licensing requirements and orders to which each of them or any of their
employees (because of such employee's activities on behalf of LSAI or LSI) is
subject, and, to the actual acknowledge of LSAI, each of LSAI and LSI possesses
all necessary licenses, franchises and permits to conduct its business in the
manner in which and in the jurisdictions and places where such businesses are
now conducted.
14
<PAGE>
3.12 Finder's Fees. No director, officer or employee of LSAI has incurred
-------------
or will incur any brokerage, finder's or similar fee in connection with the
transactions contemplated by this Agreement.
3.13 Full Disclosure. To the actual acknowledge of LSAI, (i) all written
---------------
information regarding LSAI and LSI previously delivered to the NPLI Shareholders
by LSAI, including all financial information and statements provided to the NPLI
Shareholders, is true and correct, (ii) all additional information regarding
LSAI and LSI delivered to the NPLI Shareholders pursuant to this Agreement is or
will be true and correct, and (iii) other than the properties shown on the LSAI
Balance Sheet, and previously disclosed to the NPLI Shareholders pursuant to
this Agreement, there are no properties, tangible or intangible, which are used
in and material to the normal day-to-day operations of LSAI or LSI as conducted
by LSAI or LSI prior to the date of this Agreement.
3.14 Accuracy of Representations, Covenants and Warranties. No
-----------------------------------------------------
representation, covenant or warranty by LSAI in this Agreement and, to the
actual acknowledge of LSAI, no written information, agreements or documents
furnished to the NPLI Shareholders by LSAI in connection with the transactions
contemplated in this Agreement, contain or will contain any untrue statement of
a material fact or omits or will omit to contain a material fact necessary in
order to make the statements or information contained herein or therein, in
light of the circumstances under which they were made, not misleading.
3.15 Promissory Notes and LSAI Common Stock Deliveries. Each of the
-------------------------------------------------
Promissory Notes to be delivered to the respective NPLI Shareholders pursuant to
Sections 1.2.2 and 1.7.1.1, and, if applicable, each of the Replacement Notes to
be delivered to the respective NPLI Shareholders (or the holder or holders of
each of the Promissory Notes) pursuant to Section 1.7.1.6, when delivered as
provided herein, will be legally and validly issued, will constitute a binding
obligation of LSAI, will (subject to applicable bankruptcy, insolvency and other
laws affecting the enforceability of creditors' rights generally) be enforceable
in accordance with its terms, and the respective NPLI Shareholders (or the
holder or holders thereof) will be entitled to the benefits provided by the
respective Promissory Notes, or if applicable, the respective Replacement Notes.
If applicable, the shares of LSAI Common Stock to be delivered to the NPLI
Shareholders (or the holder or holders of each of the respective Promissory
Notes or, if applicable, the respective Replacement Notes) pursuant to Sections
1.2.2.2(b) and 1.7.1.5, when delivered as provided herein, will be validly
issued and outstanding, fully paid and non-assessable.
ARTICLE IV
COVENANTS OF THE NPLI SHAREHOLDERS
The NPLI Shareholders covenant and agree with LSAI that, at all times between
the date hereof and the Closing, the NPLI Shareholders will cause NPLI to comply
with all covenants and provisions of this Article IV, except to the extent LSAI
may otherwise consent in writing or to the extent otherwise expressly required
or permitted by this Agreement.
4.1 Approvals. The NPLI Shareholders will (i) take all commercially
---------
reasonable steps and use all commercially reasonable efforts necessary or
desirable to recommend the granting of and to obtain, as promptly as
practicable, all approvals, authorizations and clearances of governmental
authorities and of third parties, required of them to consummate the
transactions contemplated by this Agreement, (ii) provide such other information
and communications to such governmental authorities as LSAI or such authorities
may reasonably request, and (iii) cooperate with LSAI in obtaining, as promptly
as practicable, all approvals, authorizations and clearances of governmental
authorities required of NPLI or the NPLI Shareholders, or LSAI to consummate the
transactions contemplated in this Agreement.
15
<PAGE>
4.2 No Negotiations. Except as contemplated in this Agreement, NPLI and the
---------------
NPLI Shareholders will not take (or permit any other person acting for or on
behalf of NPLI and the NPLI Shareholders to take), directly or indirectly, any
action to (i) seek or encourage any offer or proposal from any person to acquire
any shares of capital stock or any other securities of NPLI or any interest
therein, (ii) merge, consolidate or combine, or permit any other person to
merge, consolidate or combine, with NPLI, (iii) liquidate, dissolve or
reorganize NPLI, (iv) acquire or transfer any assets or properties of NPLI or
any interests therein, other than in the ordinary course of business or in
accordance with the terms of this Agreement; or (v) reach any agreement or
understanding (regardless of whether such agreement or understanding is
absolute, revocable, contingent or conditional) for, or otherwise to attempt to
consummate, any such acquisition, transfer, merger, consolidation, combination,
liquidation, dissolution or reorganization.
4.3 Due Diligence Investigation by LSAI. NPLI and the NPLI Shareholders
-----------------------------------
shall cause NPLI to afford to the officers and authorized representatives of
LSAI reasonable access to the offices, properties, books and records of NPLI and
will furnish LSAI with such additional financial and operating data and other
information as to the business and properties of NPLI as may be reasonable
necessary for LSAI thoroughly to evaluate, prior to the Closing, the business
assets, operations and financial condition of NPLI, including, without
limitation, tax returns filed and those in preparation of NPLI. If, for any
reason, the transactions contemplated by this Agreement are not consummated,
LSAI will cause all confidential information obtained by it from the NPLI
Shareholders related to NPLI to be treated as such and will not use such
information in a manner detrimental to NPLI and the NPLI Shareholders. LSAI
hereby agrees to indemnify and hold NPLI and the NPLI Shareholders harmless from
all claims, losses or damages arising out of LSAI's exercise of such access
rights. The NPLI Shareholders shall cause NPLI to provide to LSAI timely notice
of and access to minutes of all meetings (and all actions by written consent in
lieu thereof) of the Board of Directors and shareholders of NPLI.
4.4 Conduct of Business. The NPLI Shareholders shall cause NPLI to conduct
-------------------
its business only in the ordinary course and consistent with past practice and
shall use its commercially reasonable efforts to preserve intact the present
business organization, keep available the services of its present officers and
employees, maintain its properties and business and to preserve the goodwill of
employees, customers and others having business dealings with NPLI. Without the
prior written consent of LSAI, the NPLI Shareholders shall cause NPLI to not
engage in any activity or enter into any transaction that would cause any of the
representations or warranties set forth in this Agreement to be inaccurate if
made as of a date subsequent to such activity or transaction. Without limiting
the generality of the foregoing, the NPLI Shareholders shall cause the
following:
(a) Books and Records. NPLI will maintain its books and records in the
-----------------
usual manner and consistent with past practice and custom and will not make a
material change in any operational or financial reporting or accounting practice
or policy of NPLI or in any assumption underlying such a practice or policy.
(b) Reports and Returns. NPLI will (i) prepare properly and file duly and
-------------------
timely all reports and all tax returns required to be filed with governmental
authorities with respect to its business, operations or affairs, and (ii) pay
duly and fully all taxes indicated by such tax returns or otherwise levied or
assessed upon it or any of its assets and properties, and withhold or collect
and pay to the proper taxing authorities or reserve for such payment all taxes
that it is required to so withhold or collect and pay, unless such taxes are
being contested in good faith.
(c) Capital Expenditures. NPLI will not make any capital expenditures in
--------------------
excess of $5,000, individually, or $10,000, in the aggregate.
4.5 No Dividends or Distributions. The NPLI Shareholders shall not permit
-----------------------------
or cause NPLI to (i) make any distributions of property or assets, including
cash or cash equivalents, to its shareholders, other than as contemplated in
this Agreement or (ii) declare, set aside or pay any dividend or other
distribution in respect of
16
<PAGE>
NPLI's capital stock or other equity securities, or redeem, purchase or
otherwise acquire any shares of NPLI's capital stock or other equity securities,
or any interest in or right to acquire any such shares or other equity
securities.
4.6 No Disposal of Property. Except as contemplated in this Agreement, the
-----------------------
NPLI Shareholders shall not permit or cause NPLI to (i) dispose of or assign any
of its assets or properties or permit any of NPLI's assets or properties to be
subjected to any liens, except to the extent any such disposition or lien is
made or incurred in the ordinary course of business consistent with past
practice, or (ii) sell any part of its operations or business to any third
party.
4.7 No Acquisitions. Except as contemplated in this Agreement, the NPLI
---------------
Shareholders shall not permit or cause NPLI to (i) merge, consolidate or
otherwise combine or agree to merge, consolidate or otherwise combine with any
other person, (ii) acquire all or substantially all or a material portion of the
assets, capital stock or other equity securities of any other person, or any
business division of any other person, or (iii) otherwise acquire control or
ownership of any other person.
4.8 Contracts. The NPLI Shareholders shall not permit or cause NPLI to
---------
enter into any contract involving consideration in excess of $5,000,
individually, or $10,000, in the aggregate, except contracts entered into in the
ordinary course of business consistent with past practice.
4.9 Employee Matters. (a) No Changes to Compensation. The NPLI
---------------- --------------------------
Shareholders shall not permit or cause NPLI to amend or terminate, partially or
completely, any NPLI Employee Welfare Benefit Plan, or increase or agree to
increase the rate of compensation or any other benefits or amounts payable or to
become payable by NPLI to any of its officers, directors or employees.
(b) Claims and Litigation. The NPLI Shareholders shall notify LSAI in
---------------------
writing of receipt of any notice of investigation or administrative proceeding
by the IRS, Department of Labor, or other governmental agency, involving any
NPLI employee benefit plan or arrangement or of any action or claim by any
person under any NPLI employee benefit plan or arrangement, other than ordinary
and usual claims for benefits by participants or beneficiaries.
4.10 Notice and Cure. The NPLI Shareholders will notify LSAI promptly in
---------------
writing of, and contemporaneously will provide LSAI true, complete and correct
copies of, any and all information or documents relating to, and will use all
reasonable efforts to cure prior to the Closing, any event, transaction or
circumstance occurring after the date of this Agreement that results in or will
result in any covenant or agreement of the NPLI Shareholders being breached
under this Agreement, or that renders or will render untrue any representation
or warranty of the NPLI Shareholders contained in this Agreement as if the same
were made on or as of the date of such event, transaction or circumstance. The
NPLI Shareholders also will use all commercially reasonable efforts to cure, at
the earliest practicable date and before the Closing, any violation or breach of
any representation, warranty, covenant or agreement made by the NPLI
Shareholders in this Agreement.
4.11 Execution and Delivery of Related Agreements. (i) Each of the NPLI
--------------------------------------------
Shareholders shall execute and, at Closing, deliver to LSAI the Registration
Rights Agreement attached hereto as Exhibit D-1 or Exhibit D-2 (as the case may
be), the promissory notes evidencing the Dekirmenjian Loan and the Jobson Loan,
marked "Paid in Full," and (ii) the NPLI Shareholders shall execute and
delivery to NPLI and the NPLI Shareholders shall cause NPLI to execute and
delivery, at Closing, the Bill of Sale and Assignment of Leases Agreement
attached hereto as Exhibit B, and the First Amendment of Lease Agreement
attached hereto as Exhibit C.
17
<PAGE>
4.12 Agreements and Covenants. NPLI will not make any commitment, either in
------------------------
writing or orally, which would violate any of the provisions set forth in this
Article IV.
4.13 Finder's Fees. The NPLI Shareholders shall be responsible for payment
-------------
of any and all claims or demands for any commission, fee or other compensation
by any broker, finder, agent or similar intermediary claiming to have been
employed by or on behalf of NPLI and/or the NPLI Shareholders with respect to
the transactions contemplated in this Agreement, or any other possible
transaction involving the sale, transfer, assignment, conveyance or other
disposition of the capital stock and/or assets of NPLI, or any merger,
consolidation or any other acquisition transaction.
4.14 No Amendments. The NPLI Shareholders shall not permit or cause NPLI to
-------------
amend or propose to amend NPLI's Charter or Bylaws or take any action with
respect to any such amendment.
4.15 No Issuance or Disposition of Securities. The NPLI Shareholders shall
----------------------------------------
not permit or cause NPLI to (i) authorize or issue any shares of its capital
stock or other equity securities or enter into any contract granting any option,
warrant or right calling for the authorization or issuance of any such shares or
other equity securities, (ii) create or issue any securities directly or
indirectly convertible into or exchangeable for any such shares or other equity
securities, or (iii) create or issue any options, warrants or rights to purchase
any such convertible securities. The NPLI Shareholders will not pledge, assign,
transfer or otherwise dispose of or encumber any shares of or any options,
warrants or rights to purchase the NPLI Stock. The NPLI Shareholders shall not
permit or cause NPLI to split, combine, or reclassify any capital stock or other
equity securities of NPLI. The NPLI Shareholders shall not permit or cause NPLI
to (x) authorize or issue any equity securities or enter into any contract
granting any option, warrant or right calling for the authorization or issuance
of any such equity securities, (y) create or issue any securities directly or
indirectly convertible into or exchangeable for any such equity securities, or
(z) create or issue any options, warrants or rights to purchase any such
convertible securities.
4.16 Securities and Exchange Commission Matters. The NPLI Shareholders will
------------------------------------------
furnish LSAI as soon as practicable all information (that is readily available
to NPLI as of the date of this Agreement and that may become available to NPLI
without additional cost and expense in excess, in the aggregate, of $500)
concerning NPLI as may be required for inclusion in any report required to be
prepared and filed by LSAI with the U.S. Securities and Exchange Commission
under and pursuant to the Exchange Act or the Securities Act, or otherwise, or
any other governmental or regulatory body in connection with the transactions
contemplated by this Agreement. The NPLI Shareholders represent and warrant
that all information so furnished for such reports and filings shall not contain
any untrue statement of a material fact or omit to state a material fact
required to be stated therein in order to make the statements therein, in light
of the circumstances under which they were made, not misleading.
4.17 Public Announcements. Without prior consultation with LSAI, the NPLI
--------------------
Shareholders shall not, and the NPLI Shareholders shall not permit NPLI to, make
any announcement to the public or any statement to its employees generally
concerning the transactions contemplated in this Agreement.
4.18 Shareholders Approval. Each of the NPLI Shareholders hereby
---------------------
specifically covenants and agrees that he has read and has been fully advised by
legal counsel as to the meaning and effect of this Agreement and the
transactions to be effected by this Agreement, and that he hereby approves this
Agreement and the transactions contemplated in this Agreement. By execution of
this Agreement, (i) the NPLI Shareholders hereby votes all of the issued and
outstanding shares of the NPLI Common Stock in favor of approval of this
Agreement and the transactions contemplated in this Agreement and (ii) each of
the NPLI Shareholders hereby consents in accordance with Section 48-17-104 of
the Tennessee Business Corporation Act to all corporate action required to
consummate the transactions contemplated in this Agreement without the necessity
for a meeting of the shareholders of NPLI,
18
<PAGE>
to the extent and in the event shareholder approval shall be required for
approval of this Agreement and the transactions contemplated in and to be effect
by this Agreement.
ARTICLE V
COVENANTS OF LSAI
LSAI covenants and agrees with the NPLI Shareholders that, at all times
between the date hereof and the Closing, LSAI will comply and LSAI will cause
LSI to comply with all covenants and provisions of this Article V, except to the
extent the NPLI Shareholders may otherwise consent in writing or to the extent
otherwise expressly required or permitted by this Agreement.
5.1 Approvals. LSAI will (i) take all reasonable steps and use all
---------
reasonable efforts necessary or desirable to recommend the granting of and to
obtain, as promptly as practicable, all approvals, authorizations and clearances
of governmental authorities and of third parties, required of them to consummate
the transactions contemplated by this Agreement, (ii) provide such other
information and communications to such governmental authorities as LSAI or such
authorities may reasonably request, and (iii) cooperate with the NPLI
Shareholders in obtaining, as promptly as practicable, all approvals,
authorizations and clearances of governmental authorities required of NPLI, the
NPLI Shareholders, and/or LSAI to consummate the transactions contemplated in
this Agreement.
5.2 No Negotiations. Except as contemplated in this Agreement, LSAI will
---------------
not take (or permit any other person acting for or on behalf of LSAI to take),
directly or indirectly, any action to (i) seek or encourage any offer or
proposal from any person to acquire any shares of capital stock or any other
securities of LSAI or LSI or any interest therein, (ii) merge, consolidate or
combine, or permit any other person to merge, consolidate or combine, with LSAI
or LSI, or (iii) liquidate, dissolve or reorganize LSAI or LSI.
5.3 Due Diligence Investigation by the NPLI Shareholders. LSAI shall cause
----------------------------------------------------
LSAI and LSI to afford to the officers and authorized representatives of the
NPLI Shareholders reasonable access to the offices, properties, books and
records of LSAI and LSI and will furnish the NPLI Shareholders with such
additional financial and operating data and other information as to the business
and properties of LSAI and LSI as may be reasonable necessary for the NPLI
Shareholders thoroughly to evaluate, prior to the Closing, the business assets,
operations and financial conditions of LSAI and LSI, including, without
limitation, tax returns filed and those in preparation of LSAI and LSI. If, for
any reason, the transactions contemplated by this Agreement are not consummated,
the NPLI Shareholders will cause all confidential information obtained by them
from LSAI related to LSAI and LSI to be treated as such and will not use such
information in a manner detrimental to LSAI and LSI. The NPLI Shareholders
hereby agree to indemnify and hold LSAI and LSI harmless from all claims, losses
or damages arising out of the NPLI Shareholders' exercise of such access rights.
LSAI will also provide to the NPLI Shareholders timely notice of and access to
minutes of all meetings (and all actions by written consent in lieu thereof) of
the Boards of Directors and shareholders of LSAI and LSI.
5.4 Notice and Cure. LSAI will notify the NPLI Shareholders promptly in
---------------
writing of, and contemporaneously will provide the NPLI Shareholders with true,
complete and correct copies of, any and all information or documents relating
to, and will use all reasonable efforts to cure prior to the Closing, any event,
transaction or circumstance occurring after the date of this Agreement that
results in or will result in any covenant or agreement of LSAI being breached
under this Agreement, or that renders or will render untrue any representation
or warranty of LSAI contained in this Agreement as if the same were made on or
as of the date of such event, transaction or circumstance. LSAI also will use
all commercially reasonable efforts to cure, at the
19
<PAGE>
earliest practicable date and before the Closing, any violation or breach of any
representation, warranty, covenant or agreement made by LSAI in this Agreement.
5.5 Execution and Delivery of Related Agreements. LSAI shall execute and,
---------------------------------------------
at Closing, deliver to each of the NPLI Shareholders the Registration Rights
Agreement attached hereto as Exhibit D-1 or Exhibit D-2, as the case may be.
5.6 Agreements and Covenants. LSAI and LSI will not make any commitment,
------------------------
either in writing or orally, which would violate any of the provisions set forth
in this Article V.
5.7 Finder's Fees. LSAI shall be responsible for any claim or demand for
-------------
any commission, fee or other compensation by any broker, finder, agent or
similar intermediary claiming to have been employed by or on behalf of LSAI
and/or LSI.
5.8 No Amendment. LSAI will not amend or propose to amend its Certificate
------------
of Incorporation or Bylaws or take any action with respect to any such
amendment.
5.9 Public Announcements. LSAI, without prior consultation with the NPLI
--------------------
Shareholders, shall not make any announcement to the public or any statement to
its employees generally concerning the transactions contemplated in this
Agreement.
5.10 Securities Information. LSAI has furnished to the NPLI Shareholders
----------------------
copies of LSAI's annual report on Form 10-KSB for the fiscal year ended December
31, 1994, and quarterly reports on Form 10-QSB for the calendar quarters ended
March 31, June 30, and September 30, 1995, and will furnish any amendments
thereto and any exhibit filed or required to have been filed with the Securities
and Exchange Commission (the "Commission") in connection with each such annual
or quarterly report or amendment thereof, upon the written request of the NPLI
Shareholders. The issuance of the LSAI Common Stock to the NPLI Shareholders
pursuant to Section 1.2.2.2(b) of this Agreement, if applicable, is intended to
be exempt from registration under the Securities Act by virtue of Section 4(2)
of the 1933 Act and the rules and regulations promulgated thereunder by the
Commission, and LSAI will so report the sale to the Commission and to various
state securities or blue sky commissioners, if and to the extent required. LSAI
shall make available to the NPLI Shareholders or their agents and
representatives all documents and information reasonably relating to an
investment in the shares of LSAI Common Stock requested by or on behalf of the
NPLI Shareholders. LSAI shall make available to the NPLI Shareholders the
opportunity to ask questions and receive answers concerning the terms and
conditions of the sale and to obtain any additional information from LSAI
reasonably relating to an investment in shares of LSAI Common Stock.
ARTICLE VI
CONDITIONS TO OBLIGATIONS OF ALL PARTIES
The obligations of the NPLI Shareholders, NPLI and LSAI to effect the
transactions contemplated in this Agreement are, at their respective elections,
subject to the satisfaction or waiver of the following conditions:
6.1 Consents and Approvals. Prior to Closing, all necessary orders,
----------------------
consents and approvals shall have been entered by each regulatory authority
having jurisdiction in the premises and all applicable statutory waiting periods
shall have expired, and the consent of any other party necessary to approve the
transactions contemplated in this Agreement or to the continued holding by NPLI,
the NPLI Shareholders, and LSAI of all rights in, to and
20
<PAGE>
under any contract, agreement, license, permit, franchise, lease or other
instrument and any property or assets, tangible or intangible, reasonably deemed
by NPLI or the NPLI Shareholders to be material to NPLI or the NPLI
Shareholders, taken as a whole, or to LSAI, taken as a whole, as the case may
be, shall have been obtained.
6.2 Certain Actions. There shall not have been instituted and be continuing
---------------
or threatened against the NPLI Shareholders or NPLI, LSAI or any of their
respective directors or officers, any action, suit or proceeding by or before
any governmental authority that would restrain, prohibit or invalidate, or
result in the payment of substantial damages in respect of, any of the other
transactions contemplated in this Agreement.
ARTICLE VII
FURTHER CONDITIONS TO OBLIGATIONS OF THE NPLI SHAREHOLDERS
Notwithstanding any other provision of this Agreement, the obligations of the
NPLI Shareholders to consummate the transactions contemplated in this Agreement
shall be subject to the fulfillment prior to or at the Closing, of each of the
following conditions precedent, any of which may be waived by the NPLI
Shareholders:
7.1 Accuracy of Representations and Warranties. The representations and
------------------------------------------
warranties of LSAI set forth in Article III hereof shall be true and correct in
all material respects as of the date of this Agreement and as of the Closing,
with the same effect as though such representations and warranties had been made
at and as of the Closing.
7.2 Performance of Covenants, Agreements and Conditions. LSAI shall have
---------------------------------------------------
duly performed, complied with and satisfied in all material respects all
covenants, agreements and conditions required by this Agreement to be performed,
complied with or satisfied by it at or prior to the Closing.
7.3 Officers' Certificates, Etc. The NPLI Shareholders shall have received
---------------------------
(i) certificates, dated the date of the Closing and signed by the President of
LSAI, to the effect set forth in Sections 7.1 and 7.2 above, and (ii) such other
certificates, instruments and documents as shall be reasonably requested by the
NPLI Shareholders for the purpose of verifying the accuracy of such
representations and warranties and the performance and satisfaction of such
covenants and conditions of this Agreement.
7.4 Opinion of Counsel. The NPLI Shareholders shall have received an
------------------
opinion, dated the date of the Closing, of Dunn Swan & Cunningham, A
Professional Corporation, counsel for LSAI, in form and substance satisfactory
to the NPLI Shareholders, and covering the subjects set forth in Sections 3.1,
3.3, 3.5, 3.6 and 3.15 hereof. In rendering such opinion, counsel may rely to
the extent specified therein on certificates of officers of LSAI and public
officials.
7.5 Certain Actions. There shall not have been instituted and be continuing
---------------
or threatened against the NPLI Shareholders, or NPLI or LSAI or any of their
respective directors or officers, any action, suit or proceeding by or before
any governmental authority that would impose or confirm material limitations on
the ability of the NPLI Shareholders effectively to exercise full rights of
ownership of the shares of LSAI Common Stock to be issued to the NPLI
Shareholders pursuant to Section 1.2.2.2(b) this Agreement.
7.6 No Adverse Change. No material adverse change shall have occurred in
-----------------
the business, operations, properties or financial condition of LSAI since
September 30, 1995.
21
<PAGE>
7.7 Registration Rights Agreements. LSAI shall have executed and delivered
------------------------------
to each of the NPLI Shareholders the Registration Rights Agreements attached
hereto as Exhibit D-1 and Exhibit D-2, respectively.
ARTICLE VIII
FURTHER CONDITIONS TO OBLIGATIONS OF LSAI
Notwithstanding any other provision of this Agreement, the obligations of
LSAI to consummate the transactions contemplated in this Agreement shall be
subject to the fulfillment prior to or at the Closing, of each of the following
conditions precedent, any of which may be waived by LSAI:
8.1 Accuracy of Representations and Warranties. The representations and
------------------------------------------
warranties of the NPLI Shareholders set forth in Article II hereof shall be true
and correct in all material respects as of the date of this Agreement and as of
the Closing, with the same effect as though such representations and warranties
had been made at and as of the Closing.
8.2 Performance of Covenants, Agreements and Conditions. The NPLI
---------------------------------------------------
Shareholders shall have duly performed, complied with and satisfied in all
material respects all covenants, agreements and conditions required by this
Agreement to be performed, complied with or satisfied by it at or prior to the
Closing.
8.3 Officers' Certificate, Etc. LSAI shall have received (a) a certificate,
--------------------------
dated the date of the Closing and signed by the NPLI Shareholders, to the effect
set forth in Sections 8.1 and 8.2 above, and (b) such other certificates,
instruments and documents as shall be reasonably requested by LSAI for the
purpose of verifying the accuracy of such representations and warranties and the
performance and satisfaction of such covenants and conditions.
8.4 Resignation Officers and Directors. LSAI shall have received the
----------------------------------
resignation of Dekirmenjian and Jobson as executive officers and directors of
NPLI, such resignations to be effective immediately following the Closing.
Each such resignation shall constitute a voluntary termination of any employment
agreement that Dekirmenjian or Jobson may have with NPLI, and Dekirmenjian or
Jobson, as the case may be, hereby waives and releases NPLI of any and all
obligations that NPLI may have under such employment agreement.
8.5 Opinion of Counsel. LSAI shall have received an opinion, dated the date
------------------
of the Closing, of Bass, Berry & Sims, counsel for the NPLI Shareholders, in
form and substance satisfactory to LSAI, and covering the subjects set forth in
Sections 2.1, 2.3, and 2.6 hereof. In rendering such opinion, counsel may rely
to the extent specified therein on certificates of officers of the NPLI
Shareholders and public officials.
8.6 Certain Actions. There shall not have been instituted and be continuing
---------------
or threatened against the NPLI Shareholders or NPLI, LSAI, or any of their
respective directors or officers, any action, suit or proceeding by or before
any governmental authority that would impose or confirm material limitations on
the ability of LSAI effectively to exercise full rights of ownership of the
business, operations, properties of and the shares of NPLI Stock delivered to
LSAI pursuant to this Agreement.
8.7 No Adverse Change. No material adverse change shall have occurred in
-----------------
the business, contractual arrangements with customer, operations, properties or
financial condition of NPLI since September 30, 1995. Provided, however, it is
hereby acknowledged by LSAI that NPLI has sustained a loss from operations since
September 30, 1995, and it is anticipated that such loss from operations will
continue and may further increase
22
<PAGE>
through Closing, and that such loss from operations since September 30, 1995,
will not be considered a material adverse change for purposes of this Section
8.7.
ARTICLE IX
CONTINUING OBLIGATIONS OF THE NPLI
SHAREHOLDERS AND LSAI AFTER CLOSING
Following Closing and consummation of the transactions contemplated in this
Agreement, the NPLI Shareholders covenant and agree (except to the extent LSAI
may otherwise consent in writing or to the extent otherwise expressly required
or permitted by this Agreement), and LSAI covenants and agrees (except to the
extent the NPLI Shareholders otherwise consent in writing or to the extent
otherwise expressly required or permitted by this Agreement), as follows:
9.1 Indemnifications by NPLI Shareholders. Subject to the provisions of this
-------------------------------------
Article IX, each of the NPLI Shareholders agree severally (and not jointly) to
indemnify fully in respect of, hold harmless and defend LSAI, its Affiliates and
its officers, directors and employees against any and all damages, liabilities,
costs, claims, proceedings, investigations, penalties, judgments, deficiencies,
losses, including taxes, expenses (including interest, penalties, and fees and
disbursements of attorneys, accountants and experts) ("Loss" or "Losses")
incurred or suffered by any of them arising out of or relating to (i) any
misrepresentation or breach of warranty on the part of the NPLI Shareholders
under this Agreement and (ii) any nonfulfillment or failure to perform any
covenant or agreement on the part of any of the NPLI Shareholders under this
Agreement.
9.2 Indemnifications by LSAI. Subject to the provisions of this Article IX,
------------------------
LSAI agrees to indemnify fully in respect of, hold harmless and defend the NPLI
Shareholders against, any and all Losses arising out of or relating to (i) any
misrepresentation, or breach of warranty on the part of LSAI under this
Agreement, (ii) nonfulfillment or failure to perform any covenant or agreement
on the part of LSAI under this Agreement, or (iii) related and attributable to,
or asserted against, NPLI with respect to any event or condition occurring or
arising after the Closing Date upon which the Losses are the based.
9.3 Set Off. Subject to Section 9.5, in the event that any of the NPLI
-------
Shareholders or LSAI (the "Debtor Party") shall be indebted to the NPLI
Shareholders, LSAI or any other person or entity (the "Creditor Party") for any
amounts pursuant to the terms of this Agreement, including, but not limited to,
the provisions of this Article IX, either of the Promissory Notes or the
Replacement Notes, or under any other agreement, then the Creditor Party or any
of its Affiliates may give notice to the Debtor Party of such obligation. If
such notice has been given and the Debtor Party does not fully pay such
obligation within 90 days of such notice, then the Creditor Party may retain and
apply to the payment of that amount, sums otherwise owed by the Creditor Party
or its Affiliates to the Debtor Party or its Affiliates under this Agreement,
either of the Promissory Notes, a Replacement Promissory Note, or under any
other agreement and in doing so such Creditor Party or its Affiliates shall have
no liability to such Debtor Party for such retention and application, under this
Agreement, either of the Promissory Notes, a Replacement Promissory Note, or any
such other agreement and such retention and application shall not be a violation
or breach thereof; provided, however, the amount which may be retained pursuant
to this Section 9.3 of any payment otherwise due under this Agreement, either of
the Promissory Notes, a Replacement Promissory Note, or any such other agreement
shall be an amount equal to that percentage of such payment obtained by dividing
such payment by all amounts then due and which can then be determined to become
due to the Debtor Party or its Affiliates by the Creditor Party or its
Affiliates under this Agreement, either of the Promissory Notes, a Replacement
Promissory Note, or any such other agreement.
23
<PAGE>
9.4 Remedies. The remedies provided in this Article IX shall be the sole
--------
and exclusive remedies of LSAI and its Affiliates and its officers, directors
and employees against the NPLI Shareholders or the NPLI Shareholders against
LSAI for any misrepresentation or breach of a warranty or covenant under this
Agreement.
9.5 Limitation of Liability for Certain Misrepresentations or Breaches. (i)
------------------------------------------------------------------
Except as provided in subsection (iii) of this Section 9.5, the NPLI
Shareholders shall not be liable under this Agreement for any misrepresentation
or breach of warranty, or breach of any covenant to be performed at or prior to
Closing, except to the extent that the aggregate amount of Losses for which they
would otherwise (but for this provision) be liable exceeds in the aggregate the
sum of $20,000 and then only to the extent of such excess; provided, however, in
no event shall each of the NPLI Shareholders be liable for any such
misrepresentation or such breach in excess of 50 percent of the amount of the
total Losses for such misrepresentation or breach and the liability of each NPLI
Shareholder shall not exceed, in the aggregate, for such Losses, the sum of
$600,000.
(ii) The amount of any such indemnification for any misrepresentation or
breach of warranty or breach of covenant to which the indemnification limitation
of subsection (i) this Section 9.5 is applicable shall be recoverable against
the respective NPLI Shareholders as follows: (a) first, (I) as a pro tanto
cancellation of the rights of the NPLI Shareholders to receive the Contingent
Shares pursuant to Section 1.2.2.2(b) or (II) in the event the Contingent Shares
have been previously issued and delivered in accordance with Section 1.2.2.2(b)
at the time that the Losses occurs or is determined, then by surrender by the
NPLI Shareholders of the previously issued Contingent Shares at the Agreed Value
utilized in determining the number of shares of Contingent Shares that were
issued to the NPLI Shareholders pursuant to Section 1.2.2.2(b); (b) second, as a
set-off against the Promissory Notes or, if applicable, the Replacement Notes;
and (c) third, from the NPLI Shareholders.
(iii) The provisions of subsection (i) of this Section 9.5 shall not be
applicable to any Losses occasioned by any misrepresentation or breach of any
warranty or breach of any covenant set forth in each of Sections 2.1 through
2.7, and each of Sections 2.12, 2.24, and 9.9.
(iv) LSAI shall not be liable under this Agreement for any misrepresentation
or breach of warranty except to the extent that the aggregate amount of Losses
for which it would otherwise (but for this provision) be liable exceeds in the
aggregate the sum of $20,000 and then only to the extent of such excess;
provided, however, in no event shall LSAI, its Affiliates and its officers,
directors and employees be liable for any such misrepresentation or breach for
an aggregate amount in excess of $1,200,000.
(v) The provisions of subsection (iv) of this Section 9.5 shall not be
applicable to any Losses occasioned by any misrepresentation or breach of any
warranty or breach of any covenant set forth in each of Sections 3.1 through
3.7.
9.6 Survival of Representations and Warranties. Each representation,
------------------------------------------
warranty, or covenant given or made by the NPLI Shareholders or LSAI under
Articles II, III, IV and V this Agreement shall survive the date of Closing;
provided, however, that the rights of the parties hereto to initiate any action
for breach of any such representation, warranty, or covenant shall survive only
until the close of business on April 15, 1997. Notwithstanding the foregoing,
the rights to initiate any action for breach of each representation or warranty
given or made by the NPLI Shareholders under Section 2.12 shall survive for the
period of the applicable statute of limitations (including any extensions
thereof).
9.7 Method of Asserting Claims, Etc. The party claiming indemnification
-------------------------------
under Section 9.1 or 9.2 of this Agreement hereinafter referred to as the
"Indemnified Party" and the party against whom such claims are asserted
24
<PAGE>
hereunder is hereinafter referred to as the "Indemnifying Party". All claims
for indemnification by any Indemnified Party under this Article IX shall be
asserted and conducted as follows:
9.7.1 Notification; Defense. In the event that any claim or demand for
---------------------
which an Indemnifying Party would be liable to an Indemnified Party hereunder
is asserted against or sought to be collected from such Indemnified Party by
a third party, said Indemnified Party shall with reasonable promptness notify
the Indemnifying Party of such claim or demand, specifying the nature of and
specific basis for such claim or demand and the amount or the estimated
amount thereof to the extent then feasible (which estimate shall not be
conclusive of the final amount of such claim and demand (the "Claim Notice").
The Indemnified Party's failure to so notify the Indemnifying Party in
accordance with the provisions of this Agreement shall not relieve the
Indemnifying Party of liability hereunder unless such failure materially
prejudices the Indemnifying Party's ability to defend against the claim or
demand. The Indemnifying Party shall have 30 days from the giving of the
Claim Notice (the "Notice Period") to notify the Indemnified Party (i)
whether or not the Indemnifying Party disputes the liability of the
Indemnifying Party to the Indemnified Party hereunder with respect to such
claim or demand and (ii) whether or not the Indemnifying Party desires, at
the sole cost and expense of the Indemnifying Party, to defend the
Indemnified Party against such claim or demand; provided, however, that any
Indemnified Party is hereby authorized prior to and during the Notice Period
to file any motion, answer or other pleading which it shall deem necessary or
appropriate to protect its interests or those of the Indemnifying Party and
not prejudicial to the Indemnifying Party. In the event that the Indemnifying
Party notifies the Indemnified Party within the Notice Period that he desires
to defend the Indemnified Party against such claim or demand and except as
hereinafter provided, the Indemnifying Party shall have the right to defend
by all appropriate proceedings, which proceedings shall be promptly settled
or prosecuted by him to a final conclusion. If the Indemnified Party desires
to participate in, but not control, any such defense or settlement by the
Indemnifying Party it may do so at its sole cost and expense. If requested by
the Indemnifying Party, the Indemnified Party agrees to cooperate with the
Indemnifying Party and his counsel in contesting any claim or demand which
the Indemnifying Party elects to contest, or, if appropriate and related to
the claim in question, in making any counterclaim against the person
asserting the third party claim or demand, or any cross-complaint against any
person. No claim for which indemnity is sought hereunder may be settled
without the consent of the Indemnifying Party, which consent may not be
unreasonably withheld.
9.7.2 Counterclaim Notification. In the event any Indemnified Party should
-------------------------
have a claim against any Indemnifying Party hereunder which does not involve
a claim or demand being asserted against or sought to be collected from it by
a third party, the Indemnified Party shall give a Claim Notice with respect
to such claim to the Indemnifying Party.
9.7.3 Access to Books and Records. To the extent that LSAI or NPLI may
---------------------------
claim indemnity against either or both of the NPLI Shareholders hereunder,
LSAI agrees to give either or both of the NPLI Shareholders access to the
books, records and employees of NPLI in connection with the matters for which
indemnification is sought hereunder, to the extent either or both of the NPLI
Shareholders reasonably deem necessary in connection with his or their rights
and obligations hereunder. To the extent that either of the NPLI Shareholders
may claim indemnity against LSAI hereunder, LSAI agrees to give either or
both of the NPLI Shareholders access to the books, records and employees of
LSAI in connection with the matters for which indemnification is sought
hereunder, to the extent either or both of the NPLI Shareholders reasonably
deem necessary in connection with his or their rights and obligations
hereunder.
9.8 Transition Assistance. Dekirmenjian agrees to provide NPLI with such
----------------------
transition assistance and services for a period of two years following Closing
as LSAI may reasonably request (but not requiring the devotion of more than 50
percent of Dekirmenjian's working time and efforts) in order to provide for an
orderly
25
<PAGE>
and business-like transition of the ownership of NPLI from the NPLI
Shareholders. For such assistance and services, LSAI agrees to provide medical
benefits to Dekirmenjian during the two-year period at the sole cost and expense
of LSAI, either (i) through continuation of the current medical benefits
provided by NPLI or by provision to Dekirmenjian of medical benefits currently
being provided by LSAI to its employees, or (ii) through an individual medical
benefit policy, in which event the monthly cost of such individual policy
coverage shall be paid by LSAI up to $600 per month, with the excess, if any,
above such amount, to be paid by Dekirmenjian.
9.9 Non-Competition. (a) In order to induce LSAI to enter into this
---------------
Agreement, each of the NPLI Shareholders covenants and agrees that from the
Closing until January 1, 2001, he shall not, and shall not permit any of his
Affiliates, (i) to engage in any business similar to, or in any way competitive
with, that carried on by NPLI as constituted on the date of this Agreement
within any county in any state in which NPLI is engaged in any such similar or
competitive business ("Competitive Business") (except pursuant to agreements
with LSAI or its Affiliates), (ii) to acquire any legal or beneficial interest
in, or otherwise participate in the ownership of any person, firm, corporation,
partnership or other entity or association which is or becomes engaged in a
Competitive Business, except ownership of less than one percent of a publicly
traded company shall be permissible, (iii) directly or indirectly solicit,
canvass or otherwise contact or accept any business or transaction from any
present or former clients of NPLI, or take any action which shall cause the
termination or curtailment of the business relationship between NPLI (and/or its
successor or successors) and any of its present or former customers relating to
a Competitive Business, (iv) directly or indirectly, without the prior written
consent of LSAI, solicit, entice, raid, persuade or induce any individual who at
of the date of this Agreement is, or at any time during such period shall be, an
employee of LSAI or NPLI or other their Affiliates, or any of their respective
successors, to terminate or refrain from renewing or extending his or her
employment with LSAI, NPLI or their Affiliates, or any of their respective
successors, except this clause shall not apply to any such employee whose
employment shall have been terminated by LSAI, NPLI or their Affiliates. This
covenant and agreement is included herein in order to protect the value of the
business of NPLI being acquired by LSAI pursuant to this Agreement and to assure
that LSAI and NPLI shall have the full benefit of the value thereof.
(b) If any part of the restrictions set forth in (a) should, for any reason
whatsoever, be declared invalid by a court of competent jurisdiction, the
validity or enforceability of the remainder of such restrictions shall not
thereby be adversely affected and shall be enforced to the fullest extent
permitted by law. If any of such restrictions are deemed to be unreasonable by a
court of competent jurisdiction, then the NPLI Shareholders shall submit to the
reduction or modification thereof as said court deems reasonable.
(c) If the NPLI Shareholders shall be in violation of the aforementioned
restrictive covenant in this Section 9.9, then in addition to LSAI's other
remedies, the time limitation thereof shall be extended for a period of time
equal to the period of time during which such violation occurred.
(d) The NPLI Shareholders and LSAI agree that no portion of the Stock
Purchase Price and Goodwill Purchase Price shall be allocable to the restrictive
covenant and agreement as set forth in this Section 9.9.
(e) The terms and provisions of this Section 9.9 are for the benefit of LSAI
and may be waived in whole or in part by LSAI.
9.10 Injunctive Relief. Each of the NPLI Shareholders acknowledge that LSAI,
-----------------
NPLI and its Affiliates would be irreparable damaged and that money damages and
any other remedy available at law would be inadequate to redress or remedy any
loss in the event that the provisions of Section 9.9 were not fully performed in
accordance with their specific terms or are otherwise breached, and each of the
NPLI Shareholders, therefore, agrees that LSAI and its assigns, in addition to
recovering any claim for damages or obtaining any other remedy available at
law, also may enforce the terms of Section 9.9 by injunction or specific
performance and may obtain
26
<PAGE>
may other appropriate remedy available in equity, and that each of the NPLI
Shareholders hereby waives his right to assert and will not assert in defense
against such equitable claims that an adequate legal remedy is available.
9.11 Preparation of Balance Sheet for Net Worth Adjustment. As soon as
-----------------------------------------------------
reasonably practicable and in any event within 60 days following Closing, LSAI
shall cause NPLI to prepare and deliver to the NPLI Shareholders a balance sheet
through the last day of the month immediately preceding the Closing Date or on
the Closing Date if the Closing shall have occurred on the last day of a month
(the "Balance Sheet Date") prepared in accordance with generally accepted
accounting principles consistent with past practices. LSAI shall, and LSAI
shall cause NPLI to, make available to the NPLI Shareholders all information in
LSAI's and NPLI's possession reasonably required for the NPLI Shareholders to
verify whether such balance sheet is correct. Within 30 days following delivery
of such balance sheet, the NPLI Shareholders shall notify LSAI whether they
accept such balance as correct; provided, however, that if the NPLI Shareholders
shall fail so to notify LSAI within such 30-day period, the NPLI Shareholders
shall be deemed to have agreed with that such balance sheet is correct. If the
NPLI Shareholders shall disagree with the correctness of such balance sheet,
either LSAI or the NPLI Shareholders may cause the matter to be referred to HG&A
Associates, P.C. (or such other firm of independent public accountants as LSAI
and the NPLI Shareholders may designate), the costs of which shall be borne
equally by LSAI and the NPLI Shareholders. Such accountants shall examine the
records of NPLI and prepare a balance sheet as of the Balance Sheet Date in
accordance with generally accepted accounting principles consistent with past
practices and deliver such to the NPLI Shareholders and LSAI within 60 days
following the date such matter is referred to such accountants. The balance
sheet agreed to by the NPLI Shareholders and LSAI or if there be no such balance
sheet the balance sheet prepared by the accountants is herein referred to as the
"Final Balance Sheet."
9.12 Testing Revenue Accounting for Testing Revenues Adjustment. As soon as
----------------------------------------------------------
reasonably practicable and in any event within 60 days following the Anniversary
Period, LSAI shall cause NPLI to prepare and deliver to the NPLI Shareholders a
schedule of the Testing Revenues by date and customer of NPLI and showing the
total of Testing Revenues during the Anniversary Period (the "Testing Revenue
Accounting") prepared in accordance with generally accepted accounting
principles consistent with past practices. LSAI shall, and LSAI shall cause
NPLI to, make available to the NPLI Shareholders all information in LSAI's and
NPLI's possession reasonably required for the NPLI Shareholders to verify
whether the Testing Revenue Accounting is correct. Within 30 days following
delivery of the Testing Revenue Accounting, the NPLI Shareholders shall notify
LSAI whether they accept the Testing Revenue Accounting as correct; provided,
however, that if the NPLI Shareholders shall fail so to notify LSAI within such
30-day period, the NPLI Shareholders shall be deemed to have agreed with that
the Testing Revenue Accounting is correct. If the NPLI Shareholders shall
disagree with the correctness of the Testing Revenue Accounting, either LSAI or
the NPLI Shareholders may cause the matter to be referred to Arthur Andersen LLP
(or such other firm of independent public accountants as LSAI and the NPLI
Shareholders may designate), the costs of which shall be borne equally by LSAI
and the NPLI Shareholders. Such accountants shall examine the records of NPLI
and prepare a schedule of the Testing Revenues by date and customer of NPLI and
showing the total Testing Revenues during the Anniversary Period (the
"Accountant's Testing Revenue Accounting") in accordance with generally accepted
accounting principles consistent with past practices and deliver such to the
NPLI Shareholders and LSAI within 60 days following the date such matter is
referred to such accountants. The Testing Revenue Accounting agreed to by the
NPLI Shareholders and LSAI or, if there is no agreement regarding the
correctness of the Testing Revenue Accounting, the Accountant's Testing Revenue
Accounting prepared by the accountants shall herein be referred to as the "Final
Testing Revenue Accounting."
9.13 Additional Post-Closing Performances of LSAI. After Closing, LSAI shall
--------------------------------------------
(i) make, issue and deliver the Replacement Notes to the NPLI Shareholders (or
the holder or holders of the Promissory Note), in accordance with Section
1.7.1.6 (providing for adjustment of the Note Principal pursuant to Section
1.2.2.1 and 1.2.2.2, as the case may be), (ii) pay, in accordance with Section
1.2.4 the Goodwill Purchase Price to Dekirmenjian, (iii)
27
<PAGE>
subject to Section 9.5, issue and delivery to the NPLI Shareholders (or the
holder or holders of the Promissory Notes) the Contingent Shares pursuant to
Section 1.2.2.2(b), such Contingent Shares shall be fully paid and non-
assessable, and (iv) pay, in accordance with Section 11.2, any and all costs of
litigation.
9.14 Additional Post-Closing Performances of the NPLI Shareholders. After
-------------------------------------------------------------
Closing, if not paid at Closing, the NPLI Shareholders shall pay (i) any and all
commissions, fees and other compensation payable to any broker, finder, agent or
similar intermediary claiming to have been employed by or on behalf of NPLI
and/or the NPLI Shareholders with respect to the transactions contemplated in
this Agreement, or any other possible transaction involving the sale, transfer,
assignment, conveyance or other disposition of the capital stock and/or assets
of NPLI, or any merger, consolidation, or any other acquisition transactions,
and (ii) any and all of their costs and expenses incurred in connection with
this Agreement and the transactions contemplated in this Agreement, including
without limitation fees and expenses of counsel, irrespective of when incurred,
and (iii) in accordance with Section 11.2, any and all costs of litigation.
ARTICLE X
TERMINATION AND AMENDMENT
10.1 Termination. This Agreement may be terminated and the transactions
-----------
contemplated in this Agreement abandoned at any time prior to the Closing (i) by
mutual agreement of the NPLI Shareholders and LSAI, (ii) at the option of the
NPLI Shareholders in the event the Closing shall not have been completed on or
before January 15, 1996, (iii) by LSAI, on the one hand, or the NPLI
Shareholders, on the other hand, in the event there shall have been entered or
rendered against the NPLI Shareholders or NPLI, LSAI, or any of their respective
directors or officers in any action or proceeding referred to in Sections 6.2,
7.5 or 8.6 hereof an injunction or a final judgment having one of the effects
specified in such Sections. In the event of termination by LSAI or the NPLI
Shareholders, as provided in this Section 10.1, written notice shall forthwith
be given to the other parties.
10.2 Effective of Termination. In the event of termination by LSAI or the
------------------------
NPLI Shareholders, as provided in Section 10.1 above, (i) this Agreement shall
forthwith become wholly void and of no effect, and there shall be no obligation
or liability on the part of the NPLI Shareholders and NPLI, LSAI, or their
respective officers, directors or shareholders, except as provided in Section
12.7; provided, however, that such limitation shall not apply in the event of a
willful breach by the NPLI Shareholders or LSAI of any of their respective
material covenants contained herein in which case the non-breaching party shall
be entitled to recover form the breaching party all out-of-pocket costs
(including without limitation reasonable attorney fees and expenses) which the
non-breaching party has incurred in connection with this Agreement.
10.3 Amendment. This Agreement may be amended by the parties thereto, at
---------
any time prior to the Closing. This Agreement may not be amended except by an
instrument in writing signed on behalf of each of the parties hereto.
ARTICLE XI
REMEDIES; LITIGATION COSTS
11.1 Available Remedies. Each party expressly agrees that, consistent with
------------------
its or his intention and agreement to be bound by the terms of this Agreement
and to consummate the transactions contemplated hereby, subject only to the
satisfaction of conditions precedent, the remedy of specific performance shall
be available to
28
<PAGE>
a non-breaching and non-defaulting party to enforce performance of this
Agreement by a breaching or defaulting party, including, without limitation, to
require the consummation of the Closing pursuant to Section 1.10 hereof.
Except as otherwise expressly provided herein, no remedy herein conferred
upon any party is intended to be exclusive of any other remedy, and each and
every such remedy shall be cumulative and shall be in addition to every other
remedy given hereunder or now or hereafter existing at law or in equity or by
statute or otherwise. No single or partial exercise by any party of any right,
power or remedy hereunder shall preclude any other or further exercise thereof.
11.2 Attorneys' Fees and Costs. In the event any party hereto shall be
-------------------------
required to employ an attorney or attorneys to institute a legal proceeding
against the other party or parties for the purpose of enforcing any of the
provisions of this Agreement or protecting its or his interest in any matter
arising under this Agreement, the non-prevailing party in any such action
pursued in courts of competent jurisdiction (the finality of which is not
legally contestable) shall pay to the prevailing party all reasonable costs,
damages and expenses, including attorneys' fees, expended or incurred in
connection with such proceeding. The standard to be applied in determining who
is a prevailing party for purposes of this Section 11.2 shall be the same
standard as applied by the courts in determining who is a prevailing party for
purposes of Rule 54(d) of the Federal Rules of Civil Procedure.
ARTICLE XII
MISCELLANEOUS
12.1 Expenses. Except as otherwise provided herein, LSAI hereby covenants
--------
and agrees to pay its own costs and expenses, and the NPLI Shareholders hereby
covenants and agrees to pay their the costs and expenses and the costs and
expenses, incurred in connection with this Agreement and the transactions
contemplated in this Agreement, including without limitation fees and expenses
of counsel, irrespective of when incurred and regardless of whether this
transaction is consummated.
12.2 Notices. All notices and other communications required or permitted
-------
hereunder shall be in writing and shall be deemed to have been given when
delivered personally, or on the next day after being sent by facsimile
transmission or a nationally recognized overnight delivery service, or on the
third (3rd) day after being sent by registered or certified mail (return receipt
requested), postage prepaid to the parties to this Agreement at the following
addresses or at such other address for a party as shall be specified by like
notice:
If to Dekirmenjian: Haroutune K. Dekirmenjian, PhD.
724 Swaps Lane
Knoxville, Tennessee 37923
If to Jobson Kenneth O. Jobson, M.D.
9405 Park West Boulevard
Knoxville, Tennessee 37923
With a copy to: Samuel E. Stumpf, Jr.
Bass, Berry & Sims
First American Center
Nashville, Tennessee 37238-2700
Facsimile: (615) 742-6293
29
<PAGE>
If to LSAI: Laboratory Specialists of America, Inc.
1101-A Sovereign Row
Oklahoma City, Oklahoma 73108-1827
Attention: John Simonelli
Facsimile: (405) 949-1787
With copies to: Michael E. Dunn, Esq.
Dunn Swan & Cunningham
2800 Oklahoma Tower
210 Park Avenue
Oklahoma City, Oklahoma 73102-5604
Facsimile: (405) 235-9605
12.3 Entire Agreement. This Agreement (including the Exhibits and Schedules
----------------
hereto and the documents and instruments referred to herein) constitutes the
entire agreement between the parties with respect to the subject matter hereof
and supersedes all prior agreements and undertakings, written and oral.
12.4 Binding Effect; Benefits. This Agreement shall be binding upon and
------------------------
inure to the benefit of the parties to this Agreement and their respective
successors and permitted assigns. Prior to Closing, neither this Agreement nor
any right, remedy, obligation or liability hereunder or by reason hereof shall
be assignable by any of the parties to this Agreement without the prior written
consent of the others. Nothing expressed or implied in this Agreement is
intended to or shall be construed to give any person other than the parties to
this Agreement or their respective successors or permitted assigns any legal or
equitable right, remedy or claim under or in respect of this Agreement, it being
the intention of the parties to this Agreement that this Agreement shall be for
the sole and exclusive benefit of the parties hereto or such successors or
assigns and for the benefit of no other person.
12.5 Waiver. Any term or provision of this Agreement may be waived in
------
writing at any time by the NPLI Shareholders, if they are entitled to the
benefits thereof, or by LSAI, if it is entitled to the benefits thereof. No
such waiver shall, unless explicitly stated, be a continuing waiver. No failure
to exercise or delay in exercising any right hereunder shall constitute a waiver
thereof.
12.6 Applicable Law. This Agreement shall be governed by and construed in
--------------
accordance with the laws of the State of Oklahoma applicable to contracts made
and to be performed within that State.
12.7 Confidentiality. Prior to consummation of the transactions
---------------
contemplated in this Agreement, LSAI and its representatives and the NPLI
Shareholders and their representatives will each keep confidential, and not
disclose to any third party, information and data obtained as a result of such
access; provided, however, that this restriction shall not apply to information
and data which (i) are now in or may hereafter enter the public domain without
breach of this covenant, (ii) were already in the possession of LSAI, and/or the
NPLI Shareholder, as the case may be, prior to receipt from the other, (iii) are
lawfully received by LSAI and/or the NPLI Shareholders, as the case may be, from
an unrelated third party after receipt of the same from the other, (iv) LSAI
and/or the NPLI Shareholders or NPLI, as the case may be, is required by law to
disclose, or (v) LSAI and/or the NPLI Shareholders, as the case may be,
discloses to joint venture partners, independent consultants, financial
institutions, investment bankers or broker-dealers, provided there are
restrictions prohibiting further dissemination of such information by any such
joint venture partners, consultant, financial institution investment bankers or
broker-dealers. If the transactions contemplated in this Agreement are not
consummated, each of the NPLI Shareholders and LSAI shall return to the other
all information and data obtained pursuant to this Agreement.
30
<PAGE>
If LSAI or any of its officers, directors, employees, agents or
representatives is required to disclose any information supplied to LSAI by the
NPLI Shareholders pursuant to this Agreement, or if either of the NPLI
Shareholders or any of his agents or representatives is required to disclose any
information supplied to the NPLI Shareholders by LSAI pursuant to this
Agreement, the parties hereto agree that LSAI will provide the NPLI Shareholders
with prompt notice, or the NPLI Shareholders will provide LSAI prompt notice, of
such request(s) so that LSAI or the NPLI Shareholders, as the case may be, may
seek an appropriate protective order and/or waive compliance with the provisions
of this Section 12.7. It is further agreed that, if in the absence of a
protective order or the receipt of a waiver hereunder, LSAI or either of the
NPLI Shareholders, as the case may be, is nonetheless, in the opinion of its or
his legal counsel, compelled to disclose information and data concerning LSAI or
the NPLI Shareholders or NPLI to any tribunal or else stand liable for contempt
or suffer other censure or penalty, LSAI or either of the NPLI Shareholders, as
the case may be, may disclose such information to such tribunal without
liability hereunder.
12.8 Publicity. All press releases and other publicity concerning the
---------
transactions contemplated in this Agreement shall be jointly planned and
coordinated by and between LSAI and the NPLI Shareholders.
12.9 Counterparts. This Agreement may be executed in any number of
------------
counterparts, each of which shall be deemed to be an original and all of which
together shall be deemed to be a single agreement.
12.10 Headings and Captions. The headings contained in this Agreement are
---------------------
for convenience of reference only, are not to be considered a part hereof and
shall not limit or otherwise affect in any way the meaning or interpretation of
this Agreement.
12.11 Effect of Invalid Provisions. In the event any provision of this
----------------------------
Agreement or any other agreement entered into pursuant hereto is contrary to,
prohibited by or deemed invalid under applicable law or regulation, such
provision shall be inapplicable and deemed omitted to the extend so contrary,
prohibited or invalid, but the remainder thereof shall not be invalidated
thereby and shall be given full force and effect so far as possible. In the
event any provision of this Agreement may be construed in two or more ways, one
of which would render the provision invalid or otherwise voidable or
unenforceable and another of which would render the provision valid and
enforceable, such provision shall have the meaning which renders it valid and
enforceable.
12.12 Waiver of Performance. The failure or delay of any party at any time
---------------------
to require performance by another party of any provision of this Agreement, even
if known, shall not affect the right of such party to require performance of
that provision or to exercise any right, power or remedy hereunder. Any waiver
by any party of any breach of any provision of this Agreement shall not be
construed as a waiver of any continuing or succeeding breach of such provision,
a waiver of any continuing or succeeding breach of such right, power or remedy
under this Agreement. No notice to or demand on any party in any case shall, of
itself, entitle such party to any other or further notice or demand in similar
or other circumstances.
IN WITNESS WHEREOF, the Board of Directors of LSAI has duly authorized and
caused this Agreement to be signed by the respective officers of LSAI, and the
NPLI Shareholders have executed this Agreement in his individual capacity, as
of the date first above written.
"NPLI Shareholders"
"Dekirmenjian" /s/ HAROUTUNE K. DEKIRMENJIAN
--------------------------------------------
Haroutune K. Dekirmenjian
31
<PAGE>
"Jobson" /s/ KENNETH O. JOBSON
--------------------------------------------
Kenneth O. Jobson
"NPLI"
NATIONAL PSYCHOPHARMACOLOGY
LABORATORY, INC.
By: /s/ HAROUTUNE K. DEKIRMENJIAN
-----------------------------------------
Haroutune K. Dekirmenjian, President
ATTEST:
/s/ KENNETH O. JOBSON
- -----------------------------
Kenneth O. Jobson, Secretary
[CORPORATE SEAL]
"LSAI"
LABORATORY SPECIALISTS OF AMERICA, INC.
By: /s/ LARRY E. HOWELL
-----------------------------------------
Larry E. Howell, President
ATTEST:
/s/JOHN SIMONELLI
- ------------------------------
John Simonelli, Secretary
[CORPORATE SEAL]
32
<PAGE>
LIST OF SCHEDULES (Omitted)
Schedule 2.4 Equity Interests
Schedule 2.10 Absent of Certain Events
Schedule 2.12 Tax Matters
Schedule 2.14 Litigation
Schedule 2.15 Contracts
Schedule 2.16 Defaults
Schedule 2.17(a) Employee Welfare Benefit Plans
Schedule 2.17(b) Other Employee Arrangements
Schedule 2.18 Contractual Commitments
Schedule 2.19 Insurance
Schedule 2.20 Finder's Fees
Schedule 2.22 Patents, Trademarks, Etc.
LIST OF EXHIBITS (Omitted)
Exhibit A-1 Promissory Note
Exhibit A-2 Promissory Note
Exhibit B Bill of Sale and Assignment of Leases
Exhibit C First Amendment of Lease Agreement
Exhibit D-1 Registration Rights Agreement
Exhibit D-2 Registration Rights Agreement
33
<PAGE>
EXHIBIT 2.2
REGISTRATION RIGHTS AGREEMENT
THIS REGISTRATION RIGHTS AGREEMENT (this"Agreement") is made and entered
into this 2nd day of January, 1996, by and between Laboratory Specialists of
America, Inc., an Oklahoma corporation (the "Company"), and Haroutune K.
Dekirmenjian, PhD., an individual ("Dekirmenjian").
BACKGROUND. The Company and the Dekirmenjian are parties to that certain
Stock Purchase Agreement dated the 1st day of January, 1996 (the "Stock Purchase
Agreement"), pursuant to which, on the date hereof, Dekirmenjian sold his shares
of the capital stock of National Psychopharmacology Laboratory, Inc. to the
Company and may become entitled to receive the Company's common stock, $.001 par
value per share (the "Common Stock") in accordance with the provisions of the
Stock Purchase Agreement.
In consideration of the background of the transactions and the mutual
covenants and agreements herein set forth, the parties to this Agreement hereby
agree, subject to the terms and conditions hereinafter set forth, as follows:
1. DEFINITIONS. As used herein, unless the context otherwise requires, the
following terms shall have the following respective meanings:
COMMISSION: The Securities and Exchange Commission or any other
governmental authority at the time administering the Securities Act or the
Exchange Act.
EXCHANGE ACT: The Securities Exchange Act of 1934, as amended, or any
similar or successor federal statute, and the rules and regulations of the
Commission promulgated thereunder, all as the same shall be in effect at the
time. References to a particular section of the Exchange Act shall include a
reference to the comparable section, if any, of any such similar or successor
federal statute.
PERSON: A corporation, an association, a partnership, an individual, a
joint venture, a trust or estate, an unincorporated organization, or a
government or any department or agency thereof.
REGISTRABLE SECURITIES: (i) Any shares of Common Stock issued to the
Dekirmenjian under the terms of or in conjunction with the Stock Purchase
Agreement, and (ii) any securities issued or issuable with respect to any Common
Stock referred to in the foregoing clause by way of stock dividend or stock
split or in connection with a combination of shares, recapitalization, merger,
consolidation or other reorganization or otherwise. As to any particular
Registrable Securities, once issued, such securities shall cease to be
Registrable Securities, unless such securities are not sold pursuant to such
registration as a result of non-compliance by the Company with this Agreement,
upon (i) a registration statement with respect to the sale of such securities
shall have been declared effective by the Commission, (ii) the securities shall
have been otherwise transferred, new certificates for them not bearing a legend
restricting further transfer shall have been delivered by the Company and
subsequent disposition of the securities shall not require registration or
qualification under the Securities Act or any similar state law then in force,
or (iii) the securities shall have ceased to be outstanding.
REGISTRATION EXPENSES: All expenses incident to the Company's performance
of or compliance with Section 2 of this Agreement, including without limitation
all registration, filing and listing or NASDAQ fees, all fees and expenses of
complying with securities or blue sky laws, all word processing, duplicating and
printing expenses, all messenger and delivery expenses, the fees and
disbursements of counsel for the Company and of the Company's independent public
accountants, including without limitation the expenses of any special audits or
"cold comfort" letters required by or incident to such performance and
compliance, the fees and disbursements of any counsel retained by the holder or
holders of the Registrable Securities being registered, premiums and other costs
of policies of insurance, if any, against liabilities arising out of the public
offering of the Registrable Securities being registered, and any fees and
disbursements of underwriters customarily paid by issuers or sellers of
securities, but excluding
<PAGE>
underwriting discounts and commissions and transfer taxes, if any, relating to
the Registrable Securities being registered.
SECURITIES ACT: The Securities Act of 1933, as amended, or any similar or
successor federal statute, and the rules and regulations of the Commission
promulgated thereunder, all as the same shall be in effect at the time.
References to a particular section of the Securities Act shall include a
reference to the comparable section, if any, of any such similar or successor
federal statute.
2. REGISTRATION UNDER SECURITIES ACT.
2.1 RIGHT TO INCLUDE REGISTRABLE SECURITIES. In the event the Company at
any time proposes to registered any of its securities under the Securities Act
(other than by registration on Form S-8 or Form S-4 or any successor or similar
form), whether or not for sale for the Company's own account, each such time the
Company will give prompt written notice (the "Registration Notice") to all
holders of Registrable Securities of the Company's intention to register its
securities under the Securities Act, of the intended method of disposition of
such securities, and of such holder's or holders' rights under this Section 2.1.
Upon the written request of any such holder made within 15 days after the
receipt of such Registration Notice (which request shall specify the
Registrable Securities intended to be disposed of by such holder and the
intended method of disposition thereof, which can be by an underwritten
offering, even if such was not intended by the Company), subject to the
provisions of this Agreement, the Company will use its best efforts to effect
the registration under the Securities Act which the Company has been requested
to register by a holder or holders of Registrable Securities to the extent
necessary to permit the disposition in accordance the intended method or methods
of the Registrable Securities to be registered.
2.2 COMPANY'S RIGHT TO DELAY REGISTRATION. In the event, at any time
after giving the applicable Registration Notice pursuant to Section 2.1 and
prior to the effective date of the registration statement under the Securities
Act filed in connection with such registration, the Company shall determine for
any reason, after consultation with the holder or holders of Registrable
Securities which have requested inclusion in such registration, not to register
or to delay registration of such securities, the Company may, at its election,
give written notice of such determination to each such holder of Registrable
Securities and, thereupon, (i) in the case of a determination not to register,
the Company shall be relieved of its obligation to register any Registrable
Securities in connection with such registration; provided, however, that such
determination by the Company shall be without prejudice to the rights of any
holder or holders of Registrable Securities pursuant to Section 2 hereof to
include such holder's or holders' Registrable Securities in a subsequent
registration by the Company, and (ii) in the case of a determination by the
Company to delay registering, the Company shall be permitted to delay
registering any Registrable Securities for the same period as the delay in
registering such other securities. The Company will pay all Registration
Expenses in connection with each registration of Registrable Securities
requested pursuant to Section 2 hereof.
2.3 REGISTRATION PROCEDURES. Whenever the Company is required to used its
best efforts to effect the registration of any Registrable Securities under the
Securities Act as provided in Section 2 hereof, the Company, as expeditiously as
possible, will:
(i) with respect to the registration of Registrable Securities under the
Securities Act prepare and (as soon thereafter as possible) file with the
Commission the requisite registration statement to effect such registration and,
thereafter, use its best efforts to cause such registration to become effective;
provided however, that the Company may discontinue any registration of its
securities which are not Registrable Securities at any time prior to the
effective date of the registration statement under the Securities Act or under
any state securities or blue sky laws relating thereto;
(ii) prepare and file with the Commission which amendments and supplements
to the requisite registration statement and the prospectus used in connection
therewith as may be necessary to keep such registration statement
2
<PAGE>
effective and to comply with the provisions of the Securities Act with respect
to the disposition of all securities covered by such registration statement
until such time that all of such securities have been disposed of in accordance
with the intended methods of disposition by the seller or sellers thereof as set
forth in such registration statement, but in no event for a period which would
exceed 180 days from the date on which the registration statement became
effective under the Securities Act;
(iii) furnish to each seller of Registrable Securities covered by such
registration statement (A) such number of conformed copies of such registration
statement and such number of each amendment and supplement thereto (in each case
including all exhibits), (B) such number of copies of the prospectus contained
in such registration statement (including preliminary prospectus and any summary
prospectus) and any other prospectus filed under Rule 424 under the Securities
Act, in conformity with the requirements of the Securities Act, and (C) such
other documents, as such seller may reasonably request;
(iv) use its best efforts to register or qualify all Registrable
Securities and other securities covered by such registration statement under
such other securities or blue sky laws of each state that each seller of
Registrable Securities shall reasonably request, to keep such registration or
qualification in effect for so long as such registration statement remains in
effect (subject to Section 2.3(ii)), and take any other action which may be
reasonably necessary or advisable to enable such seller to consummate the
disposition in such states of the securities owned by such seller, except that
the Company shall not for any such purpose be required to either qualify
generally to do business as a foreign corporation, or subject itself to taxation
in any jurisdiction wherein it would not, but for the requirements of this
subsection (iv), be obligated to be so qualified or subject to taxation or to
consent to general service of process in any such jurisdiction or to any
material restrictions on the conduct of the Company's business, or any
restrictions on payments to any of the Company's shareholders, or require the
escrow, "lockup" or placing of any restrictions on the sale and disposition of
securities of the Company (other than as may have been previously imposed or
existed immediately before the effective date of the registration statement
under the Securities Act) held of record by any of the Company's officers,
directors or controlling Persons that is not a seller of Registrable Securities;
(v) use its best efforts to cause all Registrable Securities covered by
such registration statement to be registered with or approved by such other
federal or state governmental agencies or authorities as may be necessary to
enable the seller or sellers thereof to consummate the disposition of such
registrable Securities;
(vi) furnish to each seller of Registrable Securities a signed
counterpart, addressed to each seller (and the underwriters, if any) of
(A) an opinion of counsel for the Company, dated the effective date
of such registration statement (and, if such registration includes an
underwritten offering, dated the date of the closing under the underwriting
agreement) reasonably satisfactory in form and substance to such seller,
and
(B) in the event the offering is underwritten, a "comfort" letter,
dated the effective date of such registration statement (and, if such
registration includes an underwritten offering, dated the date of the
closing under the underwriting agreement), signed by the independent public
accountants who have certified the Company's financial statements included
in such registration statement,
covering substantially the same matters with respect to such registration
statement (and the prospectus included therein) and, in the case of the
accountants' letter, with respect to the events subsequent to the date of such
financial statements, as are customarily covered in opinions of issuer's counsel
and in accountants' letters delivered to the underwriters in underwritten public
offerings of securities and, in the case of the accountants' letter, such other
financial matters, and, in the case of the legal opinion, such other legal
matters, as such seller or such holder or holders (or the underwriters, if any)
may reasonably request;
3
<PAGE>
(vii) notify each seller of Registrable Securities covered by such
registration statement, at any time when a prospectus relating thereto is
required to be delivered under the Securities Act, upon discovery that, or upon
the happening of any event as a result of which, the prospectus included in such
registration statement, as then in effect, includes an untrue statement of a
material fact or omits to state any material fact required to be stated therein
or necessary to make the statements therein not misleading in the light of the
circumstances under which they were made, and at the request of any such seller
or holder promptly prepare and furnish to such seller or holder a reasonable
number of copies of a supplement to or an amendment of such prospectus as may be
necessary so that, as thereafter delivered to the purchasers of such securities,
such prospectus shall not include an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the
statement therein not misleading in the light of the circumstances under which
they were made;
(viii) otherwise use its best efforts to comply with all applicable rules
and regulations of the Commission, and make available to its security holders,
as soon as reasonably practicable, a historical earnings statement covering the
period of at least 12 months, but not more than 18 months, beginning with the
first month of the first full fiscal quarter after the effective date of such
registration statement, which earnings statement shall satisfy the provisions of
Section 11(a) of the Securities Act, and will furnish to each such seller at
least five business days prior to the filing hereof a copy of any amendment or
supplement to such registration statement or prospectus and shall not file any
amendment or supplement to the registration states to which any such seller
shall have reasonably objected on the grounds that such amendment or supplement
does not comply in all material respects with the requirements of the Securities
Act or the rules or regulations thereunder;
(ix) provide and cause to be maintained a transfer agent and registrar for
all Registrable Securities covered by such registration statement from and after
a date not later than the effective date of such registration statement; and
(x) uses its best efforts to list all Registrable Securities covered by
such registration statement on any securities exchange on which any of the
Common Stock is then listed or quoted on a recognized quotation service which
also provides quotations of the Common Stock.
The Company may require each seller of Registrable Securities as to which any
registration is being effected to furnish the Company such information regarding
such seller and the distribution of such securities as the Company may from time
to time reasonably request in writing.
Each holder of Registrable Securities agrees, as a condition of this
Agreement, that, upon receipt of any notice form the Company of the happening of
any event of the kind described in Section 2.3(vii) hereof, (i) such holder will
forthwith discontinue such holder's disposition of Registrable Securities
pursuant to the registration statement relating to such Registrable Securities
until such holder's receipt of the copies of the supplemented or amended
prospectus contemplated by Section 2.3(vii), (ii) such holder will promptly
deliver copies of such supplemented or amended prospectus to each purchaser or
potential purchaser to whom such holder had delivered the prospectus prior to
such supplementation or amendment, and (iii) if so directed by the Company, will
deliver to the Company (at the Company's expense) all copies, other than
permanent file copies, then in such holder's possession of the prospectus
relating to such Registrable Securities current at the time of receipt of such
notice.
2.4 UNDERWRITTEN OFFERINGS. If the Company at any time proposes to
register any of its securities under the Securities Act, as contemplated by
Section 2 hereof, and such securities are to be distributed by or through one or
more underwriters, the Company will, if requested by any holder of Registrable
Securities as provided in Section 2.1 and subject to the provisions of this
Section 2.4, arrange for such underwriters to include all of the Registrable
Securities to be offered and sold by such holder among the securities to be
distributed by such underwriters. In the event that the managing underwriter of
any underwritten offering informs the Company and the holder or holders of
Registrable Securities requesting the inclusion of their securities in such
offering in writing of its belief that the
4
<PAGE>
number of securities requested to be sold in such offering exceeds the number
which can be sold in such offering, then the Company will include in such
offering only securities proposed to be sold by Company for its own account and
decrease the number of Registrable Securities so proposed to be sold and
requested to be included in such offering (pro rata on the basis of the
percentage of the securities, by number of shares, of the Company requested to
be included in the offering by the holder or holders of such Registrable
Securities and all other holders of the Company's securities proposing to
include shares in such offering) to the extent necessary to reduce the number of
securities to be included in such offering to the level recommended by the
managing underwriter. The holder or holders of Registrable Securities to be
distributed by such underwriters shall be parties to the underwriting agreement
between the Company and such underwriters and any necessary or appropriate
customary agreements, shall execute appropriate powers of attorney, and may at
their option, require that any or all of the representations and warranties by,
and the other agreements on the part of, the Company to and for the benefit of
such underwriters shall also be made to and for the benefit of such holder or
holders of Registrable Securities and that any or all of the conditions
precedent to the obligations of such underwriters under such underwriting
agreement be conditions precedent to the obligations of such holder or holders
of Registrable Securities. Any such holder of Registrable Securities shall not
be required to make any representations or warranties to or agreement with the
Company or the underwriters other than representatives, warranties and
agreements regarding such holder, such holder's Registrable Securities and such
holder's intended method of distribution and any other representation required
by law.
2.5 PREPARATION; REASONABLE INVESTIGATION. In connection with the
preparation and filing of each registration statement under the Securities Act
covering Registrable Securities, the Company will give the holder or holders of
Registrable Securities registered under such registration statement, their
underwriters, if any, and their respective counsel and accountants, the
opportunity to participate in the preparation of such registration statement,
each prospectus included therein or filed with the Commission, and each
amendment or supplement thereto, and will give each of them such access to the
Company's books and records and such opportunities to discuss the business of
the Company with its offices and independent public accounts who have certified
its financial statements as shall be necessary, in the opinion of such holders'
and such underwriters' respective counsel, to conduct a reasonable investigation
within the meaning of the Securities Act.
2.6 INDEMNIFICATION.
2.6.1 INDEMNIFICATION BY THE COMPANY. In the event of any registration of
any securities of the Company under the Securities Act, the Company hereby
agrees and will indemnify and hold harmless the seller of any Registrable
Securities covered by such registration statement, it directors, officers,
representatives and agents, each other Person who participates as an underwriter
in the offering or sale of such securities and each other Person, if any, who
controls such seller or any such underwriter within the meaning of the
Securities Act, against any losses, claims, damages or liabilities, joint or
several, to which such seller or any such director, officer, representative,
agent, underwriter or controlling Person may become subject under the Securities
Act or otherwise, insofar as such losses, claims, damages or liabilities (or
actions or proceedings, whether commenced or threatened, in respect thereof)
arise out of or are based upon any untrue statement or alleged untrue statement
of a material fact contained in any registration statement under which such
securities were registered under Securities Act, any preliminary prospectus,
final prospectus or summary prospectus contained therein, or any amendment or
supplement thereto, or any omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements
therein not misleading, and the Company will indemnify such seller and each such
director, officer, representative, agent, underwriter and controlling Person for
any legal or there expenses reasonably incurred by them in connection with
investigation or defending any such loss, claim, liability, action or
proceeding; provided, however, that the Company shall not be liable in any such
case to the extent that such loss, claim, damage, liability (or action or
proceeding in respect thereof) or expense arises out of or is based upon an
untrue statement or alleged untrue statement or omission or alleged omission
made in such registration statement, any such preliminary prospectus, final
prospectus, summary prospectus, amendment or supplement in reliance upon and in
conformity with information
5
<PAGE>
furnished to the Company by such seller specifically stating that it is for use
in the preparation thereof; and provided further, that the Company shall not be
liable to any Person who participates as an underwriter in the offering or sale
of Registrable Securities or any Person, if any, who controls such underwriter
within the meaning of the Securities Act, in any such case to the extent that
any such loss, claim, damage, liability (or action or proceeding in respect
thereof) or expense arises out of such Person's failure to send or give a copy
of the final prospectus, as the same may be then supplemented or amended, to the
Person asserting an untrue statement or alleged untrue statement or omission or
alleged omission at or prior to the written confirmation of the sale of
Registrable Securities to such Person if such statement or mission was contained
in such final prospectus. Such indemnity shall remain in full force and effect
regardless of any investigation made by or on behalf of such seller or any such
director, officer, representative, agent, underwriter or controlling Person
shall survive the transfer of such securities by such seller.
2.6.2 INDEMNIFICATION BY THE SELLERS. The Company may require, as a
condition to including any Registrable Securities in any registration statement
filed pursuant to Section 2.3 hereof, that the Company shall have received an
undertaking reasonably satisfactory to it from the prospective seller of such
securities, to indemnify and hold harmless (in the same manner and to the same
extent as set forth in Section 2.6.1 hereof) the Company, each director,
officer, representative and agent of the Company and each other Person, if any,
who controls the Company within the meaning of the Securities Act, with respect
to any statement or alleged statement in or omission or alleged omission from
such registration statement, any preliminary prospectus, final prospectus or
summary prospectus contained therein, or any amendment or supplement thereto, if
such statement or alleged statement or omission or alleged omission was made in
reliance upon and in conformity with information furnished to the Company by
such seller for use in the preparation of such registration statement,
preliminary prospectus, final prospectus, summary prospectus, amendment or
supplement. Such indemnity shall remain in full force and effect, regardless of
any investigation made by or on behalf of the Company or any such director,
officer, representative, agent, or controlling Person and shall survive the
transfer of such securities by such seller.
2.6.3 NOTICES OF CLAIMS AND PROCEDURE. Promptly after receipt by an
indemnified Person of notice of the commencement of any action or proceeding
involving a claim referred to in Section 2.6.1 or 2.6.2 hereof, such indemnified
Person will, if a claim in respect thereof is to be made against an indemnified
party, give written notice to the latter of the commencement of such action;
provided, however, that the failure of any indemnified Person to give notice as
provided herein shall not relieve the indemnifying party of its obligations
under Section 2.6.1 or 2.6.2 hereof, except to the extent that the indemnifying
party is actually prejudiced by such failure to give notice. In case any such
action is brought against an indemnified Person, unless in such indemnified
Person's reasonable judgment a conflict of interest between such indemnified
Person and such indemnifying party may exist in respect of such claim, the
indemnifying party shall be entitled to participate in and to assume the defense
thereof jointly with any other indemnifying party similarly notified to the
extent that it may wish, with counsel reasonably satisfactory to such
indemnified Person, and after notice from the indemnifying party to such
indemnified Person of its election so to assume the defense thereof, the
indemnifying party shall not be liable to such indemnified Person for any legal
or other expenses subsequently incurred by the latter in connection with the
defense thereof other than reasonable costs of investigation. If, in such
indemnified Person's reasonable judgment a conflict of interest does or may
exist in respect of such claim, the indemnified Person or Persons shall the
right to select separate counsel to participate in the defense of such action on
behalf of such indemnified Person or Persons, in which case the indemnifying
party shall bear the costs of such defense. No indemnifying party shall,
without the consent of the indemnified Person, consent to the entry of any
judgment or enter into any settlement which does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such indemnified Person
of a release from all liability with respect so such claim or litigation and
otherwise in form and substance satisfactory to the indemnified Person. The
indemnifying party shall not be required to indemnify any indemnified Person
against any settlement or judgment which is consented to by an indemnified
Person without the consent of the indemnified party.
6
<PAGE>
2.6.4 OTHER INDEMNIFICATION. Indemnification similar to that specified in
Sections 2.6.1, 2.6.2 and 2.6.3 hereof (with appropriate modifications) shall be
given by the Company and each seller of Registrable Securities with respect to
any required registration or other qualification of securities under federal or
sate law or regulation of any governmental authority other than the Securities
Act.
2.6.5 INDEMNIFICATION PAYMENTS. The indemnification required by this
Section 2.6 shall be made by prompt payments of the amounts thereof during the
course of the investigation or defense, as and when bills are received or
expense, loss, damage or liability is incurred.
2.6.6 CONTRIBUTION. If any of the indemnification provisions provided for
in this Section 2.6 are determined to be unenforceable or unavailable to an
indemnified Person in respect of any claim or action, then each indemnifying
party, in lieu of indemnifying such indemnified Person, shall contribute to the
amount paid or payable by such indemnified Person as a result of such claims in
such proportion as is appropriate to reflect not only the relative benefits
received by the indemnifying party and the indemnified Person from the
registration statement, but also the relative fault of the indemnified Person
and the indemnifying party in connection with the statements or omissions which
resulted in such claim or action as well as any other relevant equitable
considerations. The relative fault of the indemnifying party and the
indemnified Person shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to the information
supplied by the indemnifying party or by the indemnified Person and their
relative intent, knowledge, access to information and opportunity to correct or
prevent such statement or omission. The amount paid or payable by a party as a
result of the claims referred to above shall be deemed to include any legal or
other fees or expenses reasonably incurred by such Person in connection with
investigation or defending any action or claim. No Person guilty of fraudulent
misrepresentation (within the meaning of the Securities Act) shall be entitled
to contribution from any Person that is not guilty of such fraudulent
misrepresentation.
2.7 ADJUSTMENTS AFFECTING REGISTRABLE SECURITIES. The Company will not
effect or permit to occur any combination or subdivision of shares which would
materially adversely affect the ability of the holder of Registrable Securities
to include such Registrable Securities in any registration of its securities
contemplated by this Section 2 or the marketability of such Registrable
Securities under any such registration.
3. RULES 144 AND 144A. The Company represents and warrants to the
Dekirmenjian that it has filed registration statements pursuant to the
requirements of Section 12(g) of the Exchange Act and/or pursuant to the
requirements of the Securities Act, and has filed the reports required to be
filed by it under the Securities Act and the Exchange Act and the rules and
regulations adopted by the Commission thereunder. The Company will take such
further action as any holder of Registrable Securities may reasonably request,
all to the extent required from time to time to enable such holder to sell
Registrable Securities without registration provided by (i) Rules 144 and 144A
under the Securities Act, as such Rules may be amended from time to time, or
(ii) any similar rule or regulation hereafter adopted by the Commission. Upon
the request of any holder of Registrable Securities, the Company will deliver to
such holder a written statement as to whether it has complied with such
requirements.
4. AMENDMENTS AND WAIVERS. This Agreement may be amended and the Company
may take any action herein prohibited or omit to perform any act herein required
to be performed by it, only if the Company shall have obtained the written
consent to such amendment, action or omission to act, of the holder or holders
of more than a majority of the Registrable Securities at the time outstanding;
provided, however, if such amendment, action or omission to act would adversely
affect the rights of any holder of Registrable Securities, no consent thereto
shall be effective without the concurrence of each holder who would be adversely
affected thereby. Each holder of Registrable Securities at the time or
thereafter outstanding shall be bound by a consent obtained by the Company given
by the holder or holders of the Registrable Securities pursuant to this Section
4, whether or not such Registrable Securities shall have been marked to indicate
such consent.
7
<PAGE>
5. NOTICES. All notices and other communications required or permitted
hereunder shall be in writing, and shall be deemed to have been delivered on the
date delivered by hand or transmitted by telegram, facsimile or by similar
means, on the first day following the day when sent by recognized courier or
overnight delivery service (fees prepaid), or on the third day following the day
when deposited in the U. S. mail, registered or certified (postage prepaid),
addressed (i) if to the holder or holders of the Registrable Securities, to the
attention of each Person at the address set forth in the stock records of the
Company or such address, or to the attention of such other Person or Persons, as
the holder or holders of the Registrable Securities shall have furnished to the
Company in writing, or (ii) if to the Company, 1101-A Sovereign Row, Oklahoma
City, Oklahoma 73108-1827, to the attention of its President, or such other
address, or to the attention of such other Person or Persons, as the Company
shall have furnished to each holder of Registrable Securities at the time
outstanding; provided, however, that any such communication to the Company may
also, at the option of the holder of Registrable Securities giving notice, be
delivered by personal delivery to any officer of the Company.
6. ASSIGNMENT. This Agreement shall be binding upon and inure to the
benefit of and be enforceable by the parties hereto and their respective
successors and assigns. In addition, and whether or not any express assignment
shall have been made, the provisions of this Agreement which are for the benefit
of the Dekirmenjian shall also be for the benefit of and enforceable by any
subsequent holder of any Registrable Securities who has executed a copy of this
Agreement or otherwise indicated its agreement to be bound hereby.
7. DESCRIPTIVE HEADINGS. The descriptive headings of the several sections
and paragraphs of this Agreement are inserted for reference only and shall not
limit or otherwise affect the meaning hereof.
8. GOVERNING LAW. This Agreement shall be construed and enforced in
accordance with, and the rights of the parties shall be governed by, the laws of
the State of Oklahoma, without regard to principles of conflicts of laws.
9. COUNTERPARTS. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original, but all such
counterparts shall together constitute one and the same instrument.
IN WITNESS WHEREOF, the parties have executed and delivered this Agreement,
or have caused this Agreement, or have caused this Agreement to be executed and
delivered by their respective duly authorized officers, on the date first above
written.
"Company" LABORATORY SPECIALISTS OF AMERICA, INC.
By: /s/JOHN SIMONELLI
------------------------------------
John Simonelli, Chief Executive Officer
"Dekirmenjian"
/s/HAROUTUNE K. DEKIRMENJIAN
---------------------------------------
Haroutune K. Dekirmenjian, PhD.
8
<PAGE>
EXHIBIT 2.3
REGISTRATION RIGHTS AGREEMENT
THIS REGISTRATION RIGHTS AGREEMENT (this"Agreement") is made and entered
into this 2nd day of January, 1996, by and between Laboratory Specialists of
America, Inc., an Oklahoma corporation (the "Company"), and Kenneth O. Jobson,
M.D., an individual ("Jobson").
BACKGROUND. The Company and the Jobson are parties to that certain Stock
Purchase Agreement dated the 1st day of January, 1996 (the "Stock Purchase
Agreement"), pursuant to which, on the date hereof, Jobson sold his shares of
the capital stock of National Psychopharmacology Laboratory, Inc. to the Company
and may become entitled to receive the Company's common stock, $.001 par value
per share (the "Common Stock") in accordance with the provisions of the Stock
Purchase Agreement.
In consideration of the background of the transactions and the mutual
covenants and agreements herein set forth, the parties to this Agreement hereby
agree, subject to the terms and conditions hereinafter set forth, as follows:
1. DEFINITIONS. As used herein, unless the context otherwise requires,
the following terms shall have the following respective meanings:
COMMISSION: The Securities and Exchange Commission or any other
governmental authority at the time administering the Securities Act or the
Exchange Act.
EXCHANGE ACT: The Securities Exchange Act of 1934, as amended, or any
similar or successor federal statute, and the rules and regulations of the
Commission promulgated thereunder, all as the same shall be in effect at the
time. References to a particular section of the Exchange Act shall include a
reference to the comparable section, if any, of any such similar or successor
federal statute.
PERSON: A corporation, an association, a partnership, an individual, a
joint venture, a trust or estate, an unincorporated organization, or a
government or any department or agency thereof.
REGISTRABLE SECURITIES: (i) Any shares of Common Stock issued to the
Jobson under the terms of or in conjunction with the Stock Purchase Agreement,
and (ii) any securities issued or issuable with respect to any Common Stock
referred to in the foregoing clause by way of stock dividend or stock split or
in connection with a combination of shares, recapitalization, merger,
consolidation or other reorganization or otherwise. As to any particular
Registrable Securities, once issued, such securities shall cease to be
Registrable Securities, unless such securities are not sold pursuant to such
registration as a result of non-compliance by the Company with this Agreement,
upon (i) a registration statement with respect to the sale of such securities
shall have been declared effective by the Commission, (ii) the securities shall
have been otherwise transferred, new certificates for them not bearing a legend
restricting further transfer shall have been delivered by the Company and
subsequent disposition of the securities shall not require registration or
qualification under the Securities Act or any similar state law then in force,
or (iii) the securities shall have ceased to be outstanding.
REGISTRATION EXPENSES: All expenses incident to the Company's performance
of or compliance with Section 2 of this Agreement, including without limitation
all registration, filing and listing or NASDAQ fees, all fees and expenses of
complying with securities or blue sky laws, all word processing, duplicating and
printing expenses, all messenger and delivery expenses, the fees and
disbursements of counsel for the Company and of the Company's independent public
accountants, including without limitation the expenses of any special audits or
"cold comfort" letters required by or incident to such performance and
compliance, the fees and disbursements of any counsel retained by the holder or
holders of the Registrable Securities being registered, premiums and other costs
of policies of insurance, if any, against liabilities arising out of the public
offering of the Registrable Securities being registered, and
<PAGE>
any fees and disbursements of underwriters customarily paid by issuers or
sellers of securities, but excluding underwriting discounts and commissions and
transfer taxes, if any, relating to the Registrable Securities being registered.
SECURITIES ACT: The Securities Act of 1933, as amended, or any similar or
successor federal statute, and the rules and regulations of the Commission
promulgated thereunder, all as the same shall be in effect at the time.
References to a particular section of the Securities Act shall include a
reference to the comparable section, if any, of any such similar or successor
federal statute.
2. REGISTRATION UNDER SECURITIES ACT.
2.1 RIGHT TO INCLUDE REGISTRABLE SECURITIES. In the event the Company at
any time proposes to registered any of its securities under the Securities Act
(other than by registration on Form S-8 or Form S-4 or any successor or similar
form), whether or not for sale for the Company's own account, each such time the
Company will give prompt written notice (the "Registration Notice") to all
holders of Registrable Securities of the Company's intention to register its
securities under the Securities Act, of the intended method of disposition of
such securities, and of such holder's or holders' rights under this Section 2.1.
Upon the written request of any such holder made within 15 days after the
receipt of such Registration Notice (which request shall specify the
Registrable Securities intended to be disposed of by such holder and the
intended method of disposition thereof, which can be by an underwritten
offering, even if such was not intended by the Company), subject to the
provisions of this Agreement, the Company will use its best efforts to effect
the registration under the Securities Act which the Company has been requested
to register by a holder or holders of Registrable Securities to the extent
necessary to permit the disposition in accordance the intended method or methods
of the Registrable Securities to be registered.
2.2 COMPANY'S RIGHT TO DELAY REGISTRATION. In the event, at any time
after giving the applicable Registration Notice pursuant to Section 2.1 and
prior to the effective date of the registration statement under the Securities
Act filed in connection with such registration, the Company shall determine for
any reason, after consultation with the holder or holders of Registrable
Securities which have requested inclusion in such registration, not to register
or to delay registration of such securities, the Company may, at its election,
give written notice of such determination to each such holder of Registrable
Securities and, thereupon, (i) in the case of a determination not to register,
the Company shall be relieved of its obligation to register any Registrable
Securities in connection with such registration; provided, however, that such
determination by the Company shall be without prejudice to the rights of any
holder or holders of Registrable Securities pursuant to Section 2 hereof to
include such holder's or holders' Registrable Securities in a subsequent
registration by the Company, and (ii) in the case of a determination by the
Company to delay registering, the Company shall be permitted to delay
registering any Registrable Securities for the same period as the delay in
registering such other securities. The Company will pay all Registration
Expenses in connection with each registration of Registrable Securities
requested pursuant to Section 2 hereof.
2.3 REGISTRATION PROCEDURES. Whenever the Company is required to used its
best efforts to effect the registration of any Registrable Securities under the
Securities Act as provided in Section 2 hereof, the Company, as expeditiously as
possible, will:
(i) with respect to the registration of Registrable Securities under the
Securities Act prepare and (as soon thereafter as possible) file with the
Commission the requisite registration statement to effect such registration and,
thereafter, use its best efforts to cause such registration to become effective;
provided however, that the Company may discontinue any registration of its
securities which are not Registrable Securities at any time prior to the
effective date of the registration statement under the Securities Act or under
any state securities or blue sky laws relating thereto;
2
<PAGE>
(ii) prepare and file with the Commission which amendments and supplements
to the requisite registration statement and the prospectus used in connection
therewith as may be necessary to keep such registration statement effective and
to comply with the provisions of the Securities Act with respect to the
disposition of all securities covered by such registration statement until such
time that all of such securities have been disposed of in accordance with the
intended methods of disposition by the seller or sellers thereof as set forth in
such registration statement, but in no event for a period which would exceed 180
days from the date on which the registration statement became effective under
the Securities Act;
(iii) furnish to each seller of Registrable Securities covered by such
registration statement (A) such number of conformed copies of such registration
statement and such number of each amendment and supplement thereto (in each case
including all exhibits), (B) such number of copies of the prospectus contained
in such registration statement (including preliminary prospectus and any summary
prospectus) and any other prospectus filed under Rule 424 under the Securities
Act, in conformity with the requirements of the Securities Act, and (C) such
other documents, as such seller may reasonably request;
(iv) use its best efforts to register or qualify all Registrable
Securities and other securities covered by such registration statement under
such other securities or blue sky laws of each state that each seller of
Registrable Securities shall reasonably request, to keep such registration or
qualification in effect for so long as such registration statement remains in
effect (subject to Section 2.3(ii)), and take any other action which may be
reasonably necessary or advisable to enable such seller to consummate the
disposition in such states of the securities owned by such seller, except that
the Company shall not for any such purpose be required to either qualify
generally to do business as a foreign corporation, or subject itself to taxation
in any jurisdiction wherein it would not, but for the requirements of this
subsection (iv), be obligated to be so qualified or subject to taxation or to
consent to general service of process in any such jurisdiction or to any
material restrictions on the conduct of the Company's business, or any
restrictions on payments to any of the Company's shareholders, or require the
escrow, "lockup" or placing of any restrictions on the sale and disposition of
securities of the Company (other than as may have been previously imposed or
existed immediately before the effective date of the registration statement
under the Securities Act) held of record by any of the Company's officers,
directors or controlling Persons that is not a seller of Registrable Securities;
(v) use its best efforts to cause all Registrable Securities covered by
such registration statement to be registered with or approved by such other
federal or state governmental agencies or authorities as may be necessary to
enable the seller or sellers thereof to consummate the disposition of such
registrable Securities;
(vi) furnish to each seller of Registrable Securities a signed
counterpart, addressed to each seller (and the underwriters, if any) of
(A) an opinion of counsel for the Company, dated the effective date
of such registration statement (and, if such registration includes an
underwritten offering, dated the date of the closing under the underwriting
agreement) reasonably satisfactory in form and substance to such seller,
and
(B) in the event the offering is underwritten, a "comfort" letter,
dated the effective date of such registration statement (and, if such
registration includes an underwritten offering, dated the date of the
closing under the underwriting agreement), signed by the independent public
accountants who have certified the Company's financial statements included
in such registration statement,
covering substantially the same matters with respect to such registration
statement (and the prospectus included therein) and, in the case of the
accountants' letter, with respect to the events subsequent to the date of such
financial statements, as are customarily covered in opinions of issuer's counsel
and in accountants' letters delivered to the underwriters in underwritten public
offerings of securities and, in the case of the accountants' letter, such other
3
<PAGE>
financial matters, and, in the case of the legal opinion, such other legal
matters, as such seller or such holder or holders (or the underwriters, if any)
may reasonably request;
(vii) notify each seller of Registrable Securities covered by such
registration statement, at any time when a prospectus relating thereto is
required to be delivered under the Securities Act, upon discovery that, or upon
the happening of any event as a result of which, the prospectus included in such
registration statement, as then in effect, includes an untrue statement of a
material fact or omits to state any material fact required to be stated therein
or necessary to make the statements therein not misleading in the light of the
circumstances under which they were made, and at the request of any such seller
or holder promptly prepare and furnish to such seller or holder a reasonable
number of copies of a supplement to or an amendment of such prospectus as may be
necessary so that, as thereafter delivered to the purchasers of such securities,
such prospectus shall not include an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the
statement therein not misleading in the light of the circumstances under which
they were made;
(viii) otherwise use its best efforts to comply with all applicable rules
and regulations of the Commission, and make available to its security holders,
as soon as reasonably practicable, a historical earnings statement covering the
period of at least 12 months, but not more than 18 months, beginning with the
first month of the first full fiscal quarter after the effective date of such
registration statement, which earnings statement shall satisfy the provisions of
Section 11(a) of the Securities Act, and will furnish to each such seller at
least five business days prior to the filing hereof a copy of any amendment or
supplement to such registration statement or prospectus and shall not file any
amendment or supplement to the registration states to which any such seller
shall have reasonably objected on the grounds that such amendment or supplement
does not comply in all material respects with the requirements of the Securities
Act or the rules or regulations thereunder;
(ix) provide and cause to be maintained a transfer agent and registrar for
all Registrable Securities covered by such registration statement from and after
a date not later than the effective date of such registration statement; and
(x) uses its best efforts to list all Registrable Securities covered by
such registration statement on any securities exchange on which any of the
Common Stock is then listed or quoted on a recognized quotation service which
also provides quotations of the Common Stock.
The Company may require each seller of Registrable Securities as to which any
registration is being effected to furnish the Company such information regarding
such seller and the distribution of such securities as the Company may from time
to time reasonably request in writing.
Each holder of Registrable Securities agrees, as a condition of this
Agreement, that, upon receipt of any notice form the Company of the happening of
any event of the kind described in Section 2.3(vii) hereof, (i) such holder will
forthwith discontinue such holder's disposition of Registrable Securities
pursuant to the registration statement relating to such Registrable Securities
until such holder's receipt of the copies of the supplemented or amended
prospectus contemplated by Section 2.3(vii), (ii) such holder will promptly
deliver copies of such supplemented or amended prospectus to each purchaser or
potential purchaser to whom such holder had delivered the prospectus prior to
such supplementation or amendment, and (iii) if so directed by the Company, will
deliver to the Company (at the Company's expense) all copies, other than
permanent file copies, then in such holder's possession of the prospectus
relating to such Registrable Securities current at the time of receipt of such
notice.
2.4 UNDERWRITTEN OFFERINGS. If the Company at any time proposes to
register any of its securities under the Securities Act, as contemplated by
Section 2 hereof, and such securities are to be distributed by or through one or
more underwriters, the Company will, if requested by any holder of Registrable
Securities as provided in Section 2.1 and subject to the provisions of this
Section 2.4, arrange for such underwriters to include all of the Registrable
Securities
4
<PAGE>
to be offered and sold by such holder among the securities to be distributed by
such underwriters. In the event that the managing underwriter of any
underwritten offering informs the Company and the holder or holders of
Registrable Securities requesting the inclusion of their securities in such
offering in writing of its belief that the number of securities requested to be
sold in such offering exceeds the number which can be sold in such offering,
then the Company will include in such offering only securities proposed to be
sold by Company for its own account and decrease the number of Registrable
Securities so proposed to be sold and requested to be included in such offering
(pro rata on the basis of the percentage of the securities, by number of shares,
of the Company requested to be included in the offering by the holder or holders
of such Registrable Securities and all other holders of the Company's securities
proposing to include shares in such offering) to the extent necessary to reduce
the number of securities to be included in such offering to the level
recommended by the managing underwriter. The holder or holders of Registrable
Securities to be distributed by such underwriters shall be parties to the
underwriting agreement between the Company and such underwriters and any
necessary or appropriate customary agreements, shall execute appropriate powers
of attorney, and may at their option, require that any or all of the
representations and warranties by, and the other agreements on the part of, the
Company to and for the benefit of such underwriters shall also be made to and
for the benefit of such holder or holders of Registrable Securities and that any
or all of the conditions precedent to the obligations of such underwriters under
such underwriting agreement be conditions precedent to the obligations of such
holder or holders of Registrable Securities. Any such holder of Registrable
Securities shall not be required to make any representations or warranties to or
agreement with the Company or the underwriters other than representatives,
warranties and agreements regarding such holder, such holder's Registrable
Securities and such holder's intended method of distribution and any other
representation required by law.
2.5 PREPARATION; REASONABLE INVESTIGATION. In connection with the
preparation and filing of each registration statement under the Securities Act
covering Registrable Securities, the Company will give the holder or holders of
Registrable Securities registered under such registration statement, their
underwriters, if any, and their respective counsel and accountants, the
opportunity to participate in the preparation of such registration statement,
each prospectus included therein or filed with the Commission, and each
amendment or supplement thereto, and will give each of them such access to the
Company's books and records and such opportunities to discuss the business of
the Company with its offices and independent public accounts who have certified
its financial statements as shall be necessary, in the opinion of such holders'
and such underwriters' respective counsel, to conduct a reasonable investigation
within the meaning of the Securities Act.
2.6 INDEMNIFICATION.
2.6.1 INDEMNIFICATION BY THE COMPANY. In the event of any registration of
any securities of the Company under the Securities Act, the Company hereby
agrees and will indemnify and hold harmless the seller of any Registrable
Securities covered by such registration statement, it directors, officers,
representatives and agents, each other Person who participates as an underwriter
in the offering or sale of such securities and each other Person, if any, who
controls such seller or any such underwriter within the meaning of the
Securities Act, against any losses, claims, damages or liabilities, joint or
several, to which such seller or any such director, officer, representative,
agent, underwriter or controlling Person may become subject under the Securities
Act or otherwise, insofar as such losses, claims, damages or liabilities (or
actions or proceedings, whether commenced or threatened, in respect thereof)
arise out of or are based upon any untrue statement or alleged untrue statement
of a material fact contained in any registration statement under which such
securities were registered under Securities Act, any preliminary prospectus,
final prospectus or summary prospectus contained therein, or any amendment or
supplement thereto, or any omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements
therein not misleading, and the Company will indemnify such seller and each such
director, officer, representative, agent, underwriter and controlling Person for
any legal or there expenses reasonably incurred by them in connection with
investigation or defending any such loss, claim, liability, action or
proceeding; provided, however, that the Company shall not be liable in any such
case to the extent that such loss, claim, damage, liability (or action or
proceeding in respect thereof) or
5
<PAGE>
expense arises out of or is based upon an untrue statement or alleged untrue
statement or omission or alleged omission made in such registration statement,
any such preliminary prospectus, final prospectus, summary prospectus, amendment
or supplement in reliance upon and in conformity with information furnished to
the Company by such seller specifically stating that it is for use in the
preparation thereof; and provided further, that the Company shall not be liable
to any Person who participates as an underwriter in the offering or sale of
Registrable Securities or any Person, if any, who controls such underwriter
within the meaning of the Securities Act, in any such case to the extent that
any such loss, claim, damage, liability (or action or proceeding in respect
thereof) or expense arises out of such Person's failure to send or give a copy
of the final prospectus, as the same may be then supplemented or amended, to the
Person asserting an untrue statement or alleged untrue statement or omission or
alleged omission at or prior to the written confirmation of the sale of
Registrable Securities to such Person if such statement or mission was contained
in such final prospectus. Such indemnity shall remain in full force and effect
regardless of any investigation made by or on behalf of such seller or any such
director, officer, representative, agent, underwriter or controlling Person
shall survive the transfer of such securities by such seller.
2.6.2 INDEMNIFICATION BY THE SELLERS. The Company may require, as a
condition to including any Registrable Securities in any registration statement
filed pursuant to Section 2.3 hereof, that the Company shall have received an
undertaking reasonably satisfactory to it from the prospective seller of such
securities, to indemnify and hold harmless (in the same manner and to the same
extent as set forth in Section 2.6.1 hereof) the Company, each director,
officer, representative and agent of the Company and each other Person, if any,
who controls the Company within the meaning of the Securities Act, with respect
to any statement or alleged statement in or omission or alleged omission from
such registration statement, any preliminary prospectus, final prospectus or
summary prospectus contained therein, or any amendment or supplement thereto, if
such statement or alleged statement or omission or alleged omission was made in
reliance upon and in conformity with information furnished to the Company by
such seller for use in the preparation of such registration statement,
preliminary prospectus, final prospectus, summary prospectus, amendment or
supplement. Such indemnity shall remain in full force and effect, regardless of
any investigation made by or on behalf of the Company or any such director,
officer, representative, agent, or controlling Person and shall survive the
transfer of such securities by such seller.
2.6.3 NOTICES OF CLAIMS AND PROCEDURE. Promptly after receipt by an
indemnified Person of notice of the commencement of any action or proceeding
involving a claim referred to in Section 2.6.1 or 2.6.2 hereof, such indemnified
Person will, if a claim in respect thereof is to be made against an indemnified
party, give written notice to the latter of the commencement of such action;
provided, however, that the failure of any indemnified Person to give notice as
provided herein shall not relieve the indemnifying party of its obligations
under Section 2.6.1 or 2.6.2 hereof, except to the extent that the indemnifying
party is actually prejudiced by such failure to give notice. In case any such
action is brought against an indemnified Person, unless in such indemnified
Person's reasonable judgment a conflict of interest between such indemnified
Person and such indemnifying party may exist in respect of such claim, the
indemnifying party shall be entitled to participate in and to assume the defense
thereof jointly with any other indemnifying party similarly notified to the
extent that it may wish, with counsel reasonably satisfactory to such
indemnified Person, and after notice from the indemnifying party to such
indemnified Person of its election so to assume the defense thereof, the
indemnifying party shall not be liable to such indemnified Person for any legal
or other expenses subsequently incurred by the latter in connection with the
defense thereof other than reasonable costs of investigation. If, in such
indemnified Person's reasonable judgment a conflict of interest does or may
exist in respect of such claim, the indemnified Person or Persons shall the
right to select separate counsel to participate in the defense of such action on
behalf of such indemnified Person or Persons, in which case the indemnifying
party shall bear the costs of such defense. No indemnifying party shall,
without the consent of the indemnified Person, consent to the entry of any
judgment or enter into any settlement which does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such indemnified Person
of a release from all liability with respect so such claim or litigation and
otherwise in form and substance satisfactory to the indemnified Person. The
indemnifying party shall
6
<PAGE>
not be required to indemnify any indemnified Person against any settlement or
judgment which is consented to by an indemnified Person without the consent of
the indemnified party.
2.6.4 OTHER INDEMNIFICATION. Indemnification similar to that specified in
Sections 2.6.1, 2.6.2 and 2.6.3 hereof (with appropriate modifications) shall be
given by the Company and each seller of Registrable Securities with respect to
any required registration or other qualification of securities under federal or
sate law or regulation of any governmental authority other than the Securities
Act.
2.6.5 INDEMNIFICATION PAYMENTS. The indemnification required by this
Section 2.6 shall be made by prompt payments of the amounts thereof during the
course of the investigation or defense, as and when bills are received or
expense, loss, damage or liability is incurred.
2.6.6 CONTRIBUTION. If any of the indemnification provisions provided for
in this Section 2.6 are determined to be unenforceable or unavailable to an
indemnified Person in respect of any claim or action, then each indemnifying
party, in lieu of indemnifying such indemnified Person, shall contribute to the
amount paid or payable by such indemnified Person as a result of such claims in
such proportion as is appropriate to reflect not only the relative benefits
received by the indemnifying party and the indemnified Person from the
registration statement, but also the relative fault of the indemnified Person
and the indemnifying party in connection with the statements or omissions which
resulted in such claim or action as well as any other relevant equitable
considerations. The relative fault of the indemnifying party and the
indemnified Person shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to the information
supplied by the indemnifying party or by the indemnified Person and their
relative intent, knowledge, access to information and opportunity to correct or
prevent such statement or omission. The amount paid or payable by a party as a
result of the claims referred to above shall be deemed to include any legal or
other fees or expenses reasonably incurred by such Person in connection with
investigation or defending any action or claim. No Person guilty of fraudulent
misrepresentation (within the meaning of the Securities Act) shall be entitled
to contribution from any Person that is not guilty of such fraudulent
misrepresentation.
2.7 ADJUSTMENTS AFFECTING REGISTRABLE SECURITIES. The Company will not
effect or permit to occur any combination or subdivision of shares which would
materially adversely affect the ability of the holder of Registrable Securities
to include such Registrable Securities in any registration of its securities
contemplated by this Section 2 or the marketability of such Registrable
Securities under any such registration.
3. RULES 144 AND 144A. The Company represents and warrants to the Jobson
that it has filed registration statements pursuant to the requirements of
Section 12(g) of the Exchange Act and/or pursuant to the requirements of the
Securities Act, and has filed the reports required to be filed by it under the
Securities Act and the Exchange Act and the rules and regulations adopted by the
Commission thereunder. The Company will take such further action as any holder
of Registrable Securities may reasonably request, all to the extent required
from time to time to enable such holder to sell Registrable Securities without
registration provided by (i) Rules 144 and 144A under the Securities Act, as
such Rules may be amended from time to time, or (ii) any similar rule or
regulation hereafter adopted by the Commission. Upon the request of any holder
of Registrable Securities, the Company will deliver to such holder a written
statement as to whether it has complied with such requirements.
4. AMENDMENTS AND WAIVERS. This Agreement may be amended and the Company
may take any action herein prohibited or omit to perform any act herein required
to be performed by it, only if the Company shall have obtained the written
consent to such amendment, action or omission to act, of the holder or holders
of more than a majority of the Registrable Securities at the time outstanding;
provided, however, if such amendment, action or omission to act would adversely
affect the rights of any holder of Registrable Securities, no consent thereto
shall be effective without the concurrence of each holder who would be adversely
affected thereby. Each holder of Registrable Securities at the
7
<PAGE>
time or thereafter outstanding shall be bound by a consent obtained by the
Company given by the holder or holders of the Registrable Securities pursuant to
this Section 4, whether or not such Registrable Securities shall have been
marked to indicate such consent.
5. NOTICES. All notices and other communications required or permitted
hereunder shall be in writing, and shall be deemed to have been delivered on the
date delivered by hand or transmitted by telegram, facsimile or by similar
means, on the first day following the day when sent by recognized courier or
overnight delivery service (fees prepaid), or on the third day following the day
when deposited in the U. S. mail, registered or certified (postage prepaid),
addressed (i) if to the holder or holders of the Registrable Securities, to the
attention of each Person at the address set forth in the stock records of the
Company or such address, or to the attention of such other Person or Persons, as
the holder or holders of the Registrable Securities shall have furnished to the
Company in writing, or (ii) if to the Company, 1101-A Sovereign Row, Oklahoma
City, Oklahoma 73108-1827, to the attention of its President, or such other
address, or to the attention of such other Person or Persons, as the Company
shall have furnished to each holder of Registrable Securities at the time
outstanding; provided, however, that any such communication to the Company may
also, at the option of the holder of Registrable Securities giving notice, be
delivered by personal delivery to any officer of the Company.
6. ASSIGNMENT. This Agreement shall be binding upon and inure to the
benefit of and be enforceable by the parties hereto and their respective
successors and assigns. In addition, and whether or not any express assignment
shall have been made, the provisions of this Agreement which are for the benefit
of the Jobson shall also be for the benefit of and enforceable by any subsequent
holder of any Registrable Securities who has executed a copy of this Agreement
or otherwise indicated its agreement to be bound hereby.
7. DESCRIPTIVE HEADINGS. The descriptive headings of the several sections
and paragraphs of this Agreement are inserted for reference only and shall not
limit or otherwise affect the meaning hereof.
8. GOVERNING LAW. This Agreement shall be construed and enforced in
accordance with, and the rights of the parties shall be governed by, the laws of
the State of Oklahoma, without regard to principles of conflicts of laws.
9. COUNTERPARTS. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original, but all such
counterparts shall together constitute one and the same instrument.
IN WITNESS WHEREOF, the parties have executed and delivered this Agreement,
or have caused this Agreement, or have caused this Agreement to be executed and
delivered by their respective duly authorized officers, on the date first above
written.
"Company" LABORATORY SPECIALISTS OF AMERICA, INC.
By: /s/JOHN SIMONELLI
---------------------------------------
John Simonelli, Chief Executive Officer
"Jobson"
/s/KENNETH O. JOBSON
------------------------------------------
Kenneth O. Jobson, M.D.
8
<PAGE>
EXHIBIT 23
CONSENT OF INDEPENDENT ACCOUNTANTS
We consent to the inclusion in this report on Form 8-K of our report dated
August 31, 1995, on our audits of the financial statements of National
Psychopharmacology Laboratory, Inc.
HG&A ASSOCIATES, P.C.
Knoxville, Tennessee
April 9, 1997
